Genesco Inc · DEFM14A · On 8/13/07
Filed On 8/13/07 4:21pm ET · SEC File 1-03083 · Accession Number 950144-7-7746
As Of Filer Filing As/For/On Docs:Pgs Issuer Agent
8/13/07 Genesco Inc DEFM14A 8/13/07 1:163 Bowne of Atlanta Inc/FA
Definitive Proxy Solicitation Material -- Merger or Acquisition · Schedule 14A
Filing Table of Contents
Document/Exhibit Description Pages Size
1: DEFM14A Genesco Inc. HTML 971K
| Page | (sequential) | | | | (alphabetic) | Top |
|---|
| | |
- Alternative Formats (RTF, XML, et al.)
- Adjournment of the Special Meeting (Proposal No. 3)
- Amendment, Extension and Waiver
- Amendment to Rights Agreement
- ANNEX A Agreement and Plan of Merger
- ANNEX B Proposed Articles of Amendment
- ANNEX C Opinion of Goldman, Sachs & Co
- ANNEX D Tennessee Dissenters Rights Statutes
- Background of the Merger
- Certain Relationships Between Finish Line and Genesco
- Charter Amendment (Proposal No. 2)
- Charter Amendment, The
- Common Stock Merger Consideration
- Common Stock, Options and Restricted Stock Consideration
- Conditions to the Merger
- Conduct of Business Pending the Merger
- Date, Time and Place of the Special Meeting
- Delisting and Deregistration of Genesco Capital Stock
- Dissenters Rights
- Efforts to Complete the Merger
- Employee Benefits
- Employees Preferred Tender Offer
- Fees and Expenses of the Merger
- Financing of the Merger
- Finish Line
- Future Shareholder Proposals
- Genesco
- Indemnification and Insurance
- Independent Registered Public Accounting Firm
- Interests of Genesco s Directors and Executive Officers in the Merger
- Litigation Related to the Merger
- Market Price of Genesco S Common Stock
- Material U.S. Federal Income Tax Consequences of the Merger to Our Shareholders
- Merger Agreement (Proposal No. 1), The
- Merger and the Merger Agreement, The
- Merger Sub
- Merger, The
- No Solicitations of Other Offers
- Opinion of Goldman, Sachs & Co
- Other Business
- Other Important Considerations
- Other Matters
- Other Matters for Action at the Special Meeting
- Part 1 Right to Dissent and Obtain Payment for Shares
- Part 2 Procedure for Exercise of Dissenters Rights
- Part 3 Judicial Appraisal of Shares
- Parties to the Merger, The
- Payment for the Shares
- Preferred Stock
- Preferred Stock Treatment
- Principal Shareholders
- Projected Financial Information
- Proposals to be Considered at the Special Meeting
- Questions and Additional Information
- Questions and Answers About the Special Meeting
- Reasons for the Merger; Recommendation of Our Board of Directors
- Recommendation Withdrawal/Termination in Connection with a Superior Proposal and Third Party Tender Offers
- Record Date; Voting Rights; Quorum; Vote Required for Approval
- Regulatory Approvals
- Representations and Warranties
- Rights of Shareholders Who Object to the Merger Agreement or the Charter Amendment Proposals
- Security Ownership of Certain Beneficial Owners and Management
- Security Ownership of Directors and Management
- Solicitation of Proxies
- Special Meeting, The
- Special Note Regarding Forward-Looking Statements
- Submission and Revocation of Proxies
- Summary Term Sheet
- Table of Contents
- Termination Fees
- Termination of the Merger Agreement
- The Charter Amendment
- The Merger
- The Merger Agreement (Proposal No. 1)
- The Merger and the Merger Agreement
- The Parties to the Merger
- The Special Meeting
- Treatment of Convertible Debentures
- Treatment of Options and Other Awards
- Where You Can Find More Information
- 48-23-101. Chapter definitions
- 48-23-102. Right to dissent
- 48-23-103. Dissent by nominees and beneficial owners
- 48-23-201. Notice of dissenters rights
- 48-23-202. Notice of intent to demand payment
- 48-23-203. Dissenters notice
- 48-23-204. Duty to demand payment
- 48-23-205. Share restrictions
- 48-23-206. Payment
- 48-23-207. Failure to take action
- 48-23-208. After-acquired shares
- 48-23-209. Procedure if shareholder dissatisfied with payment or offer
- 48-23-301. Court action
- 48-23-302. Court costs and counsel fees
|
| 1 | 1st Page
|
| " | Table of Contents
|
| " | Summary Term Sheet
|
| " | The Merger and the Merger Agreement
|
| " | The Charter Amendment
|
| " | The Special Meeting
|
| " | Other Important Considerations
|
| " | Questions and Answers About the Special Meeting
|
| " | Special Note Regarding Forward-Looking Statements
|
| " | The Parties to the Merger
|
| " | Genesco
|
| " | Finish Line
|
| " | Merger Sub
|
| " | Date, Time and Place of the Special Meeting
|
| " | Proposals to be Considered at the Special Meeting
|
| " | Record Date; Voting Rights; Quorum; Vote Required for Approval
|
| " | Submission and Revocation of Proxies
|
| " | Rights of Shareholders Who Object to the Merger Agreement or the Charter Amendment Proposals
|
| " | Solicitation of Proxies
|
| " | Other Business
|
| " | Questions and Additional Information
|
| " | The Merger
|
| " | Background of the Merger
|
| " | Reasons for the Merger; Recommendation of Our Board of Directors
|
| " | Opinion of Goldman, Sachs & Co
|
| " | Projected Financial Information
|
| " | Common Stock, Options and Restricted Stock Consideration
|
| " | Preferred Stock
|
| " | Delisting and Deregistration of Genesco Capital Stock
|
| " | Regulatory Approvals
|
| " | Financing of the Merger
|
| " | Interests of Genesco s Directors and Executive Officers in the Merger
|
| " | Material U.S. Federal Income Tax Consequences of the Merger to Our Shareholders
|
| " | Certain Relationships Between Finish Line and Genesco
|
| " | Litigation Related to the Merger
|
| " | Amendment to Rights Agreement
|
| " | Fees and Expenses of the Merger
|
| " | The Merger Agreement (Proposal No. 1)
|
| " | Common Stock Merger Consideration
|
| " | Preferred Stock Treatment
|
| " | Treatment of Options and Other Awards
|
| " | Treatment of Convertible Debentures
|
| " | Payment for the Shares
|
| " | Representations and Warranties
|
| " | Conduct of Business Pending the Merger
|
| " | Efforts to Complete the Merger
|
| " | Conditions to the Merger
|
| " | No Solicitations of Other Offers
|
| " | Recommendation Withdrawal/Termination in Connection with a Superior Proposal and Third Party Tender Offers
|
| " | Termination of the Merger Agreement
|
| " | Termination Fees
|
| " | Employee Benefits
|
| " | Employees Preferred Tender Offer
|
| " | ANNEX D Tennessee Dissenters Rights Statutes
|
| " | Indemnification and Insurance
|
| " | Amendment, Extension and Waiver
|
| " | Charter Amendment (Proposal No. 2)
|
| " | Dissenters Rights
|
| " | Market Price of Genesco S Common Stock
|
| " | Security Ownership of Certain Beneficial Owners and Management
|
| " | Principal Shareholders
|
| " | Security Ownership of Directors and Management
|
| " | Independent Registered Public Accounting Firm
|
| " | Adjournment of the Special Meeting (Proposal No. 3)
|
| " | Other Matters
|
| " | Other Matters for Action at the Special Meeting
|
| " | Future Shareholder Proposals
|
| " | Where You Can Find More Information
|
| " | ANNEX A Agreement and Plan of Merger
|
| " | ANNEX B Proposed Articles of Amendment
|
| " | ANNEX C Opinion of Goldman, Sachs & Co
|
| " | Part 1 Right to Dissent and Obtain Payment for Shares
|
| " | 48-23-101. Chapter definitions
|
| " | 48-23-102. Right to dissent
|
| " | 48-23-103. Dissent by nominees and beneficial owners
|
| " | Part 2 Procedure for Exercise of Dissenters Rights
|
| " | 48-23-201. Notice of dissenters rights
|
| " | 48-23-202. Notice of intent to demand payment
|
| " | 48-23-203. Dissenters notice
|
| " | 48-23-204. Duty to demand payment
|
| " | 48-23-205. Share restrictions
|
| " | 48-23-206. Payment
|
| " | 48-23-207. Failure to take action
|
| " | 48-23-208. After-acquired shares
|
| " | 48-23-209. Procedure if shareholder dissatisfied with payment or offer
|
| " | Part 3 Judicial Appraisal of Shares
|
| " | 48-23-301. Court action
|
| " | 48-23-302. Court costs and counsel fees
|
This is an EDGAR HTML document rendered as filed. [ Alternative Formats ]
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities
Exchange Act of 1934
Filed by a Party other than the
Registrant o
Check the appropriate box:
o Preliminary
Proxy Statement
o Confidential,
for Use of the Commission Only (as permitted by
Rule 14a-6(e)(2))
þ Definitive Proxy
Statement
o Definitive
Additional Materials
o Soliciting
Material Pursuant to
§240.14a-12
GENESCO INC.
(Name of Registrant as Specified In
Its Charter)
(Name of Person(s) Filing Proxy
Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|
|
| o |
Fee computed on table below per Exchange Act
Rules 14a-6(i)(1)
and 0-11.
|
|
|
|
| |
(1)
|
Title of each class of securities to which transaction applies:
|
|
|
|
| |
(2)
|
Aggregate number of securities to which transaction applies:
|
|
|
|
| |
(3)
|
Per unit price or other underlying value of transaction computed
pursuant to Exchange Act
Rule 0-11
(set forth the amount on which the filing fee is calculated and
state how it was determined):
|
|
|
|
| |
(4)
|
Proposed maximum aggregate value of transaction:
|
|
|
| þ |
Fee paid previously with preliminary materials.
|
$39,217.80
|
|
| o |
Check box if any part of the fee is offset as provided by
Exchange Act
Rule 0-11(a)(2)
and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its
filing.
|
|
|
|
| |
(1)
|
Amount Previously Paid:
|
|
|
|
| |
(2)
|
Form, Schedule or Registration Statement No.:
|
Dear Shareholder:
On
June 17, 2007, the board of directors of Genesco Inc.
(
“Genesco,” “we,” “us” or
“our”) approved, and Genesco entered into, an
Agreement and
Plan of Merger (the
“merger agreement”)
with The Finish Line, Inc., an Indiana corporation (
“Finish
Line”), and Headwind, Inc., a Tennessee corporation and
wholly-owned subsidiary of Finish Line (
“Merger Sub”).
Under the terms of the merger agreement, Merger Sub will be
merged with and into Genesco, with Genesco continuing as the
surviving corporation (the
“merger”). If the merger is
completed, the holders of our common stock will be entitled to
receive $54.50 in cash, without interest, for each share of
Genesco common stock owned by such holders.
You will be asked, at a special meeting of our shareholders to
be held on Monday,
September 17, 2007, at 11:00 a.m., local
time, to vote on a proposal to approve the merger agreement so
that the merger can occur. After careful consideration, our
board of directors has approved and adopted the merger agreement
and determined that the merger and the merger agreement are
advisable, fair to, and in the best interests of Genesco and our
shareholders.
Our board of directors unanimously recommends
that you vote “FOR” the approval of the merger
agreement.
You will also be asked to approve and adopt articles of
amendment (the “charter amendment”) to the restated
charter of Genesco, as amended, that would permit the redemption
of Genesco’s Employees’ Subordinated Convertible
Preferred Stock (the “Employees’ Preferred”)
after the completion of the merger at the price per share to be
paid to holders of Genesco common stock in the merger, at
Genesco’s option as the surviving corporation following the
merger. After careful consideration, our board of directors has
approved and adopted the charter amendment and determined that
the charter amendment is in the best interests of Genesco and
our shareholders. Our board of directors unanimously
recommends that you vote “FOR” the approval and
adoption of the charter amendment.
The holders of our preferred stock outstanding upon the
completion of the merger will not be entitled to any
consideration upon the completion of the merger pursuant to the
merger agreement. However, Finish Line has informed us that
it intends to redeem all outstanding preferred stock that has
not properly converted to common stock prior to the merger in
accordance with the redemption provisions of our charter,
including the Employees’ Preferred subject to the requisite
approval and filing of the proposed charter amendment.
The special meeting will be held at Genesco’s executive
offices, Genesco Park, 1415 Murfreesboro Road, Nashville,
Tennessee. Notice of the special meeting and the related proxy
statement are enclosed.
The accompanying proxy statement gives you detailed information
about the special meeting, the merger agreement and the related
transactions, including the merger, and the charter amendment
and includes a copy of the merger agreement attached thereto as
Annex A and a copy of the charter amendment attached
thereto as Annex B. The receipt of cash in exchange for
shares of Genesco common stock pursuant to the merger will
constitute a taxable transaction to U.S. persons for
U.S. federal income tax purposes. We encourage you to read
the proxy statement, the merger agreement and the charter
amendment carefully. You may also obtain additional information
about Genesco from documents filed with the Securities and
Exchange Commission.
Your vote is very important, regardless of the number of
shares you own. We cannot complete the merger unless holders
of a majority of the votes represented by the outstanding shares
of our common stock and our preferred stock, voting together as
a single group, vote to approve the merger agreement. The
failure of any shareholder to vote on the proposal to approve
the merger agreement will have the same effect as a vote against
the merger agreement. The approval and adoption of the charter
amendment requires that the votes cast in favor of the amendment
by holders of all Genesco capital stock voting together as a
single group, excluding Employees’ Preferred, exceed the
votes cast against the amendment by such holders and also
requires the separate affirmative approval of a majority of the
outstanding shares of Employees’ Preferred voting as a
group. The failure of any holder of Employees’ Preferred to
vote on the charter amendment proposal will have the same effect
as a vote against the charter amendment. The approval and
adoption of the charter amendment by Genesco’s shareholders
is not a condition to the closing of the merger.
Whether or not you plan to attend the special meeting, please
complete, date, sign and return, as promptly as possible, the
enclosed proxy in the accompanying reply envelope, or submit
your proxy by telephone or the Internet.
Our board of directors and management appreciate your continuing
support of Genesco, and we urge you to support the merger and
the charter amendment.
Sincerely,
Hal N. Pennington
Chairman and Chief Executive
Officer
Neither the Securities and Exchange Commission nor any state
securities regulatory agency has approved or disapproved the
merger, passed upon the merits or fairness of the merger or
passed upon the adequacy or accuracy of the disclosure in this
document. Any representation to the contrary is a criminal
offense.
NOTICE OF SPECIAL MEETING OF
SHAREHOLDERS
Dear Shareholder:
NOTICE IS HEREBY GIVEN that a special meeting of shareholders of
Genesco Inc., a Tennessee corporation (
“Genesco,”
“we,” “us” or
“our”), will be held
on Monday,
September 17, 2007, at 11:00 a.m., local time,
at Genesco’s executive offices, located at Genesco Park,
1415 Murfreesboro Road, Nashville, Tennessee, for the following
purposes:
1. To consider and vote on a proposal to approve the
Agreement and
Plan of Merger (the
“merger agreement”),
dated as of
June 17, 2007, by and among Genesco, The Finish
Line, Inc., an Indiana corporation (
“Finish Line”),
and Headwind, Inc., a Tennessee corporation and a wholly-owned
subsidiary of Finish Line (
“Merger Sub”), as the
merger agreement may be amended from time to time;
2. To approve and adopt articles of amendment (the
“charter amendment”) to the restated charter of
Genesco, as amended, permitting the redemption of Genesco’s
Employees’ Subordinated Convertible Preferred Stock (the
“Employees’ Preferred”) after the completion of
the merger at the price per share to be paid to holders of
Genesco common stock in the merger in cash, without interest, at
Genesco’s option as the surviving corporation following the
merger;
3. To approve the adjournment of the special meeting, if
necessary, to solicit additional proxies if there are
insufficient votes at the time of the meeting to approve the
merger agreement or the charter amendment; and
4. To transact such other business as may properly come
before the special meeting and any and all adjourned or
postponed sessions thereof.
This Notice of Special Meeting of Shareholders and the
related proxy statement shall serve to provide to holders of
preferred stock any and all notices of the merger required by
Genesco’s charter, including, but not limited to, any
notice required by Part I, Article Sixth,
Part C-I,
Section 4(g) and Part I, Article Sixth,
Part E, Section 5(f).
The record date for the determination of shareholders entitled
to notice of and to vote at the special meeting is
August 6, 2007. Accordingly, only shareholders of record as
of the close of business on that date will be entitled to notice
of and to vote at the special meeting or any adjournment or
postponement of the special meeting.
We urge you to read the accompanying proxy statement carefully
as it sets forth details of the proposed merger and other
important information related to the merger agreement and the
charter amendment.
Please note that space limitations may make it necessary to
limit attendance at the special meeting to shareholders. If you
attend, please note that you may be asked to present valid
picture identification. “Street name” holders will
need to bring a copy of a brokerage statement reflecting stock
ownership as of the record date. Cameras, recording devices and
other electronic devices will not be permitted at the special
meeting.
Under Tennessee law, holders of Genesco common stock will have
no dissenters’ rights in connection with the proposed
merger. However, dissenting holders of Genesco preferred stock
who comply with the provisions of Chapter 23 of the
Tennessee Business Corporation Act are entitled to dissent from
the merger and receive payment of the fair value of their shares
of Genesco preferred stock if the merger is consummated.
Additionally, dissenting holders of the Employees’
Preferred who comply with the provisions of Chapter 23 of
the Tennessee Business Corporation Act are entitled to dissent
from the charter amendment and receive payment of the fair value
of their shares of Genesco preferred stock if the charter
amendment becomes effective. A copy of Chapter 23 of the
Tennessee Business Corporation Act is attached as Annex D
to the proxy statement. Please see the section entitled
“Dissenters’ Rights” in the proxy statement for a
summary of the procedures to be followed in asserting these
dissenters’ rights. A dissenting shareholder will be
entitled to payment only if written notice of intent to demand
payment is delivered to Genesco before the vote is taken and the
shareholder does not vote in favor of the merger agreement (or
the charter amendment, as applicable).
By Order of the Board of Directors,
Roger G. Sisson
Secretary
Nashville, Tennessee
YOUR VOTE IS IMPORTANT! WHETHER OR NOT YOU PLAN TO ATTEND THE
SPECIAL MEETING, PLEASE COMPLETE, DATE, SIGN AND RETURN, AS
PROMPTLY AS POSSIBLE, THE ENCLOSED PROXY IN THE ACCOMPANYING
REPLY ENVELOPE, OR SUBMIT YOUR PROXY BY TELEPHONE OR THE
INTERNET.
TABLE OF
CONTENTS
| |
|
|
|
|
|
1
|
|
|
|
1
|
|
|
|
4
|
|
|
|
4
|
|
|
|
4
|
|
|
|
7
|
|
|
|
11
|
|
|
|
13
|
|
|
|
13
|
|
|
|
13
|
|
|
|
13
|
|
|
|
14
|
|
|
|
14
|
|
|
|
14
|
|
|
|
14
|
|
|
|
16
|
|
|
|
16
|
|
|
|
17
|
|
|
|
17
|
|
|
|
17
|
|
|
|
18
|
|
|
|
18
|
|
|
|
26
|
|
|
|
28
|
|
|
|
35
|
|
|
|
38
|
|
|
|
38
|
|
|
|
40
|
|
|
|
40
|
|
|
|
40
|
|
|
|
43
|
|
|
|
48
|
|
|
|
50
|
|
|
|
51
|
|
|
|
51
|
|
|
|
51
|
|
|
|
52
|
|
|
|
52
|
|
|
|
52
|
|
|
|
52
|
|
|
|
53
|
|
|
|
53
|
|
|
|
53
|
|
|
|
54
|
i
| |
|
|
|
|
|
56
|
|
|
|
59
|
|
|
|
59
|
|
|
|
61
|
|
|
|
62
|
|
|
|
63
|
|
|
|
64
|
|
|
|
65
|
|
|
|
66
|
|
|
|
66
|
|
|
|
67
|
|
|
|
68
|
|
|
|
70
|
|
|
|
72
|
|
|
|
73
|
|
|
|
73
|
|
|
|
75
|
|
|
|
76
|
|
|
|
76
|
|
|
|
76
|
|
|
|
76
|
|
|
|
76
|
|
|
|
77
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ii
References to
“Genesco,” “we,”
“our” or
“us” in this proxy statement refer
to Genesco Inc. and its
subsidiaries unless otherwise indicated
by context.
SUMMARY
TERM SHEET
This Summary Term Sheet, together with the “Questions
and Answers About the Special Meeting” beginning on
page 7, summarizes selected information in the proxy
statement and may not contain all the information important to
you. You should carefully read this entire proxy statement and
the other documents to which this proxy statement refers you for
a more complete understanding of the matters being considered at
the special meeting. In addition, this proxy statement
incorporates by reference important business and financial
information about Genesco. You may obtain the information
incorporated by reference into this proxy statement without
charge by following the instructions in “Where You Can Find
More Information” beginning on page 77.
The
Merger and the Merger Agreement
(Proposal No. 1)
|
|
|
| |
•
|
The Parties to the Merger (see
page 13). Genesco, a Tennessee corporation,
is a leading retailer of branded footwear and licensed and
branded headwear and a wholesaler of branded footwear. The
Finish Line, Inc., an Indiana corporation (“Finish
Line”), together with its subsidiaries, is one of the
largest mall-based specialty retailers in the United States and
operates under the Finish Line, Man Alive, and Paiva brand
names. Headwind, Inc., a Tennessee corporation and a
wholly-owned subsidiary of Finish Line (“Merger Sub”),
was formed solely for the purpose of effecting the merger.
Merger Sub has not engaged in any business except in furtherance
of this purpose.
|
|
|
|
| |
•
|
The Merger. You are being asked to vote to
approve an Agreement and Plan of Merger (the “merger
agreement”) pursuant to which Merger Sub will merge with
and into Genesco (the “merger”) on the terms and
subject to the conditions in the merger agreement. Genesco will
be the surviving corporation following the merger (the
“surviving corporation”) and will continue to do
business as “Genesco” following the merger. As a
result of the merger, Genesco will cease to be a publicly traded
company and will become a subsidiary of Finish Line. See
“The Merger Agreement” beginning on page 52.
|
|
|
|
| |
•
|
Common Stock Merger Consideration. If the
merger is completed, holders of Genesco common stock will be
entitled to receive $54.50 in cash, without interest, for each
share of Genesco common stock they own. Holders of Genesco
common stock will not own shares in the surviving corporation.
See “The Merger Agreement — Common Stock Merger
Consideration” beginning on page 52.
|
|
|
|
| |
•
|
Treatment of Preferred Stock. The holders
of our preferred stock outstanding upon the completion of the
merger will not be entitled to any consideration upon the
completion of the merger pursuant to the merger agreement.
Each share of Genesco preferred stock issued and outstanding,
and not otherwise properly converted to common stock, if
applicable, immediately before the merger will remain
outstanding following the merger. Finish Line has informed us
that it intends to redeem all outstanding shares of redeemable
preferred stock following the completion of the merger in
accordance with our charter, and that they also intend to redeem
the outstanding Employees’ Subordinated Convertible
Preferred Stock (the “Employees’ Preferred”)
subject to the requisite approval and filing of the proposed
charter amendment (Proposal No. 2). See “The
Merger — Preferred Stock” beginning on
page 38, for further discussion of the treatment and rights
of our preferred stock in connection with the merger, including
the current conversion ratios and redemption prices for our
outstanding preferred stock as applicable.
|
|
|
|
| |
•
|
Treatment of Outstanding Options and Other Awards.
|
|
|
|
| |
•
|
all outstanding options to acquire Genesco common stock under
Genesco’s equity incentive plans will become fully vested
and immediately exercisable upon completion of the merger, and
each option will be cancelled and converted into the right to
receive a cash payment equal to the number of shares of Genesco
common stock underlying the option multiplied by the amount by
which
|
1
|
|
|
| |
|
$54.50 exceeds the option exercise price, without interest and
less any applicable withholding taxes; and
|
|
|
|
| |
•
|
restrictions applicable to all shares of restricted stock will
lapse and those shares will be cancelled and converted into the
right to receive a cash payment equal to the number of
outstanding restricted shares multiplied by $54.50, without
interest and less any applicable withholding taxes.
|
See “The Merger Agreement — Treatment of Options
and Other Awards” beginning on page 53.
|
|
|
| |
•
|
Conditions to the Merger (see
page 59). The completion of the merger
depends on the satisfaction or waiver of a number of conditions,
including the following:
|
|
|
|
| |
•
|
the merger agreement must have been approved by the affirmative
approval of the holders of a majority of the votes represented
by the outstanding shares of our common stock and our preferred
stock, voting together as a single group;
|
| |
| |
•
|
no statute, rule, executive order, regulation, order or
injunction which prevents or prohibits the merger shall be in
effect;
|
| |
| |
•
|
the waiting period (and any extension thereof) under the
Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended (the
“HSR Act”), and applicable foreign antitrust laws must
have expired or been terminated;
|
|
|
|
| |
•
|
Genesco must not have experienced an uncured company material
adverse effect, as described under the caption “The Merger
Agreement — Conditions to the Merger” beginning
on page 59;
|
|
|
|
| |
•
|
the respective representations and warranties of Genesco, Finish
Line and Merger Sub in the merger agreement must be true and
correct as of the closing date subject to the qualifications
described under the caption “The Merger
Agreement — Conditions to the Merger” beginning
on page 59; and
|
|
|
|
| |
•
|
Genesco, Finish Line and Merger Sub must have performed and
complied in all material respects with all covenants and
agreements that each is required to perform or comply with under
the merger agreement.
|
|
|
|
| |
•
|
No Solicitations of Other Offers (see
page 61).
|
|
|
|
| |
•
|
The merger agreement provides that we are generally not
permitted to:
|
|
|
|
| |
•
|
solicit, initiate, or knowingly encourage the submission of an
acquisition proposal for us or engage in any negotiations or
discussions with respect thereto, or otherwise participate,
engage or knowingly assist in, or knowingly facilitate, an
acquisition proposal; or
|
| |
| |
•
|
approve or recommend any acquisition proposal for us or adopt or
enter into any letter of intent, memorandum of understanding,
option agreement or other similar agreement with respect to any
acquisition proposal for us or withdraw or modify, in a manner
adverse to Finish Line or Merger Sub, the approval or
recommendation of our board of directors of the merger agreement
or the merger or publicly announce that it has resolved to take
that action or publicly propose to do any of the foregoing.
|
|
|
|
| |
•
|
Notwithstanding these restrictions, under certain circumstances,
our board of directors may respond to an unsolicited proposal
for an alternative acquisition or terminate the merger agreement
and enter into an acquisition agreement with respect to a
superior proposal, so long as we comply with certain terms of
the merger agreement described under “The Merger
Agreement — Recommendation Withdrawal/Termination in
Connection with a Superior Proposal and Third Party Tender
Offers” beginning on page 62.
|
2
|
|
|
| |
•
|
Termination of the Merger Agreement (see
page 63).
|
The merger agreement may be terminated at any time prior to the
completion of the merger, whether before or after shareholder
approval has been obtained:
|
|
|
| |
•
|
by mutual written consent of Genesco and Finish Line;
|
| |
| |
•
|
by either Genesco or Finish Line, if:
|
|
|
|
| |
•
|
the merger is not consummated on or before December 31,
2007, except that this right to terminate will not be available
to any party whose action or failure to fulfill any obligation
under the merger agreement or failure to act in good faith has
been the principal cause of, or resulted in, the failure of the
merger to be consummated by that date;
|
| |
| |
•
|
a court of competent jurisdiction or other governmental entity
has issued a final, non-appealable order, decree or ruling or
taken any other action, or there exists any statute, rule or
regulation, in each case preventing or otherwise prohibiting the
completion of the merger or that otherwise has the effect of
making the merger illegal, and the party seeking to terminate
the merger agreement has used all reasonable efforts to prevent
the entry of and to remove the order, decree, ruling, action, or
statute, rule or regulation to the extent of its control or
influence; or
|
| |
| |
•
|
our shareholders fail to approve the merger agreement at a duly
held meeting; or
|
|
|
|
| |
•
|
our board of directors withdraws or modifies, or publicly
proposes to withdraw or modify, in a manner adverse to Finish
Line or Merger Sub, the approval or recommendation of our board
of directors of the merger agreement or the merger or publicly
announces that it has resolved to take such action;
|
| |
| |
•
|
our board of directors recommends to our shareholders or
approves any other acquisition proposal;
|
| |
| |
•
|
our board of directors fails to include in this proxy statement
its recommendation that our shareholders approve the merger
agreement and the merger; or
|
| |
| |
•
|
there has been a breach of, or inaccuracy in, any
representation, warranty, covenant or agreement of Genesco under
the merger agreement which would result in the failure of
certain conditions to closing and where the breach or inaccuracy
is reasonably incapable of being cured, or is not cured, within
20 business days after Genesco receives written notice of the
breach or inaccuracy, and neither Finish Line nor Merger Sub is
in material breach of its representations, warranties, covenants
and obligations under the merger agreement so as to cause the
failure of certain conditions to closing; or
|
|
|
|
| |
•
|
Genesco concurrently enters into a definitive agreement with
respect to a superior proposal, provided that we have paid, or
simultaneously with doing so, pay to Finish Line the termination
fee as described below; or
|
| |
| |
•
|
there has been a breach of, or inaccuracy in, any
representation, warranty, covenant or agreement of Finish Line
or Merger Sub under the merger agreement which would result in
the failure of certain conditions to closing and where the
breach or inaccuracy is reasonably incapable of being cured, or
is not cured, within 20 business days after Finish Line receives
written notice of the breach or inaccuracy and Genesco is not in
material breach of our representations, warranties, covenants
and obligations under the merger agreement so as to cause the
failure of certain conditions to closing.
|
|
|
|
| |
•
|
Termination Fees (see page 64). If
the merger agreement is terminated under certain circumstances:
|
|
|
|
| |
•
|
Genesco will be obligated to reimburse Finish Line’s
reasonable, actual and documented
out-of-pocket
fees and expenses, up to a limit of $10 million; and
|
| |
| |
•
|
Genesco will be obligated to pay Finish Line a termination fee
of $46 million.
|
3
The
Charter Amendment (Proposal No. 2)
|
|
|
| |
•
|
You are also being asked to approve and adopt articles of
amendment (the “charter amendment”) to the restated
charter of Genesco, as amended, permitting the redemption of the
Employees’ Preferred after the completion of the merger at
the price to be paid per share of Genesco common stock in the
merger in cash, or $54.50, without interest and net of any
unpaid amounts on such shares, at Genesco’s option as the
surviving corporation following the merger. The approval and
adoption of the charter amendment is not a condition to the
completion of the merger. See page 68 and the text of the
proposed charter amendment included as Annex B to this
proxy statement.
|
The
Special Meeting
See “Questions and Answers About the Special Meeting”
beginning on page 7 and “The Special Meeting”
beginning on page 14.
Other
Important Considerations
|
|
|
| |
•
|
Board Recommendations. After careful
consideration, our board of directors unanimously approved and
adopted the charter amendment and the merger agreement and
determined that the merger agreement and the merger are
advisable, fair to and in the best interests of Genesco and our
shareholders, and unanimously recommend that our shareholders
vote “FOR” the approval of the merger agreement, as
the same may be amended from time to time, “FOR” the
approval and adoption of the charter amendment and
“FOR” the adjournment of the special meeting, if
necessary, to solicit additional proxies to approve the merger
agreement or the charter amendment. For a discussion of the
factors our board of directors considered in deciding to
recommend the approval of the merger agreement, see “The
Merger — Reasons for the Merger; Recommendation of Our
Board of Directors” beginning on page 26.
|
|
|
|
| |
•
|
Share Ownership of Directors and Executive
Officers. As of August 6, 2007, the record
date for the special meeting, the directors and executive
officers of Genesco held and were entitled to vote, in the
aggregate, 579,658 shares of Genesco common stock,
representing approximately 2.5% of the votes entitled to be cast
on the merger agreement proposal and the proposal to adjourn the
meeting and 2.5% of the votes entitled to be cast on the charter
amendment by the voting group comprised of holders of all
Genesco capital stock, except holders of Employees’
Preferred. As of the record date, the directors and executive
officers held no shares of Genesco preferred stock. See
“The Special Meeting — Record Date; Voting
Rights; Quorum; Vote Required for Approval” beginning on
page 14.
|
|
|
|
| |
•
|
Interests of Genesco’s Directors and Executive Officers
in the Merger. In reaching its decision
concerning the merger agreement, our board of directors
consulted extensively with our management team and legal and
financial advisors. Certain senior members of management
generally participated in meetings of our board of directors,
including Hal N. Pennington, our chairman and chief executive
officer and Robert J. Dennis, our president and chief operating
officer, who are members of the board of directors. In
considering the recommendation of our board of directors with
respect to the merger, you should be aware that some of
Genesco’s directors and executive officers (including
Mr. Pennington and Mr. Dennis) who participated in
meetings of our board of directors have interests in the merger
that may be different from, or in addition to, the interests of
our shareholders generally. For example, the merger agreement
provides that, at the effective time of the merger, each option
to purchase shares of our common stock, including those options
held by our directors and executive officers, will accelerate
and become fully vested and will generally be cashed out in an
amount equal to the excess of $54.50 over the option exercise
price, and all shares of restricted stock, including those held
by our directors and executive officers, will become free of
restrictions and will be cashed out at $54.50 per share.
Our executive officers may be entitled to severance payments
under certain circumstances following the merger pursuant to
existing employment protection agreements with us. It is
currently anticipated that Mr. Pennington will not be
retained to continue his role as chairman and chief executive
officer of the surviving corporation following the merger or
otherwise in a formal capacity. These and other interests or
potential interests of our directors and executive officers are
more fully described under “The
|
4
|
|
|
| |
|
Merger — Interests of Genesco’s Directors and
Executive Officers in the Merger” beginning on
page 43. Our board of directors was aware of these
interests in making its decisions.
|
|
|
|
| |
•
|
Opinion of Goldman, Sachs &
Co. Goldman, Sachs & Co. (“Goldman
Sachs”) rendered its oral opinion, which was subsequently
confirmed in writing, to our board of directors that, as of
June 17, 2007, and based upon and subject to the factors
and assumptions set forth in the opinion, the $54.50 per
share in cash to be received by the holders of the outstanding
shares of Genesco’s common stock pursuant to the merger
agreement was fair from a financial point of view to such
holders. The full text of the written opinion of Goldman Sachs,
dated June 17, 2007, which sets forth the assumptions made,
procedures followed, matters considered and limitations on the
review undertaken in connection with the opinion, is attached as
Annex C to this proxy statement. Goldman Sachs provided its
opinion for the information and assistance of the board of
directors of Genesco in connection with its consideration of the
merger. Goldman Sachs’ opinion is not a recommendation as
to how any holder of Genesco’s common stock should vote
with respect to the merger. Pursuant to an engagement letter
dated April 20, 2007, between Genesco and Goldman Sachs,
Goldman Sachs is entitled to receive a transaction fee of 1.2%
of the aggregate consideration payable in the merger, or
approximately $18.5 million, minus an initial fee of
$250,000 that became payable upon execution of the engagement
letter, with one fourth of the transaction fee payable upon
execution of the merger agreement and the remainder of the
transaction fee payable upon the completion of the merger. See
“The Merger — Opinion of Goldman, Sachs &
Co.” beginning on page 28 and the opinion of Goldman
Sachs reproduced in its entirety as Annex C.
|
|
|
|
| |
•
|
Sources of Financing. In connection with the
merger, Finish Line will obtain the financing necessary to cause
the merger consideration to be paid out to Genesco’s
shareholders, to make any redemption payments made to holders of
issued and outstanding preferred stock of Genesco following the
merger, to refinance certain existing indebtedness of Genesco,
and to pay customary fees and expenses in connection with the
proposed merger, the financing arrangements and the related
transactions. Funding of the debt financing is subject to the
satisfaction of the conditions set forth in the commitment
letter pursuant to which the financing will be provided. Finish
Line has agreed to use its reasonable best efforts to arrange
the debt financing on the terms and conditions set forth in the
debt commitment letter. The following arrangements are in place
to provide, subject to the satisfaction of the conditions
provided in the commitment letter, the necessary financing for
the merger and related transactions, including the payment of
related transaction costs, charges, fees and expenses:
|
|
|
|
| |
•
|
new senior secured credit facilities in the aggregate amount of
$1.14 billion, consisting of a $690.0 million senior
secured term loan and a $450.0 million senior secured
revolving credit facility;
|
| |
| |
•
|
$700.0 million aggregate principal amount of debt
securities or, in lieu thereof, a senior unsecured bridge loan
facility in the amount of $700.0 million; and
|
| |
| |
•
|
cash and cash equivalents of approximately $11.0 million
held by Finish Line and its subsidiaries.
|
See “The Merger — Financing of the Merger”
beginning on page 40.
|
|
|
| |
•
|
Regulatory Approvals (see
page 40). Under the HSR Act, and the rules
promulgated thereunder by the Federal Trade Commission (the
“FTC”), the merger may not be completed until
notification and report forms have been filed with the FTC and
the Antitrust Division of the Department of Justice (the
“DOJ”), and the applicable waiting period has expired
or has been terminated. Genesco and Finish Line each filed
notification and report forms under the HSR Act with the FTC and
the Antitrust Division of the DOJ on July 17, 2007. If
Genesco and Finish Line do not receive a request for additional
information, the waiting period will expire at 11:59 p.m.
on August 16, 2007, if not terminated earlier.
|
|
|
|
| |
•
|
Tax Consequences. The merger will be a taxable
transaction for U.S. federal income tax purposes for
holders of Genesco common stock. Your receipt of cash in
exchange for your shares of Genesco common stock pursuant to the
merger generally will cause you to recognize gain or loss
measured by the difference, if any, between the cash you receive
pursuant to the merger (determined before the deduction of any
applicable withholding taxes) and your adjusted tax basis in
your shares of Genesco
|
5
|
|
|
| |
|
common stock. If you are a
non-U.S. holder
(as defined below) of Genesco common stock, the merger generally
will not be a taxable transaction to you under U.S. federal
income tax law unless you have certain connections to the United
States. Under U.S. federal income tax law, you will be
subject to information reporting on cash received pursuant to
the merger unless an exemption applies. Backup withholding may
also apply with respect to cash you receive pursuant to the
merger, unless you provide proof of an applicable exemption or a
correct taxpayer identification number and otherwise comply with
the applicable requirements of the backup withholding rules. You
should consult your own tax advisor for a full understanding of
how the merger will affect your particular tax consequences,
including federal, state, local
and/or
foreign taxes and, if applicable, the tax consequences of the
receipt of cash in connection with the cancellation of your
options to purchase shares of Genesco common stock
and/or your
shares of restricted stock. See “The Merger —
Material U.S. Federal Income Tax Consequences of the Merger
to Our Shareholders” beginning on page 48, which also
contains information regarding the potential tax consequences of
the merger or related transactions to our preferred shareholders.
|
|
|
|
| |
•
|
Dissenters’ Rights. Under Tennessee law,
holders of Genesco common stock do not have dissenters’
rights unless our common stock is delisted from the New York
Stock Exchange (the “NYSE”) and the Chicago Stock
Exchange (the “CHX”) prior to the completion of the
merger, which we do not currently anticipate. However, under
Tennessee law, holders of Genesco preferred stock who do not
vote in favor of approving the merger agreement will have the
right to be paid the “fair value” of their shares, if
the merger is completed, but only if they comply with all
requirements of Tennessee law, which are summarized in this
proxy statement. The right to dissent is subject to a number of
restrictions and technical requirements. Generally, in order to
exercise your dissenters’ rights, you must:
|
|
|
|
| |
•
|
Not vote in favor of the merger agreement; and
|
| |
| |
•
|
Prior to the vote on the merger agreement, notify us in writing
of your intent to demand payment for your shares if the merger
is completed.
|
In addition, you must not convert your shares of preferred stock
into common stock prior to the merger.
A dissenting shareholder will be entitled to payment only if
written notice of intent to demand payment is properly delivered
to Genesco before the vote on the merger is taken and the
shareholder does not vote in favor of the merger. You will
not protect your dissenters’ rights by merely voting
against the merger agreement. Additionally, under Tennessee law,
holders of the Employees’ Preferred will have the right to
be paid the “fair value” of their shares with respect
to the charter amendment proposal if the charter amendment
becomes effective, but only if they comply with the analogous
procedures and requirements stated above with respect to the
merger agreement proposal; provided, however, that holders of
Employees’ Preferred will only be entitled to one payment
with respect to their shares. See “Dissenters’
Rights” beginning on page 70 and the text of the
Tennessee dissenters’ rights statute reproduced in its
entirety as Annex D.
|
|
|
| |
•
|
Market Price of Genesco’s Common Stock (see
page 72). The closing sale price of Genesco
common stock on the NYSE on June 15, 2007, the last trading
date before the date of the merger agreement, was $49.60 per
share or a premium of 9.9%. The $54.50 per share to be paid
for each share of Genesco common stock pursuant to the merger
represents a premium of 48.7% to the closing price reported by
the NYSE on March 9, 2007, the last trading day prior to
market speculation about potential interest by Foot Locker, Inc.
in an acquisition of Genesco, a premium of 37.7% to the average
closing price reported by the NYSE for the three months prior to
March 9, 2007, and a premium of 50.0% to the average
closing price reported by the NYSE for the one year prior to
March 9, 2007.
|
6
QUESTIONS
AND ANSWERS ABOUT THE SPECIAL MEETING
The following questions and answers are intended to address
briefly some commonly asked questions regarding the special
meeting. These questions and answers do not address all
questions that may be important to you as a Genesco shareholder.
You should still carefully read the “Summary Term
Sheet” and the more detailed information contained
elsewhere in this proxy statement, the annexes to this proxy
statement and the documents referred to or incorporated by
reference in this proxy statement.
|
|
|
|
Q. |
|
When and where is the special meeting? |
|
|
|
|
A. |
|
The special meeting of shareholders of Genesco will be held on
Monday, September 17, 2007 at 11:00 a.m., local time, at
Genesco’s executive offices, Genesco Park, 1415
Murfreesboro Road, Nashville, Tennessee. |
|
|
|
|
Q. |
|
What matters will be voted on at the special meeting? |
| |
|
A. |
|
You will be asked to consider and vote on the following
proposals: |
| |
|
|
|
• to approve the merger agreement, as the same may be
amended from time to time;
|
| |
|
|
|
• to approve and adopt the charter amendment
permitting the redemption of the Employees’ Preferred after
the completion of the merger at the price to be paid per share
of Genesco’s common stock in the merger, or $54.50, without
interest, at Genesco’s option as the surviving corporation
following the merger;
|
| |
|
|
|
• to approve the adjournment of the special meeting,
if necessary, to solicit additional proxies if there are
insufficient votes at the time of the meeting to approve the
merger agreement or the charter amendment; and
|
| |
|
|
|
• to transact such other business that may properly
come before the special meeting or any adjournment or
postponement of the special meeting.
|
| |
|
Q. |
|
How does Genesco’s board of directors recommend that I
vote on the proposals? |
| |
|
A. |
|
Our board of directors unanimously recommend that you vote: |
| |
|
|
|
• “FOR” the proposal to approve the merger
agreement, as the same may be amended from time to time;
|
| |
|
|
|
• “FOR” the approval and adoption of the
charter amendment; and
|
| |
|
|
|
• “FOR” the adjournment proposal.
|
| |
|
Q. |
|
Who is entitled to vote at the special meeting? |
|
|
|
|
A. |
|
On August 6, 2007, the record date for determining who is
entitled to receive notice of and to vote at the special
meeting, the number of voting shares issued and outstanding and
the number of votes entitled to be cast were as follows: |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Votes per
|
|
|
|
|
|
Class of Capital Stock
|
|
No. of Shares
|
|
|
Share
|
|
|
Total Votes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subordinated Serial Preferred
Stock:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 1 ($2.30)
|
|
|
35,134
|
|
|
|
1
|
|
|
|
35,134
|
|
|
Series 3 ($4.75)
|
|
|
14,447
|
|
|
|
2
|
|
|
|
28,894
|
|
|
Series 4 ($4.75)
|
|
|
3,579
|
|
|
|
1
|
|
|
|
3,579
|
|
|
Subordinated Cumulative Preferred
Stock ($1.50)
|
|
|
30,017
|
|
|
|
1
|
|
|
|
30,017
|
|
|
Employees’ Preferred
|
|
|
59,989
|
|
|
|
1
|
|
|
|
59,989
|
|
|
Common Stock
|
|
|
22,788,798
|
|
|
|
1
|
|
|
|
22,788,798
|
|
|
|
|
|
|
|
The various classes of preferred stock and common stock will
vote together as a single group at the special meeting with
respect to all matters except the charter amendment. On the
charter amendment proposal, all classes of preferred stock,
except the Employees’ Preferred, will vote together with
the |
7
|
|
|
|
|
|
common stock and constitute one voting group, and the
Employees’ Preferred will constitute a second voting group
and will vote as a separate class. |
| |
|
|
|
Please note that space limitations may make it necessary to
limit attendance at the special meeting to shareholders. If you
attend, please note that you may be asked to present valid
picture identification. “Street name” holders will
need to bring a copy of a brokerage statement reflecting stock
ownership as of the record date. Cameras, recording devices and
other electronic devices are not permitted at the special
meeting. |
| |
|
Q. |
|
What vote is required for Genesco’s shareholders to
approve the merger agreement? |
| |
|
A. |
|
An affirmative vote of the holders of a majority of the votes
represented by the outstanding shares of our common stock and
our preferred stock, voting together as a single group, is
required to approve the merger agreement. |
| |
|
Q. |
|
What vote is required for Genesco’s shareholders to
approve and adopt the charter amendment? |
| |
|
A. |
|
The approval and adoption of the charter amendment requires that
the votes cast in favor of the charter amendment by holders of
all Genesco capital stock voting together as a single group,
excluding the Employees’ Preferred, exceed the votes cast
against the amendment by such holders and also requires the
affirmative approval of a majority of the outstanding shares of
the Employees’ Preferred voting as a separate group. |
| |
|
Q. |
|
What vote is required for Genesco’s shareholders to
approve the proposal to adjourn the special meeting, if
necessary, to solicit additional proxies to approve the merger
agreement or the charter amendment? |
| |
|
A. |
|
The proposal to adjourn the special meeting, if necessary, to
solicit additional proxies to approve the merger agreement or
the charter amendment requires that the votes cast in favor of
adjournment exceed the votes cast against adjournment. |
| |
|
Q. |
|
Who is soliciting my vote? |
| |
|
A. |
|
This proxy solicitation is being made and paid for by us. We
have retained Georgeson Inc. to assist in the solicitation. We
will pay Georgeson Inc. approximately $20,000 plus
out-of-pocket
expenses for its assistance. Our directors, officers and
employees may also solicit proxies by mail,
e-mail,
telephone, facsimile or by other means of communication. These
individuals will not be paid additional remuneration for their
efforts. We will also request brokers and other fiduciaries to
forward proxy solicitation materials to the beneficial owners of
shares of Genesco capital stock that the brokers and fiduciaries
hold of record. We will reimburse them for their reasonable
out-of-pocket
expenses. |
| |
|
Q. |
|
What do I need to do now? |
| |
|
A. |
|
Even if you plan to attend the special meeting, after carefully
reading and considering the information contained in this proxy
statement, if you hold your shares in your own name as the
shareholder of record, please complete, sign, date and return
the enclosed proxy card; submit a proxy using the telephone
number printed on your proxy card; or submit a proxy using the
Internet proxy submission instructions printed on your proxy
card. You can also attend the special meeting and vote, or
change your prior vote, in person. Do NOT enclose or return
your common stock certificate(s) with your
proxy. If you hold your shares in “street
name” through a broker, bank or other nominee, then you
received this proxy statement from the nominee, along with the
nominee’s proxy card which includes voting instructions and
instructions on how to change your vote. |
| |
|
Q. |
|
How do I vote? How can I revoke my vote? |
| |
|
A. |
|
You may cause your shares to be voted by signing and dating each
proxy card you receive and returning it in the enclosed prepaid
envelope, or as described below if you hold your shares in
“street name.” If you return your signed proxy card,
but do not mark the boxes showing how you wish your shares to be
voted, your shares will be voted “FOR” the proposal to
approve the merger agreement, as the same may be |
8
|
|
|
|
|
|
amended from time to time, “FOR” the approval and
adoption of the charter amendment, and “FOR” the
adjournment proposal. You have the right to revoke your proxy at
any time before the vote taken at the special meeting by taking
the following steps: |
| |
|
|
|
• if you hold your shares in your name as a
shareholder of record, by notifying us in writing at Corporate
Secretary, Genesco Inc., 1415 Murfreesboro Road, Nashville,
Tennessee 37217;
|
| |
|
|
|
• if you hold your shares in your name as a
shareholder of record, by attending the special meeting and
voting in person (your attendance at the meeting will not, by
itself, revoke your proxy; you must vote in person at the
meeting);
|
|
|
|
|
|
|
• if you hold your shares in your name as a
shareholder of record, by submitting a later-dated proxy card; or
|
|
|
|
|
|
|
• if you have instructed a broker, bank or other
nominee to vote your shares, by following the directions
received from your broker, bank or other nominee to change those
instructions.
|
| |
|
Q. |
|
Can I submit a proxy by telephone or electronically? |
| |
|
A. |
|
If you hold your shares in your name as a shareholder of record,
you may submit a proxy by telephone or electronically through
the Internet by following the instructions included with your
proxy card. |
| |
|
|
|
If your shares are held by your broker, bank or other nominee,
often referred to as held in “street name,” please
check your proxy card or contact your broker, bank or other
nominee to determine whether you will be able to provide voting
instructions by telephone or electronically. |
| |
|
Q. |
|
What do I do if I receive more than one proxy or set of
voting instructions? |
| |
|
A. |
|
If you hold shares both as a record holder and in “street
name,” or if your shares are otherwise registered
differently or you hold shares of more than one class or series
of our capital stock, you may receive more than one proxy
and/or set
of voting instructions relating to the special meeting. These
should each be returned separately in order to ensure that all
of your shares are voted. |
| |
|
Q. |
|
How are votes counted? |
| |
|
A. |
|
For the proposal to approve the merger agreement
(Proposal No. 1), you may vote FOR, AGAINST or
ABSTAIN. Abstentions will not be counted as votes cast or shares
voting on the proposal to approve the merger agreement, but will
count for the purpose of determining whether a quorum is
present. If you abstain, it will have the same effect as if you
vote against the approval of the merger agreement. In addition,
if your shares are held in the name of a broker, bank or other
nominee, your broker, bank or other nominee will not, under the
current NYSE rules, be entitled to vote your shares in the
absence of specific instructions. These non-voted shares,
commonly referred to as “broker non-votes,” will be
counted for purposes of determining a quorum, but will have the
same effect as a vote against the approval of the merger
agreement. |
| |
|
|
|
For the proposal to approve and adopt the charter amendment
(Proposal No. 2), you may vote FOR, AGAINST or
ABSTAIN, and your vote will be counted as described below. |
| |
|
|
|
• With respect to the Employees’ Preferred,
abstentions will not be counted as votes cast or shares voting
on the proposal to approve the merger agreement, but will count
for the purpose of determining whether a quorum is present. If
you abstain, it will have the same effect as if you vote against
the charter amendment. In addition, if your shares are held in
the name of a broker, bank or other nominee, your broker, bank
or other nominee will not, under the current NYSE rules, be
entitled to vote your shares in the absence of specific
instructions. Broker non-votes will be counted for purposes of
determining a quorum, but will have the same effect as a vote
against the approval of the charter amendment.
|
| |
|
|
|
• With respect to votes cast by all other holders of
Genesco capital stock, abstentions will be counted for the
purpose of determining whether a quorum is present, but will
have no effect on the vote to approve and adopt the charter
amendment, which requires that the votes cast in favor of the
matter exceed the votes cast against the matter. If your shares
are held in the name of a broker, bank or other nominee, your
broker, bank or other nominee will not, under the current NYSE
rules, be entitled to vote your shares in the absence of
specific instructions. Broker non-votes will be counted for the
purpose of
|
9
|
|
|
|
|
|
determining whether a quorum is present, but will have no effect
on the vote to approve and adopt the charter amendment with
respect to votes cast by all holders of Genesco capital stock
other than holders of the Employees’ Preferred. |
| |
|
|
|
For the proposal to adjourn the special meeting (Proposal
No. 3), if necessary, to solicit additional proxies to
approve the merger agreement or the charter amendment, you may
vote FOR, AGAINST or ABSTAIN. Abstentions and broker
non-votes will count for the purpose of determining whether a
quorum is present, but will have no effect on the vote to
adjourn the meeting, which requires that the votes cast in favor
of adjournment exceed the votes cast against such matter. If
your shares are held in the name of a broker, bank or other
nominee, your broker, bank or other nominee will be entitled to
vote your shares in the absence of specific instructions as this
matter is considered routine under the current NYSE rules. |
| |
|
|
|
If you sign your proxy card without indicating your vote, your
shares will be voted “FOR” the approval of the merger
agreement, as the same may be amended from time to time,
“FOR” the approval and adoption of the charter
amendment, and “FOR” the adjournment of the special
meeting, if necessary, to solicit additional proxies, and in
accordance with the recommendations of our board of directors on
any other matters properly brought before the special meeting
for a vote. |
| |
|
Q: |
|
Who will count the votes? |
| |
|
A: |
|
Either our corporate secretary or designee of our corporate
secretary, or a representative of our transfer agent
Computershare Investor Services, LLC, will count the votes and
act as an inspector of election. Questions concerning stock
certificates or other matters pertaining to your shares may be
directed to Paul Amante at Computershare Investor Services, LLC
at
(781) 575-2879. |
| |
|
Q. |
|
When is the merger expected to be completed? |
|
|
|
|
A. |
|
We are working toward completing the merger as soon as possible.
However, in order to complete the merger, we must obtain
shareholder approval and the other closing conditions set forth
in the merger agreement must be satisfied or waived. In
addition, Finish Line has advised Genesco that it currently
estimates that it will obtain the financing necessary to
consummate the merger pursuant to the terms of the commitment
letter during the third week of October 2007, but the expected
financing timeline could vary. Subject to the terms and
conditions of the merger agreement, Genesco expects the merger
to be consummated at that time. |
|
|
|
|
Q. |
|
Is the merger contingent upon the approval of the charter
amendment? |
| |
|
A. |
|
No. The merger may be consummated even if the charter
amendment is not approved. Our board of directors recommends,
however, that your vote “FOR” the charter amendment
proposal (Proposal No. 2). |
| |
|
Q. |
|
Should I send in my common stock certificates now? |
| |
|
A. |
|
No. After the merger is completed, you will be sent a
letter of transmittal with detailed written instructions for
exchanging your Genesco common stock certificates for the merger
consideration. |
| |
|
|
|
If your shares are held in “street name” by your
broker, bank or other nominee, you will receive instructions
from your broker, bank or other nominee as to how to effect the
surrender of your “street name” shares in exchange for
the merger consideration. Please do not send your
certificates in now. |
| |
|
Q. |
|
How do I convert my shares of preferred stock into shares of
common stock? |
| |
|
A. |
|
Except for the $1.50 Subordinated Cumulative Preferred Stock and
shares of Employees’ Preferred that are not fully paid,
each outstanding class and series of our preferred stock is
convertible into common stock at the holder’s option.
Generally, your right to convert your shares of preferred stock,
if applicable, may be exercised by surrendering the applicable
preferred stock certificates to our transfer agent,
Computershare Investor Services, LLC, for such purpose at 250
Royall Street, Canton MA 02021, attention: Corporate Actions,
Paul Amante, or to Genesco at its principal office at 1415
Murfreesboro Road, Nashville, Tennessee 37217, attention:
Corporate Secretary. Certificates surrendered for conversion
must be properly endorsed in blank or accompanied by proper
instruments of assignment. Questions regarding the conversion
process, including with respect to lost certificates and proper
assignment documentation, should be directed to Paul Amante at
Computershare Investor Services, LLC at
(781) 575-2879. |
10
|
|
|
|
Q. |
|
Does the Company recommend that I convert my preferred stock
prior to the merger? |
|
|
|
|
A. |
|
We are not making a recommendation as to whether you should
convert your preferred stock, if applicable. However, certain
considerations with respect to the preferred stock are set forth
for your reference under “The Merger — Preferred
Stock” beginning on page 38. You should consult your
financial and tax advisors regarding your decision whether to
convert your shares of preferred stock in advance of the merger. |
|
|
|
|
Q. |
|
How can I obtain additional information about Genesco? |
|
|
|
|
A. |
|
We will provide a copy of our Annual Report to shareholders
and/or our
Annual Report on
Form 10-K
for the year ended February 3, 2007, excluding certain of
its exhibits, and other filings, including our reports on
Form 10-Q,
which have been filed with the Securities and Exchange
Commission (the “SEC”) without charge to any
shareholder who makes an oral or written request to the
Corporate Secretary, Genesco Inc., 1415 Murfreesboro Road,
Nashville, Tennessee 37217, telephone:
(615) 367-7000.
Our Annual Report on
Form 10-K
and other SEC filings also may be accessed on the Internet at
http://www.sec.gov
or on the Investor Relations page of Genesco’s website at
http://www.genesco.com.
Our website address is provided as an inactive textual reference
only. The information provided on our website is not part of
this proxy statement and is not incorporated by reference. For a
more detailed description of how to obtain additional
information about Genesco, please refer to “Where You Can
Find More Information” beginning on page 77. |
|
|
|
|
Q. |
|
Who can help answer my questions? |
| |
|
A. |
|
If you need assistance in completing your proxy card or have
questions regarding the special meeting, please contact:
Georgeson Inc., 17 State Street, 10th Floor, New York, New
York 10004. Banks and brokers should call Georgeson at
(212) 440-9800.
All others should call Georgeson toll-free at
(866) 605-7510.
If your broker, bank or other nominee holds your shares, you can
also call your broker, bank or other nominee for additional
information. |
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This proxy statement, and the documents to which we refer you in
this proxy statement, contain forward-looking statements based
on estimates and assumptions. Forward-looking statements include
information concerning possible or assumed future results of
operations of Genesco, the expected completion and timing of the
merger and other information relating to the merger. There are
forward-looking statements throughout this proxy statement,
including, without limitation, under the headings
“Summary
Term Sheet,” “The Merger,” “Charter
Amendment,” “Projected Financial Information,”
and in statements containing the words
“believes,”
“plans,” “expects,” “anticipates,”
“intends,” “estimates” or other similar
expressions. For each of these statements, we claim the
protection of the safe harbor for forward-looking statements
contained in Section 21E of the United States Securities
Exchange Act of 1934, as amended (the
“Exchange Act”).
You should be aware that forward-looking statements involve
known and unknown risks and uncertainties. Although we believe
that the expectations reflected in these forward-looking
statements are reasonable, we cannot assure you that the actual
results or developments we anticipate will be realized, or even
if realized, that they will have the expected effects on our
business or operations. These forward-looking statements speak
only as of the date on which the statements were made and we
undertake no obligation to publicly update or revise any
forward-looking statements made in this proxy statement or
elsewhere as a result of new information, future events or
otherwise. In addition to other factors and matters contained or
incorporated in this document, we believe the following factors
could cause actual results to differ materially from those
discussed in the forward-looking statements:
|
|
|
| |
•
|
the occurrence of any event, change or other circumstances that
could give rise to the termination of the merger agreement,
including a termination that under certain circumstances could
require us to pay Finish Line a $46 million termination fee
and up to $10 million for reasonable, actual and documented
out-of-pocket
expenses and fees;
|
11
|
|
|
| |
•
|
the outcome of any legal proceedings that have been or may be
instituted against us and others relating to the merger
agreement;
|
| |
| |
•
|
the failure of the merger to close for any reason, including the
inability to complete the merger due to the failure to obtain
shareholder approval or the failure to satisfy other conditions
to the completion of the merger, or the failure of Finish Line
to obtain the necessary debt financing arrangements set forth in
the commitment letter received in connection with the merger,
and the risk that any failure of the merger to close may
adversely affect our business and the price of our common stock;
|
| |
| |
•
|
the potential adverse effect on our business, properties and
operations of any covenants (including negative operational
covanants) we agreed to in the merger agreement;
|
| |
| |
•
|
risks that the proposed transaction diverts management’s
attention and disrupts current plans and operations, and
potential difficulties in employee retention as a result of the
merger;
|
| |
| |
•
|
the effect of the announcement of the merger and actions taken
in anticipation of the merger on our business relationships,
operating results and business generally;
|
| |
| |
•
|
the impact of the substantial indebtedness incurred to finance
the completion of the merger;
|
| |
| |
•
|
the amount of the costs, fees, expenses and charges related to
the merger and the actual terms of certain financings that will
be obtained for the merger; and
|
|
|
|
| |
•
|
other risks detailed in our current filings with the SEC,
including our most recent filings on
Forms 8-K,
10-Q and
10-K. See
“Where You Can Find More Information” beginning on
page 77.
|
Many of the factors that will determine our future results are
beyond our ability to control or predict. In light of the
significant uncertainties inherent in the forward-looking
statements contained herein, readers should not place undue
reliance on forward-looking statements, which reflect our views
only as of the date of this proxy statement. We cannot guarantee
any future results, levels of activity, performance or
achievements. The statements made in this proxy statement
represent our views as of the date of this proxy statement, and
it should not be assumed that the statements made herein remain
accurate as of any future date. Moreover, we assume no
obligation to update forward-looking statements or update the
reasons that actual results could differ materially from those
anticipated in forward-looking statements, except as required by
law.
12
THE
PARTIES TO THE MERGER
Genesco
Genesco is a Tennessee corporation and is headquartered in
Nashville, Tennessee. Our principal offices are located at
Genesco Park, 1415 Murfreesboro Road, Nashville, Tennessee and
our telephone number is
(615) 367-7000.
Genesco is a leading retailer of branded footwear and licensed
and branded headwear and a wholesaler of branded footwear, with
net sales for its fiscal year ended
February 3, 2007
(
“fiscal year 2007”) of $1.5 billion. During
fiscal year 2007, Genesco operated five reportable business
segments (not including corporate): Journeys Group, comprised of
the Journeys, Journeys Kidz and Shi by Journeys retail footwear
chains, catalog and
e-commerce
operations; Underground Station Group, comprised of the
Underground Station and Jarman retail footwear chains and
e-commerce
operations; Hat World Group, comprised of the Hat World, Lids,
Hat Shack, Hat Zone, Head Quarters, Cap Connection and Lids Kids
retail headwear chains and
e-commerce
operations; Johnston & Murphy Group, comprised of
Johnston & Murphy retail operations, catalog and
e-commerce
operations and wholesale distribution; and Licensed Brands,
comprised primarily of
Dockers
®
footwear, sourced and marketed under a license from Levi
Strauss & Company. Genesco also designs, sources,
markets and distributes footwear under its own
Johnston & Murphy brand and under the licensed
Dockers
®
brand to over 1,000 retail accounts in the United States,
including a number of leading department, discount, and
specialty stores.
For a more detailed description of the business and properties
of Genesco, see our Annual Report on
Form 10-K
for fiscal year 2007, which is
incorporated by reference herein,
or visit our
website at
www.genesco.com. Our
website address is
provided as an inactive textual reference only. The information
provided on our
website is not part of this proxy statement and
is not
incorporated by reference. Genesco’s common stock is
listed on the NYSE (Symbol: GCO) and the CHX. See
“Where
You Can Find More Information” beginning on page 77.
Finish
Line
The Finish Line, Inc. (which we refer to as Finish Line) is an
Indiana corporation and is headquartered in Indianapolis,
Indiana. Finish Line’s principal offices are located at
3308 North Mitthoeffer Road,
Indianapolis,
Indiana 46235 and its
telephone number is
(317) 899-1022.
Finish Line operates under the Finish Line, Man Alive and Paiva
brand names and is one of the largest mall-based specialty
retailers in the United States. Finish Line currently operates
694 Finish Line stores in 47 states and online, 93 Man
Alive stores in 19 states and 15 Paiva stores in
10 states and online. Finish Line’s common stock is
listed on the NASDAQ Global Select Market (Symbol: FINL).
For a more detailed description of the business and properties
of Finish Line, see its Annual Report on
Form 10-K
for its fiscal year ended
March 3, 2007, or visit its
website at
www.finishline.com. Finish Line’s
website is
provided as an inactive textual reference only. The information
set forth in the above-referenced Annual Report and the
information provided on Finish Line’s
website are not part
of this proxy statement and are not
incorporated by reference.
Merger
Sub
Headwind, Inc. (which we refer to as Merger Sub) is a Tennessee
corporation that was formed solely for the purpose of completing
the proposed merger. Upon the completion of the proposed merger,
Merger Sub will cease to exist and Genesco will continue as the
surviving corporation. Merger Sub is wholly-owned by Finish Line
and has not engaged in any business except as contemplated by
the merger agreement. The principal office address of Merger Sub
is Headwind, Inc.,
c/o The
Finish Line, Inc., 3308 North Mitthoeffer Road,
Indianapolis,
Indiana 46235 and its telephone number is
(317) 899-1022.
13
THE
SPECIAL MEETING
This proxy statement is furnished in connection with the
solicitation of proxies by our board of directors in connection
with the special meeting of our shareholders relating to the
merger and the charter amendment.
Date,
Time and Place of the Special Meeting
The special meeting is scheduled to be held as follows:
Time: 11:00 a.m., local time
Place: Genesco Park, 1415 Murfreesboro Road,
Nashville, Tennessee
Proposals
to be Considered at the Special Meeting
At the special meeting, you will be asked to vote on a proposal
to approve the merger agreement, as the same may be amended from
time to time (Proposal No. 1). If our shareholders
fail to approve the merger agreement, the merger will not occur.
A copy of the merger agreement is attached as Annex A to
this proxy statement, and we encourage you to read it carefully
and in its entirety. At the special meeting, you will also be
asked to vote on the charter amendment
(Proposal No. 2). A copy of the charter amendment is
attached as Annex B to this proxy statement, and we
encourage you to read it carefully and in its entirety. You will
also be asked to approve the adjournment of the special meeting,
if necessary, to solicit additional proxies if there are
insufficient votes at the time of the meeting to approve the
merger agreement or the charter amendment
(Proposal No. 3).
Record
Date; Voting Rights; Quorum; Vote Required for
Approval
We have fixed the close of business on
August 6, 2007 as
the record date for the special meeting, and only holders of
record of Genesco capital stock on the record date are entitled
to vote at the special meeting. On that date, the number of
voting shares outstanding and the number of votes entitled to be
cast were as follows:
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Votes per
|
|
|
|
|
|
Class of Capital Stock
|
|
No. of Shares
|
|
|
Share
|
|
|
Total Votes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subordinated Serial Preferred
Stock:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 1 ($2.30)
|
|
|
35,134
|
|
|
|
1
|
|
|
|
35,134
|
|
|
Series 3 ($4.75)
|
|
|
14,447
|
|
|
|
2
|
|
|
|
28,894
|
|
|
Series 4 ($4.75)
|
|
|
3,579
|
|
|
|
1
|
|
|
|
3,579
|
|
|
Subordinated Cumulative Preferred
Stock ($1.50)
|
|
|
30,017
|
|
|
|
1
|
|
|
|
30,017
|
|
|
Employees’ Subordinated
Convertible Preferred Stock
|
|
|
59,989
|
|
|
|
1
|
|
|
|
59,989
|
|
|
Common Stock
|
|
|
22,788,798
|
|
|
|
1
|
|
|
|
22,788,798
|
|
The presence in person or representation by proxy of
shareholders entitled to cast a majority of the votes of all
issued and outstanding shares of Genesco capital stock entitled
to be voted shall constitute a quorum for the purpose of
considering each of the proposals except the charter amendment
proposal. A quorum for the charter amendment proposal requires
the presence in person or representation by proxy of
shareholders entitled to cast (1) a majority of the votes
of all issued and outstanding shares of Genesco capital stock,
except the Employees’ Preferred, entitled to be voted and
(2) a majority of the shares of all issued and outstanding
shares of the Employees’ Preferred entitled to vote. Shares
of Genesco capital stock represented at the special meeting but
not voted, including shares of Genesco capital stock for which
proxies have been received but for which shareholders have
abstained, will be treated as present at the special meeting for
purposes of determining the presence or absence of a quorum for
the transaction of all business. In the event that a quorum for
the proposal to approve the merger agreement is not present at
the special meeting, it is expected that the meeting will be
adjourned to solicit additional proxies; provided, however, that
in the event a quorum is present with respect to such proposal
and there are sufficient votes to approve the merger agreement
at the
14
date the special meeting is initially convened, the shareholders
will take final action at that meeting to approve the merger
agreement, regardless of whether the meeting is adjourned to a
later date solely for further consideration of the charter
amendment proposal.
If your shares are registered in your name or if you have stock
certificates, they will not be voted if you do not vote at the
meeting in person or as described below under
“— Submission and Revocation of Proxies.” If
your shares are held in “street name” through a
nominee (such as a bank, broker or other nominee) and you do not
provide voting instructions to the nominee that holds your
shares, the nominee has the discretionary authority to vote your
unvoted shares on certain matters. A “broker non-vote”
arises when a broker, financial institution or other holder of
record that holds shares in street name does not receive
instructions from a beneficial owner and does not have the
discretionary authority to vote on a particular item. Under
current NYSE rules, brokers have discretionary authority to vote
on the proposal regarding adjournment. Under current NYSE rules,
brokers do not have discretionary authority to vote on the
proposal regarding the merger agreement or the proposal
regarding the charter amendment. We encourage you to provide
voting instructions to your bank, broker or other nominee. Doing
so will ensure that your shares will be voted in the manner you
desire.
Approval of the merger agreement
(Proposal No. 1) requires the affirmative vote of
the holders of a majority of the votes represented by the
outstanding shares of our common stock and our preferred stock,
voting together as a single group. For the proposal to approve
the merger agreement, you may vote FOR, AGAINST or ABSTAIN.
Abstentions and broker non-votes will not be counted as votes
cast or shares voting on the proposal to approve the merger
agreement, but will count for the purpose of determining whether
a quorum is present. Abstentions and broker non-votes will
have the same effect as a vote against the approval of the
merger agreement.
As of
August 6, 2007, the record date, the directors and
executive officers of Genesco held and were entitled to vote, in
the aggregate, shares of Genesco common stock, representing
approximately 2.5% of the outstanding votes of Genesco capital
stock. As of the record date, the directors and executive
officers held no shares of Genesco preferred stock. If our
directors and executive officers vote their shares in favor of
approving the merger agreement, approximately 2.5% of the
outstanding votes of Genesco capital stock will have voted for
the proposal to approve the merger agreement. This means that
additional holders of approximately 10,893,548 votes, or
approximately 47.5%, of all votes entitled to be cast at the
special meeting would need to vote for the proposal to approve
the merger agreement in order for it to be approved.
For the proposal to approve and adopt the charter amendment
(Proposal No. 2), holders may vote FOR, AGAINST
or ABSTAIN. There are two separate voting groups:
|
|
|
| |
•
|
Approval and adoption of the charter amendment requires the
affirmative approval of a majority of the outstanding shares of
the Employees’ Preferred entitled to vote on such matter.
Abstentions by holders of Employees’ Preferred and broker
non-votes will not be counted as votes cast or shares voting on
the proposal to approve the charter amendment, but will count
for the purpose of determining whether a quorum is present.
Abstentions and broker non-votes by holders of
Employees’ Preferred and broker non-votes will have the
same effect as a vote against the adoption and approval of the
charter amendment.
|
|
|
|
| |
•
|
Approval and adoption of the charter amendment also requires
that the votes cast in favor of the matter by holders of all
Genesco capital stock, excluding the Employees’ Preferred,
exceed the votes cast against such matter. Abstentions and
broker non-votes will count for the purpose of determining
whether a quorum is present but do not count in the voting
results and have no effect on the result of this vote.
|
If our directors and executive officers vote their shares in
favor of the approval and adoption of the charter amendment,
approximately 2.5% of the outstanding votes of Genesco capital
stock, excluding the Employees’ Preferred, will have voted
for the proposal to approve and adopt the charter amendment.
This means that additional holders of approximately
10,863,554 votes, or approximately 47.5%, of all votes
entitled to be cast at the special meeting by this voting group
would need to vote for the proposal to approve and
15
adopt the charter amendment, in addition to the holders of a
majority of all votes entitled to be cast by the Employees’
Preferred, in order for it to be approved and adopted.
The outcome of the vote with respect to the charter amendment
proposal will not impact the outcome of the vote with respect to
the merger agreement, and the approval of either proposal is
independent of, and not conditioned upon the approval of, the
other proposal. The charter amendment, however, will not take
effect unless the merger is consummated. The merger is not
contingent upon the approval of the charter amendment.
The proposal to adjourn the special meeting
(Proposal No. 3), if necessary, to solicit additional
proxies to approve the merger agreement or the charter amendment
requires that the votes cast in favor of the matter exceed the
votes cast against the matter. For the proposal to adjourn the
special meeting, if necessary, to solicit additional proxies,
you may vote FOR, AGAINST or ABSTAIN. Abstentions and
broker non-votes will count for the purpose of determining
whether a quorum is present but do not count in the voting
results and have no effect on the result of the vote on the
adjournment proposal.
Submission
and Revocation of Proxies
Shareholders of record may submit proxies by mail. Shareholders
who wish to submit a proxy by mail should mark, date, sign and
return the proxy card in the envelope furnished. If you hold
your shares in your name as a shareholder of record, you may
submit a proxy by telephone or electronically through the
Internet by following the instructions included with your proxy
card. Shareholders who hold shares beneficially through a
nominee (such as a bank or broker) may be able to submit a proxy
by mail, or by telephone or the Internet if those services are
offered by the nominee.
Proxies received at any time before the special meeting, and not
revoked or superseded before being voted, will be voted at the
special meeting. Where a specification is indicated by the
proxy, it will be voted in accordance with the specification. If
you sign your proxy card without indicating your vote, your
shares will be voted “FOR” the approval of the merger
agreement, as the same may be amended from time to time,
“FOR” the approval and adoption of the charter
amendment, and “FOR” the adjournment of the special
meeting, if necessary, to solicit additional proxies, and in
accordance with the recommendations of our board of directors on
any other matters properly brought before the special meeting
for a vote.
You have the right to revoke your proxy at any time before the
vote taken at the special meeting by taking the following
actions:
|
|
|
| |
•
|
if you hold your shares in your name as a shareholder of record,
by notifying us in writing at Corporate Secretary, Genesco Inc.,
1415 Murfreesboro Road, Nashville, Tennessee 37217;
|
| |
| |
•
|
if you hold your shares in your name as a shareholder of record,
by attending the special meeting and voting in person (your
attendance at the meeting will not, by itself, revoke your
proxy; you must vote in person at the meeting);
|
| |
| |
•
|
if you hold your shares in your name as a shareholder of record,
by submitting a later-dated proxy card; or
|
| |
| |
•
|
if you have instructed a broker, bank or other nominee to vote
your shares, by following the directions received from your
broker, bank or other nominee to change those instructions.
|
Please do not send in your common stock certificates with
your proxy card. When the merger is completed, a separate
letter of transmittal will be mailed to holders of Genesco
common stock that will enable you to receive the merger
consideration in exchange for your stock certificates.
Rights of
Shareholders Who Object to the Merger Agreement or the Charter
Amendment Proposals
Holders of Genesco common stock are not entitled to
dissenters’ rights under Tennessee law in connection with
the merger unless our common stock is delisted from the NYSE and
the CHX prior to completion of the merger, which we do not
currently anticipate. However, holders of Genesco preferred
stock are entitled to dissenters’ rights under Tennessee
law in connection with the merger. Holders of the
16
Employees’ Preferred are also entitled to dissenters’
rights under Tennessee law in connection with the charter
amendment. With respect to the holders of Genesco preferred
stock, Tennessee law permits you to dissent from the merger and
to have the fair value of your stock appraised by a court and
paid to you in cash. To do this, you must follow certain
procedures, including: (1) filing certain notices with us;
and (2) refraining from voting your shares in favor of the
merger. In addition, you must not convert your shares of
preferred stock into Genesco common stock before the merger. If
you properly dissent from the merger, your shares of Genesco
preferred stock cannot be converted into Genesco common stock
prior to the merger and will not be entitled to receive the
price per share to be paid to holders of Genesco common stock in
the merger. If you properly dissent from the merger, your shares
will not be redeemed by the surviving corporation following the
merger. Your only right will be to receive the appraised value
of your shares in cash. The procedures for holders of
Employees’ Preferred to dissent from the charter amendment
are substantially similar; provided, however, that holders of
Employees’ Preferred will in no event be entitled to more
than one payment with respect to their shares.
A dissenting shareholder will be entitled to payment only if
written notice of intent to demand payment is properly delivered
to Genesco before the vote on the merger agreement (or the
charter amendment, as applicable) is taken and the shareholder
does not vote in favor of the merger agreement (or the charter
amendment, as applicable). A holder of preferred stock will not
protect their dissenters’ rights by merely voting against
the merger agreement (or the charter amendment, as applicable).
Your failure to follow exactly the procedures specified under
Tennessee law will result in the loss of your dissenters’
rights. See “Dissenters’ Rights” beginning on
page 70 and the text of the Tennessee dissenters’
rights statute reproduced in its entirety as Annex D.
Solicitation
of Proxies
This proxy solicitation is being made and paid for by Genesco on
behalf of our board of directors. We have retained Georgeson
Inc. to assist in the solicitation. We will pay Georgeson Inc.
approximately $20,000 plus
out-of-pocket
expenses for their assistance. Our directors, officers and
employees may also solicit proxies by mail,
e-mail,
telephone, facsimile or other means of communication. These
individuals will not be paid additional remuneration for their
efforts. We will also request brokers and other fiduciaries to
forward proxy solicitation material to the beneficial owners of
shares of Genesco capital stock that the brokers and fiduciaries
hold of record. We will reimburse them for their reasonable
out-of-pocket
expenses. In addition, we will indemnify Georgeson Inc. against
any losses arising out of that firm’s proxy soliciting
services on our behalf.
Other
Business
We are not currently aware of any business to be acted upon at
the special meeting other than the matters discussed in this
proxy statement. Under our
bylaws, business transacted at the
special meeting is limited to the purposes stated in the notice
of the special meeting, which is provided at the beginning of
this proxy statement. If other matters do properly come before
the special meeting, or at any adjournment or postponement of
the special meeting, we intend that shares of Genesco capital
stock represented by properly submitted proxies will be voted in
accordance with the recommendations of our board of directors.
Questions
and Additional Information
If you have more questions about the merger or how to submit
your proxy, or if you need additional copies of this proxy
statement or the enclosed proxy card or voting instructions,
please call our proxy solicitor, Georgeson Inc., toll-free at
(888) 605-7510
(banks and brokerage firms call collect at
(212) 440-9800),
or contact Genesco in writing at our principal executive offices
at Corporate Secretary, Genesco Inc., 1415 Murfreesboro Road,
Nashville,
Tennessee 37217, or by telephone at
(615) 367-7000.
17
THE
MERGER
This discussion of the merger is qualified by reference to
the merger agreement, which is attached to this proxy statement
as Annex A. You should read the entire merger agreement
carefully as it is the legal document that governs the
merger.
Background
of the Merger
On
January 19, 2007, our chief executive officer, Hal
Pennington, received an unsolicited call from Matthew Serra, the
chief executive officer of Foot Locker, Inc. (
“Foot
Locker”). During this conversation, Mr. Serra
indicated that Foot Locker was interested in pursuing a
negotiated acquisition of Genesco and that he believed Foot
Locker could potentially offer a purchase price of $48.00 to
$50.00 per share for our outstanding common stock, subject to
satisfactory due diligence. Mr. Pennington informed
Mr. Serra that Genesco was committed to its strategic plan
and that management believed in the value that could be created
for our shareholders by executing this plan.
During the week of
January 22, 2007, Mr. Pennington
contacted each of our board members individually to advise them
of the call from Mr. Serra. During the week, one board
member received a call from an investment banker indicating that
a letter was being prepared by Foot Locker to send to our board
outlining a proposal, but we received no such letter.
On
February 5, 2007, Mr. Pennington received another
call from Mr. Serra. Mr. Serra did not discuss a
specific proposal on this call and indicated that his purpose
was to follow up on his previous conversation of
January 19, 2007. Mr. Serra indicated again that Foot
Locker intended to pursue a negotiated acquisition of us on a
friendly basis. Mr. Pennington told Mr. Serra that his
views about such an acquisition had not changed since the prior
call. On
February 8, 2007, our directors participated in a
telephone call conducted by Mr. Pennington for the purpose
of advising them of the February 5 call from Mr. Serra.
During the first several weeks of March 2007, various media
outlets began reporting on rumors and speculation about a
potential tender offer for the outstanding shares of Genesco by
Foot Locker. On
March 19, 2007, our directors participated
in a telephone call conducted by Mr. Pennington for the
purpose of informing the board of the media reports and of
management’s concerns regarding certain key employees who
were anxious about their job security in light of the Foot
Locker rumors and speculation. Mr. Pennington told the
board that management believed the concerns could be reduced if
change-in-control
severance agreements were provided for those key employees. He
explained that the proposed agreements would be substantially
similar to the existing agreements with our executive officers,
which are described under
“The Merger — Interests
of Genesco’s Directors and Executive Officers in the
Merger,” provided that these agreements would generally
provide for a severance payment equal to an amount calculated
for each such employee by multiplying one times the sum of the
employee’s base salary, annual bonus and certain employee
benefits amounts. It was the consensus of the board members on
the call that such agreements would not present a material
deterrent to any future acquisition of Genesco and that the
execution of such agreements was in the best interests of our
shareholders in order to encourage such employees to remain with
us during the existing period of uncertainty and in the event an
unsolicited takeover attempt was announced. Our board then acted
by unanimous written consent, effective
March 22, 2007,
approving the
change-in-control
severance agreements for certain key employees.
As part of the ongoing evaluation of our business, our board and
senior management regularly evaluate our long-term strategic
alternatives and prospects for continued operations as an
independent company. This evaluation took on renewed emphasis in
light of the media speculation and our belief that Foot Locker
might make a hostile tender offer for the acquisition of Genesco
or otherwise attempt to elect its own slate of directors at our
annual meeting of shareholders on
June 27, 2007.
Accordingly, in a telephone call on
March 22, 2007, it was
the consensus of participating directors that management should
engage Goldman Sachs as our financial advisor to assist us in
preparing for any potential acquisition proposal, proxy contest,
or any other attempt to acquire control of Genesco. The board
also asked management to update the forecasts set forth in
management’s annual five-year financial plan to facilitate
Goldman Sachs’ financial analysis and to assist the board
in evaluating any potential acquisition proposal.
18
On
April 4, 2007, Mr. Pennington received a letter
setting forth a purportedly confidential proposal from Foot
Locker for the acquisition of all of the outstanding shares of
common stock of Genesco for $46.00 per share in cash.
Mr. Serra called Mr. Pennington immediately before
sending the letter, indicating that Foot Locker might be able to
“go higher” than the proposed price per share if
increased value could be demonstrated through a due diligence
process. The proposal set forth in the letter was not subject to
any financing condition but was subject to due diligence.
Mr. Pennington provided this letter to all of our directors.
On
April 5, 2007, our directors participated in a telephone
call conducted by Mr. Pennington for the purpose of
discussing the Foot Locker letter. Representatives of Bass
Berry & Sims PLC (
“Bass Berry”), our outside
corporate counsel, and Goldman Sachs participated on this call.
A representative of Bass Berry reviewed the board’s
fiduciary duties in considering and responding to the proposal.
After discussing the proposal with their legal and financial
advisors, it was the consensus of the participating directors
that the proposal should be formally considered at a special
meeting of our board to be held on
April 20, 2007. In
preparation for the April 20 board meeting, the board asked
Goldman Sachs to review management’s most current financial
forecasts and consider our strategic alternatives to enhance
shareholder value, including the Foot Locker proposal.
Mr. Pennington delivered to Foot Locker on
April 5,
2007 a letter confirming receipt of its proposal and indicating
that we would provide a response in due course.
On
April 19, 2007, Mr. Serra sent a letter to
Mr. Pennington expressing his disappointment in the lack of
a substantive response to his April 4 letter and indicating that
Foot Locker was considering disclosing the April 4 and April 19
letters publicly before the market opened on
April 20,
2007. Mr. Serra also stated in his letter that Foot Locker
would welcome the opportunity to conduct due diligence and might
be prepared to increase its offer if increased value could be
demonstrated. Lehman Brothers Inc. (
“Lehman
Brothers”), the financial advisor for Foot Locker,
contacted Goldman Sachs that day to discuss the April 19 letter.
Goldman Sachs indicated to Lehman Brothers that our board was
meeting to consider the proposal on
April 20, 2007 and that
it was our preference that Foot Locker not disclose the letters
until the board held its meeting and we could respond to
Mr. Serra’s April 4 letter. Lehman Brothers indicated
on that call that it could not commit that Foot Locker would
refrain from making the letters public. On the morning of
April 20, 2007, Foot Locker made the April 4 and April 19
letters public. On
April 20, 2007, we issued a press
release announcing that we had received, and that our board
intended to consider with the assistance of Goldman Sachs, the
Foot Locker proposal set forth in the April 4 letter.
On
April 20, 2007, Bob Dennis, our president and chief
operating officer, received a call from Alan Cohen, the chief
executive officer of Finish Line, regarding Finish Line’s
potential interest in a business combination transaction.
Mr. Dennis referred Mr. Cohen to Goldman Sachs in case
Finish Line desired to pursue its interest further.
On
April 20, 2007, our board met to consider the Foot
Locker proposal set forth in the April 4 letter. Representatives
of Bass Berry and Goldman Sachs attended the meeting, together
with certain members of management. At the meeting,
Mr. Pennington discussed the various media articles about a
potential acquisition proposal from Foot Locker since the April
5 board call. Mr. Pennington described the discussions
between Goldman Sachs and Lehman Brothers, which preceded the
public announcement by Foot Locker of its proposal. A
representative of Bass Berry reviewed with the board their
confidentiality obligations, stock trading limitations and our
no-comment and document retention policies, as well as their
fiduciary duties and responsibilities in the context of
considering the Foot Locker proposal. Management presented an
update of financial results for the first fiscal quarter to date
and a general business and operating plan update, together with
management’s preliminary five-year financial forecasts.
This discussion included a detailed explanation of the process
thus far undertaken to update the forecasts and certain
operational and financial assumptions underlying the forecasts.
Management responded to questions regarding the risks and
opportunities that may impact management’s forecasts and
assumptions and confirmed their belief that the financial
forecasts were reasonable financial projections based on
currently available information, and that these forecasts were
provided to Goldman Sachs for purposes of performing its
financial analysis. See
“The Merger — Projected
Financial Information — Initial Projections”
beginning on page 36.
19
At the April 20 board meeting, representatives of Goldman Sachs
discussed with our board the retail merger and acquisition
market and reported on the discussions they had had with Lehman
Brothers in connection with the Foot Locker proposal. They also
reviewed with the board the calls they had received from parties
other than Foot Locker expressing potential interest in
acquiring us. Indications of interest had been received from six
private equity financial sponsors. Representatives of Goldman
Sachs then discussed their financial analysis of our strategic
alternatives. In addition to the Foot Locker and other sale
possibilities, these strategic alternatives included a leveraged
recapitalization, the sale of a material division or assets, the
acquisition of assets, and the execution of our current
strategic plan. Representatives of Goldman Sachs discussed the
benefits and issues relating to each of the strategic
alternatives. They then discussed the Foot Locker proposal in
detail, including the discussions with Lehman Brothers, as well
as the indications of interest which had been received from
other parties. The board and its financial and legal advisors
then discussed the possible contents of a response letter to,
and potential communication strategies with, Foot Locker and the
media, should our board determine to reject the Foot Locker
proposal as not in the best interests of our shareholders.
At the April 20 board meeting, the board also discussed the
strategic alternatives available to us and the next steps we
might take to explore further these strategic alternatives.
Among the next steps considered was the contacting of the third
parties who had indicated to us or to Goldman Sachs an interest
in pursuing a business combination transaction with us. The
board also evaluated Foot Locker’s April 4 proposal in
light of the financial analyses of our other strategic
alternatives and in light of the current market price of our
common stock. The board determined that while it had confidence
in our long-term strategic plan and, accordingly, we were not
for sale, it was in the best interests of our shareholders to
engage in a feasibility process to gauge the potential interest
in a business combination transaction with us and to allow the
board to consider in light of that interest the strategic
alternatives available to us, including the alternative of
remaining an independent public company and executing our
long-term strategic plan. After the representatives of Goldman
Sachs were excused from the meeting, further discussion ensued
and the board unanimously voted to reject the Foot Locker
proposal as not in the best interests of our shareholders. The
board then discussed further the general nature of the response
letter to Foot Locker and our next steps, and determined to
instruct Goldman Sachs to contact the parties who had previously
contacted us or Goldman Sachs in order to determine their level
of interest in a business combination with us. The board also
approved the sharing of confidential information with such
parties, subject to the execution of customary confidentiality
and standstill agreements, and limited informational meetings
with management in order to facilitate this process. Bass Berry
noted at this time that management should not discuss personal
arrangements during these meetings or otherwise show favoritism
to any particular participant and advised that representatives
of Goldman Sachs should be present at these meetings.
On
April 23, 2007, Mr. Pennington sent a letter to
Mr. Serra indicating that our board was aware of its
fiduciary duties to consider an acquisition proposal that fairly
values
our company and that, after consulting with Goldman
Sachs, had unanimously rejected Foot Locker’s April 4
proposal as not being in the best interests of our shareholders.
We also issued a
press release announcing this response.
On
April 23, 2007, UBS Securities LLC (
“UBS”),
Finish Line’s financial advisor, contacted Goldman Sachs to
discuss Finish Line’s interest in pursuing a transaction
with us.
Beginning the week of
April 23, 2007 and through
May 8, 2009, as directed by our board, Goldman Sachs
approached Finish Line and the six potential private equity
financial sponsors that had previously indicated a potential
interest in considering a transaction with us and provided
confidentiality and standstill agreements to each of these
potential purchasers. Following execution of confidentiality and
standstill agreements by four of the six potential financial
sponsor purchasers as well as Finish Line, pursuant to which
these parties were subject to a customary
“standstill”
provision of at least 18 months in duration (during which
period these parties were required to refrain, unless
specifically requested by us in writing, from seeking to acquire
control of us, directly or indirectly, including by tender
offer, merger proposal, proxy contest or other attempts to
influence or control our board, management or the policies of
our company), informational presentations were made by senior
members of our management, with the participation of Goldman
Sachs, to
20
each of these potential purchasers. Non-public information
packages were also distributed to these parties in conjunction
with the management presentations.
On
April 23, 2007 and
April 25, 2007, Lehman Brothers
contacted Goldman Sachs and indicated Foot Locker’s
continuing interest in acquiring us and their interest in
meeting with our senior management to discuss their interest.
Goldman Sachs indicated to Lehman Brothers that
Mr. Pennington would be willing to meet with Mr. Serra
solely for this purpose, accompanied by representatives of
Lehman Brothers and Goldman Sachs. A meeting was scheduled to
occur on
May 4, 2007. On
April 26, 2007, Lehman
Brothers indicated to Goldman Sachs that Foot Locker desired to
receive confidential information in connection with its due
diligence review and would be willing to execute a
confidentiality agreement as a condition to the receipt of this
information. Goldman Sachs indicated that any sharing of
confidential information would also be subject to the execution
by Foot Locker of a customary standstill agreement.
On
May 2, 2007, our board held a regularly scheduled
meeting. Representatives of Goldman Sachs and Bass Berry
participated in this meeting, as well as certain members of
senior management. At this meeting, senior management reviewed
for the board our anticipated financial results for the first
quarter. In particular, management discussed the financial
performance of our Underground Station retail stores in detail
and described a potential plan to close or convert our worst
performing urban stores, primarily in our Underground Station
chain. Mr. Pennington then reviewed the management
presentations that had taken place to date in connection with
the board’s instruction to explore the feasibility of the
sale alternative. Bass Berry reviewed the board’s fiduciary
responsibilities in connection with its consideration of that
strategic alternative. Thereafter, representatives of Goldman
Sachs discussed their contacts with the interested potential
purchasers and possible next steps, including the coordination
of second round management presentations with interested
potential purchasers. Representatives of Goldman Sachs also
discussed other strategic alternatives available to us.
On
May 4, 2007, Mr. Pennington met with
Mr. Serra, together with representatives of Goldman Sachs
and Lehman Brothers, to allow Mr. Serra to explain Foot
Locker’s interest in acquiring us. No specific terms or
prices were discussed at this meeting. Mr. Serra discussed
his perception of strategic benefits flowing from Foot
Locker’s proposed acquisition of Genesco.
Mr. Pennington agreed that an acquisition would afford
benefits to Foot Locker’s shareholders, but noted that his
responsibilities as chief executive officer and a director of
Genesco were to Genesco’s shareholders. In that regard,
Mr. Pennington again advised Mr. Serra that our
management had confidence in our strategic plan and its
potential to deliver value to our shareholders. He stated that
he believed that our board understood its fiduciary duties and
would pursue the best interests of Genesco’s shareholders,
and that he would promptly report to the board regarding his
meeting with Mr. Serra.
On
May 7, 2007, Finish Line executed a confidentiality and
standstill agreement with us as discussed above, which included
an 18 month standstill period as well as an agreement to
give Finish Line the benefit of any more favorable standstill
provisions agreed to by us with other strategic process
participants. On
May 8, 2007, our senior management
conducted its initial management presentation for Finish Line.
Representatives of Goldman Sachs attended this meeting.
On
May 9, 2007, our board met telephonically.
Representatives of Goldman Sachs and Bass Berry attended this
meeting, as well as certain members of senior management.
Management updated the board on the preliminary financial
results for the first quarter. Management also presented its
plan for closing certain of our worst-performing urban stores,
and the financial impact of this plan. Mr. Pennington and
Goldman Sachs then reviewed with the board the parties for which
management had made presentations and the initial feedback
received by Goldman Sachs following these meetings. In this
review, Mr. Pennington discussed his meeting with
Mr. Serra on May 4. Representatives of Goldman Sachs
indicated that they had heard nothing from Lehman Brothers on
behalf of Foot Locker since the May 4 meeting with
Mr. Serra. They also noted that one private equity
financial sponsor indicated that it was not interested in moving
forward in the process as result of that party’s concern
about whether it was worth the time and expense to commit to
this process in light of Foot Locker’s publicly expressed
interest, but that the three remaining private equity financial
sponsors stated that they would like to move forward and
indicated that their preliminary review of value was a per share
price in the range of $50.00 to $52.00. They also advised the
board that they had received from UBS, on behalf of Finish Line,
a positive response from Finish Line following the initial
management
21
presentation and its preliminary view of value in excess of
$51.00 per share and that UBS had expressed confidence in Finish
Line’s ability to finance an all-cash transaction.
At the May 9 board meeting, the board discussed the level of
interest of each potential purchaser, including Foot Locker, and
the strategic alternatives available to us other than a sale
transaction. Representatives of Goldman Sachs discussed with the
board the strategic alternatives available to us, including
various stock repurchase plans and the sale of a material
division or assets. The board discussed the various strategic
alternatives, as well as the risks associated with each
alternative. After the representatives of Goldman Sachs left the
call, the board discussed the alternative of moving toward a
more definitive indication of interest with one or more of the
private equity financial sponsors and Finish Line and a
potential process for doing so. The board also expressed an
interest in further analysis of the recapitalization
alternatives. The board excused management from the meeting and
continued in executive session to discuss the matters presented
during the meeting. The board determined to ask management to
review for presentation at a future meeting its business plan
and financial forecasts in light of the recapitalization
alternatives to determine if the assumptions continued to be
reasonable and appropriate. After further discussion, the board
determined to continue to refine and to pursue all strategic
alternatives reasonably available to us and instructed Goldman
Sachs to contact Foot Locker regarding their signing a
confidentiality agreement containing a standstill provision on
the same terms as the one signed by Finish Line in order to
allow Foot Locker to perform its requested due diligence. In
addition, Goldman Sachs was instructed to contact the potential
purchasers with a continuing interest to allow them to conduct a
more detailed due diligence investigation, including second
meetings with management, in order to obtain more definitive
indications of interest.
On
May 10, 2007, Lehman Brothers called Goldman Sachs to
discuss the Foot Locker due diligence requests and the need for
a confidentiality and standstill agreement with Foot Locker. On
May 14, 2007, Lehman Brothers sent a due diligence request
list to Goldman Sachs on behalf of Foot Locker and Bass Berry
sent the form of confidentiality and standstill agreement to
counsel for Foot Locker. Representatives of Bass Berry and Foot
Locker’s counsel discussed the terms of the confidentiality
and standstill agreement over the next several weeks. Lehman
Brothers also contacted Goldman Sachs periodically during this
period to express Foot Locker’s continuing interest in
pursuing a transaction and to discuss the terms of the
confidentiality and standstill agreement. On
May 14, 2007,
we opened an electronic data room for all potential purchasers
which had executed the confidentiality and standstill agreement.
On
May 14, 2007, one of the three remaining interested
private equity financial sponsor groups withdrew from the
process over concern, similar to other potential private equity
financial sponsors that had withdrawn previously, about whether
it was worth the time and expense to commit further to this
process in light of Foot Locker’s publicly expressed
interest. Beginning the week of
May 21, 2007, senior
management conducted its second round of management
presentations for the two remaining interested private equity
financial sponsor groups as well as with Finish Line.
On
May 18, 2007, another private financial sponsor executed
a confidentiality and standstill agreement for the purpose of
partnering, with our consent, with one of the financial sponsors
who previously met with management in an effort to facilitate
the likelihood of receiving a bid from this combined private
equity financial sponsor team, which we refer to as Party X.
On
May 24, 2007, Mr. Serra sent a letter to
Mr. Pennington setting forth a proposal to acquire all of
the outstanding common stock of Genesco for $51.00 per share,
conditioned upon confirmatory due diligence and the acceptance
by us of the form of confidentiality and standstill agreement
attached to the letter. The form of confidentiality and
standstill agreement proposed by Foot Locker was significantly
different from the form Bass Berry previously provided to
Foot Locker’s counsel and the form other potential
purchasers had executed, and included a limited standstill
provision of only three months. The standstill provision
contained in the agreements with all other potential purchasers
was broader and more restrictive in application and was
effective for a period of at least 18 months.
On
May 29, 2007, our board met at the offices of Bass
Berry. Representatives of Goldman Sachs and Bass Berry attended
this meeting, as well as certain members of senior management.
Bass Berry discussed the board’s fiduciary duties and
responsibilities, including those applicable to considering and
responding to the
22
May 24 Foot Locker proposal. Mr. Pennington described the
terms of Foot Locker’s May 24 proposal and the recent
discussions between the respective financial and legal advisors
for Foot Locker and Genesco, including with respect to the
confidentiality and standstill agreement. Mr. Pennington
and representatives of Goldman Sachs then gave an overview of
the second round of diligence meetings senior management had
conducted over the prior two weeks in accordance with the
board’s directive to further explore the feasibility of
sale alternatives. Representatives from Goldman Sachs then
reviewed their financial analysis of our strategic alternatives.
The board discussed with representatives of Goldman Sachs the
benefits and issues relating to each of the strategic
alternatives, which were generally the same as discussed at the
April 20 meeting. During this presentation, management reviewed
its revised financial projections, indicating that the revised
numbers reflected the most recent information available to
management. See
“The Merger — Projected Financial
Information — Updated Projections” beginning on
page 37. The board discussed with representatives of
Goldman Sachs how a sale process could be structured in the
current context to maximize shareholder value should the board
choose to pursue the sale alternative. The Goldman Sachs
representatives were excused from the meeting and Bass Berry
summarized the board’s fiduciary duties and
responsibilities in connection with its determination of how to
respond to the May 24 Foot Locker proposal, as well as in
connection with its consideration of whether to undertake a
formal sale process. After this discussion, the board
unanimously determined to instruct Goldman Sachs and Bass Berry,
with the assistance of management as appropriate, to help us
refine and pursue all available strategic alternatives to
maximize shareholder value, including the possible sale of our
company. It was also determined that, in order to help ensure a
fair and level playing field for all process participants and in
light of the potential chilling effect on the process should
Foot Locker be allowed to participate without a standstill,
Goldman Sachs and Bass Berry were instructed to encourage Foot
Locker to participate in the process but that participation was
contingent on Foot Locker’s agreement to accept the form of
confidentiality and standstill agreement that other potential
purchasers had executed, subject to reasonably acceptable
modifications of the previously executed forms of
confidentiality and standstill agreement (including the
board’s agreement to reduce the requested standstill period
from 18 months to six months). Additionally, in light of
our agreement to give Finish Line the benefit of any more
favorable standstill provisions agreed to by us with other
strategic process participants, Finish Line’s standstill
agreement would need to be waived if Foot Locker did not have a
standstill, which would remove a critical aspect of our
board’s ability to control the process and create
uncertainty as to whether either of these strategic participants
would put their best offer forward as part of the sale process.
Goldman Sachs was also instructed to continue to assess and
refine, with management’s assistance, our other strategic
alternatives so that the board would be fully prepared and
informed when and if it was presented with a definitive
transaction for approval. The board also discussed with its
advisors and management the making of a public announcement
regarding the May 24 Foot Locker proposal. Bass Berry advised
the board that the next steps would include the distribution of
a draft definitive
contract for each potential purchaser to
respond to and indicated that any negotiated
contract would be
subject to board approval.
On
May 30, 2007, our board met telephonically.
Representatives of Goldman Sachs and Bass Berry attended this
meeting, as well as certain members of senior management. The
primary purpose of the meeting was for the board to consider
whether to accept or reject Foot Locker’s May 24 proposal
to acquire us for $51.00 per share in cash so that we could
fully communicate the board’s position with respect to the
May 24 Foot Locker proposal, both to the public and to Foot
Locker. Bass Berry updated the board on the status of the
negotiations regarding the confidentiality and standstill
agreement with Foot Locker, indicating that Foot Locker was
still not willing to sign the confidentiality and standstill
agreement in the form presented, and as proposed to be modified,
by us. Bass Berry summarized the modifications from the form
executed by other potential purchasers which had been proposed
to Foot Locker, including the reduced standstill period.
Representatives of Goldman Sachs then discussed the May 24 Foot
Locker proposal that Goldman Sachs had previously reviewed with
the board and the fact that the board had, at its meeting the
prior day, authorized a process to pursue strategic
alternatives, including a possible sale of
our company, as well
as the possibility that this process would lead to a transaction
proposal offering a higher price to our shareholders. Goldman
Sachs responded to questions during this discussion.
Mr. Pennington then reviewed drafts of a proposed press
release and a letter to Mr. Serra regarding the
board’s decision to reject the May 24 proposal should the
board so determine in light of the process authorized at the May
29 board meeting. After responding to questions,
23
Goldman Sachs updated the board on discussions with the
remaining process participants, which at that point included
Party X and Finish Line, and the next steps which would be taken
in this process. Goldman Sachs noted that Finish Line had shown
the most interest among the two remaining participants and that
Finish Line had indicated that it believed it would be in a
position to finalize a proposal within two weeks and was willing
to use its best efforts to work with us to meet that timeline.
After discussion, the board unanimously determined, after
consultation with representatives of Goldman Sachs, to reject
the May 24 Foot Locker proposal as not in the best interests of
our shareholders, and to instruct management to carry out the
communication plans discussed earlier in the meeting.
On
May 31, 2007, we issued a
press release, concurrent with
our first quarter earnings release, announcing our receipt of
the May 24 Foot Locker proposal, indicating our rejection of the
proposal as not in the best interests of our shareholders and
announcing the board’s determination to explore, with the
assistance of Goldman Sachs, strategic alternatives to maximize
shareholder value, including a possible sale of Genesco. Later
that day, Foot Locker publicly announced it was no longer
pursuing its May 24 proposal. Also on that day, upon the request
of Finish Line through UBS, Bass Berry sent an initial form of
merger agreement to Gibson Dunn & Crutcher LLP,
outside corporate counsel for Finish Line.
From the period from
June 5, 2007 through
June 16,
2007, the respective advisors of Genesco and Finish Line
negotiated the terms of the proposed merger agreement as well as
the related debt financing commitment letter. Finish Line was
also given access during this period to additional documents
upon its request and was allowed to meet telephonically with
members of our management for purposes of completing their due
diligence. Party X was also given additional documents during
this period. Documents provided to all parties were generally
made available in the electronic data room.
On
June 11, 2007, Finish Line verbally conveyed through UBS
a definitive proposal at $54.00 per share of our common stock in
cash and indicated that a financing commitment letter from UBS
Loan Finance LLC and UBS Securities LLC was finalized in all
material respects. See
“The Merger — Financing of
the Merger” beginning on page 40. Over the course of
the next two days, the representatives of the parties continued
to negotiate the terms of the merger agreement, including the
price and whether we should reimburse Finish Line for its
expenses in addition to the
break-up fee
in the event the merger agreement is terminated under certain
circumstances, the
“company material adverse effect”
definition and a related termination right, required consents as
a condition to closing, the
“knowledge” definition and
certain negative operational covenants during the pre-closing
period, among other terms, as well as the debt financing
commitment letter. On
June 13, 2007, Finish Line indicated
its best and final offer of $54.50 per share in cash, which
increase in price was expressly subject to our agreement to
Finish Line’s expense reimbursement proposal, and indicated
that it was substantially done with its due diligence and
prepared to execute a definitive merger agreement.
We and our representatives continued to work with Finish Line to
finalize the merger agreement and the debt financing commitment
letter over the course of the next two days, which were in
substantially final form, subject to the respective board
approvals, the night of
June 15, 2007. Party X had not
provided a definitive proposal or indicated any significant
continuing interest through this point and therefore we did not
request that Party X submit a final bid for our board’s
consideration at the meeting to consider the Finish Line
proposal.
On
June 15, 2007, Messrs. Pennington and Dennis had
preliminary general discussions with Alan Cohen, Finish
Line’s chief executive officer, regarding potential roles
with the combined company, but no specific arrangements or terms
were proposed or accepted.
On
June 16, 2007, our board met telephonically for the
primary purpose of receiving an update regarding the results of
the Company’s review of its strategic alternatives,
including the acquisition proposal from Finish Line.
Representatives of Goldman Sachs and Bass Berry attended this
meeting, as well as certain members of senior management. A
representative of Bass Berry reviewed with the board their
applicable fiduciary duties and responsibilities in the context
of the present situation. Representatives of Goldman Sachs
reviewed the process that we had engaged in to assess our
strategic alternatives following Foot Locker’s initial
proposal on
April 4, 2007, including the contacts made with
potential buyers of Genesco and their related due diligence
efforts. They indicated that Finish Line was the party in the
process that displayed the strongest interest in pursuing a
transaction and that among the other initial interested parties
only Party X remained potentially
24
interested but that this party was not as actively engaged.
Representatives of Goldman Sachs confirmed that they had not
received any additional indication of interest from Foot Locker
following Foot Locker’s public withdrawal of its May 24
proposal. The board discussed with representatives of Goldman
Sachs and Bass Berry the scope and reasonableness of the process
conducted by us. The representatives of Goldman Sachs noted that
the process was conducted following the public disclosure of the
Foot Locker proposal and that Goldman Sachs had contacted all
parties who had expressed interest in pursuing a transaction
with us. Bass Berry then provided an overview of the terms of
the proposed Finish Line merger agreement, and the related
proposed debt financing commitment, drafts of which had been
previously provided to the board together with a detailed
summary prepared by Bass Berry. Members of the board asked
questions regarding the foregoing, including with respect to the
“fiduciary out” provision, the
break-up fee
and expense reimbursement provisions, financing conditions,
solvency and other matters. Bass Berry indicated that Finish
Line would not agree to a transaction without the proposed
break-up fee
equal to 3.1% of the equity value (or $46 million) together
with an agreement to reimburse up to $10 million in
documented reasonable expenses of Finish Line in the event the
agreement were to be terminated under certain circumstances.
Bass Berry indicated that the expense reimbursement provision
was negotiated extensively and that Finish Line’s agreement
to raise its offer to $54.50 was conditioned on our accepting
the expense reimbursement provision. Bass Berry indicated its
belief that the terms of the transaction were reasonable under
the circumstances in order to attract a proposal which was in
the best interests of the shareholders and reflected a
reasonable course of action under the circumstances to secure
the highest price reasonably available.
On
June 17, 2007, our board met at the offices of Bass
Berry for the primary purpose of considering the Finish Line
proposal. Representatives of Goldman Sachs and Bass Berry
attended this meeting, as well as certain members of senior
management. Following confirmation of the Finish Line board
approval of the proposed transaction and their receipt of the
executed financing commitment letter, a representative of Bass
Berry reviewed with the board their applicable fiduciary duties
and responsibilities. Representatives of Goldman Sachs then
presented their financial analysis with respect to us, the
proposed merger and certain other available alternatives for
enhancing shareholder value. See
“The Merger —
Opinion of Goldman, Sachs & Co.” beginning
on page 28 for a description of the presentation of Goldman
Sachs. The board considered the $54.50 per share proposal by
Finish Line compared to the potential stock price appreciation
assumed (based on management’s assumptions as to future
financial performance) with respect to our other available
alternatives for enhancing shareholder value (and the execution
and other risks associated with each alternative), including a
leveraged recapitalization
and/or the
sale of a material division or assets of
the company. Management
stated that that they did not believe there was an actionable or
otherwise reasonably available company or asset for us to
acquire that would create the value associated with the Finish
Line proposal.
Bass Berry then reviewed in detail the proposed terms of the
merger agreement, including the provisions relating to the
payment of termination fees and expense reimbursement, the
disclosure schedules to the merger agreement, and the debt
financing commitment. Following further discussion, the board
requested that Goldman Sachs provide its view regarding the
fairness from a financial point of view of the $54.50 per share
in cash to be received by holders of our common stock pursuant
to the proposed merger agreement. Representatives of Goldman
Sachs then rendered an oral opinion, subsequently confirmed by
delivery of a written opinion dated
June 17, 2007, that, as
of that date, and subject to the matters and assumptions set
forth in the opinion, the $54.50 per share in cash to be
received by the holders of outstanding shares of our common
stock pursuant to the merger agreement was fair, from a
financial point of view, to such holders. The full text of the
written opinion of Goldman Sachs, which sets forth the
assumptions made, procedures followed, matters considered and
limitations on the review undertaken in connection with such
opinion, is attached as Annex C to this proxy statement.
The representatives of Goldman Sachs were then excused from the
meeting and Mr. Pennington presented the views of
management regarding the proposed transaction, concluding with
management’s recommendation that the Finish Line proposal
be approved. Mr. Pennington then provided the board a
current business and financial update. Questions were asked
regarding Mr. Pennington’s recommendation and the
basis for such recommendation, including as to the viability of
other strategic alternatives available to us. At this point, the
25
representatives of management and the non-independent members of
the board were excused from the meeting so the independent
members of the board could discuss the proposed transaction in
executive session. The remaining directors discussed the
transaction, the recommendation of management and the
presentation by representatives of Goldman Sachs. Management,
the non-independent board members and the representatives of
Goldman Sachs were then invited to rejoin the meeting. After
discussion, the board unanimously adopted and approved the
merger agreement and the transactions contemplated by the merger
agreement, and unanimously determined that the merger agreement
and the transactions contemplated by the merger agreement are
advisable and in the best interests of
the Company and its
shareholders and are fair to our shareholders. Our board further
directed management to include in this proxy statement their
recommendation that our shareholders vote for the approval of
the merger agreement and the consummation of the merger.
The merger agreement was executed by the parties on
June 17, 2007, following our board meeting. Before the open
of the stock market on
June 18, 2007, we issued a joint
press release with Finish Line announcing the transaction.
Reasons
for the Merger; Recommendation of Our Board of
Directors
In reaching its decision to approve the merger agreement and to
recommend that our shareholders approve the merger agreement,
our board of directors consulted with management, our financial
advisor, Goldman Sachs, and our outside corporate legal counsel,
Bass Berry. Our board of directors considered a number of
factors, including, without limitation, the following
potentially positive factors in support of the merger:
|
|
|
| |
•
|
its belief that the merger was more favorable to our
shareholders than any other alternative reasonably available to
us and our shareholders. The board of directors considered
possible alternatives to the sale of our company, including
continuing to operate on a stand-alone basis, pursuing potential
acquisitions, engaging in a leveraged recapitalization
(including additional share repurchases)
and/or
divesting a division or other significant assets, and the risks
(including execution risks) and uncertain returns associated
with these alternatives, each of which the board of directors
determined not to pursue when compared to the opportunity of our
shareholders to realize the merger consideration in cash in
connection with the merger;
|
| |
| |
•
|
the historical market prices of the Genesco common stock, and
the fact that the $54.50 per share to be paid for each share of
Genesco common stock pursuant to the merger represents: a
premium of 48.7% to the closing price reported by the NYSE on
March 9, 2007, the last trading day prior to market
speculation about Foot Locker’s potential interest in
acquiring Genesco, a premium of 37.7% to the average closing
price reported by the NYSE for the three months prior to
March 9, 2007, and a premium of 50.0% to the average
closing price reported by the NYSE for the one year prior to
March 9, 2007;
|
| |
| |
•
|
the public awareness of the Foot Locker proposal and our
strategic alternative review process which it believed allowed
all parties with legitimate interest in pursuing a combination
transaction with us to contact Goldman Sachs or us regarding
such interest, and the sale process we conducted with the
assistance of Goldman Sachs and Bass Berry, which involved
engaging in discussions with approximately seven parties that
had expressed interest in considering a transaction with us, and
that the final price proposed by Finish Line as a result of this
sale process was the highest price that we had received for the
acquisition of our company, and represented an increase of $3.50
(or approximately 6.9%) per share over the final conditional
Foot Locker proposal prior to Foot Locker’s public
withdrawal of such proposal;
|
| |
| |
•
|
its belief that the cash consideration of $54.50 per share was
likely the most favorable financial terms that could be obtained
from Finish Line, and that further negotiation could have caused
Finish Line to abandon the transaction;
|
| |
| |
•
|
the financial presentation of Goldman Sachs described below
under “The Merger — Opinion of Goldman,
Sachs & Co.,” and its opinion, dated
June 17, 2007, to our board of directors, to the effect
|
26
|
|
|
| |
|
that, as of June 17, 2007 and based upon and subject to the
factors and assumptions set forth in the opinion, the $54.50 per
share in cash to be received by the holders of outstanding
shares of our common stock pursuant to the merger agreement was
fair, from a financial point of view, to such holders (see
“The Merger — Opinion of Goldman,
Sachs & Co.” and Annex C to this proxy
statement); and
|
|
|
|
| |
•
|
the terms of the merger agreement, including without limitation:
|
|
|
|
| |
a.
|
the absence of a financing condition to the consummation of the
merger, the limited number and nature of the conditions to the
obligations of Finish Line and Merger Sub to consummate the
merger, and the limited risk of non-satisfaction of the
conditions, including that for purposes of the merger agreement
a “company material adverse effect” for Genesco does
not include events, circumstances, developments or changes
resulting from the numerous circumstances or events as described
under “The Merger Agreement — Representations and
Warranties;”
|
| |
| |
b.
|
the ability of our board of directors, under certain
circumstances, to change its recommendation that our
shareholders vote in favor of the approval of the merger
agreement;
|
| |
| |
c.
|
the provisions of the merger agreement that allow us, under
certain circumstances, to furnish information to and conduct
negotiations with respect to certain proposals by third parties,
and, upon the payment to Finish Line of a termination fee of
$46 million and reimbursement of up to $10 million of
Finish Line’s out-of-pocket expenses and fees, to terminate
the merger agreement to accept a third party proposal;
|
|
|
|
| |
d.
|
the conclusion of the board of directors that both the
$46 million termination fee (and the circumstances when the
fee is payable) and the requirement to reimburse Finish Line for
certain expenses, up to a limit of $10 million, in the
event that the merger agreement is terminated as a result of
certain circumstances (see “The Merger
Agreement — Termination Fees”), were reasonable
in light of the benefits of the merger, the additional $.50 per
share in purchase price we were able to obtain in connection
with the negotiation of the expense reimbursement provision, the
sale process conducted by Genesco with the assistance of Goldman
Sachs, the conditioning by Finish Line of their proposal on our
acceptance of these provisions, and commercial practice; and
|
|
|
|
| |
e.
|
the favorable debt commitment letter obtained by Finish Line,
including the absence of “market outs,” and Finish
Line’s obligation under the merger agreement to use
reasonable best efforts to arrange and consummate the debt
financing.
|
The board of directors also considered and balanced against the
potentially positive factors the following potentially negative
factors concerning the merger:
|
|
|
| |
•
|
the risk that the merger might not be completed;
|
| |
| |
•
|
the fact that our shareholders will not participate in any
future earnings or growth of Genesco or the combined company
following the merger and will not benefit from any future
appreciation in value of Genesco or the combined company
following the merger;
|
| |
| |
•
|
the restrictions on our ability to solicit or engage in
discussions or negotiations with a third party regarding other
proposals and the requirement that Genesco pay Finish Line a
$46 million termination fee and up to $10 million in
expenses in order for the board of directors to accept a third
party proposal;
|
| |
| |
•
|
the merger consideration consists of cash, and gains will
therefore be taxable to our holders of our common stock for
U.S. federal income tax purposes;
|
| |
| |
•
|
the risk of diverting management focus and resources from other
strategic opportunities and from operational matters while
working to implement the merger, and the possibility of employee
disruption and attrition associated with the pending merger;
|
27
|
|
|
| |
•
|
if the merger is not completed, the potential adverse effect of
the public announcement of the merger on our business, including
our significant customers, suppliers, vendors and other key
relationships, our ability to attract and retain key personnel
and our overall competitive position; and
|
| |
| |
•
|
the fact that the holders of our common stock do not have any
appraisal rights under Tennessee law.
|
During its consideration of the transaction with Finish Line,
our board of directors was also aware that some of our directors
and executive officers may have interests in the merger that may
be different than or in addition to those of our shareholders
generally, described under “The Merger —
Interests of Directors and Executive Officers in the
Merger.”
After taking into account all of the factors set forth above, as
well as others, the board of directors determined that the
potentially positive factors outweighed the potentially negative
factors and that the merger agreement and the merger are
advisable and fair and in the best interests of Genesco and our
shareholders. Our board of directors has unanimously approved
the merger agreement and the merger and recommends that our
shareholders vote “FOR” the approval of the merger
agreement at the special meeting.
This discussion of the information and factors considered and
given weight by our board of directors is not intended to be
exhaustive but is believed to address the material information
and factors considered by our board of directors. In view of the
number and variety of these factors, our board of directors did
not find it practicable to make specific assessments of, or
otherwise assign relative weights to, the specific factors and
analyses considered in reaching its determination. The
determination to approve the merger agreement and the
transactions contemplated thereby, including the merger, was
made after consideration of all of the factors and analyses as a
whole. In addition, individual members of our board of directors
may have given different weights to different factors.
Opinion
of Goldman, Sachs & Co.
Goldman Sachs rendered its oral opinion, which was subsequently
confirmed in writing, to our board of directors that, as of
June 17, 2007, and based upon and subject to the factors
and assumptions set forth in the opinion, the $54.50 per share
in cash to be received by the holders of the outstanding shares
of Genesco common stock pursuant to the merger agreement was
fair, from a financial point of view, to such holders.
The full text of the written opinion of Goldman Sachs, dated
June 17, 2007, which sets forth the assumptions made,
procedures followed, matters considered and limitations on the
review undertaken in connection with the opinion, is attached as
Annex C to this proxy statement. Goldman Sachs provided its
opinion for the information and assistance of the board of
directors of Genesco in connection with its consideration of the
merger. Goldman Sachs’ opinion is not a recommendation as
to how any holder of our common stock should vote with respect
to the merger.
In connection with rendering the opinion described above and
performing its related financial analyses, Goldman Sachs
reviewed, among other things:
|
|
|
| |
•
|
the merger agreement;
|
| |
| |
•
|
annual reports to shareholders and Annual Reports on
Form 10-K
of Genesco for the five fiscal years ended February 3, 2007;
|
| |
| |
•
|
certain interim reports to shareholders and Quarterly Reports on
Form 10-Q
of Genesco;
|
| |
| |
•
|
certain other communications from Genesco to its shareholders;
and
|
| |
| |
•
|
certain internal financial analyses and forecasts for Genesco
prepared by its management.
|
Goldman Sachs also held discussions with members of our senior
management regarding their assessment of our past and current
business operations, financial condition, and future prospects.
In addition, Goldman Sachs reviewed the reported price and
trading activity for our common stock, compared certain
financial and stock market information for Genesco with similar
information for certain other companies, the securities of
28
which are publicly traded, reviewed the financial terms of
certain recent business combinations in the footwear, apparel,
and retail industries specifically and in other industries
generally and performed such other studies and analyses, and
considered such other factors, as it considered appropriate.
Goldman Sachs relied upon and assumed, without assuming any
responsibility for independent verification, the accuracy and
completeness of all of the financial, accounting, legal, tax and
other information provided to, discussed with or reviewed by it.
Goldman Sachs assumed that the internal financial analyses and
forecasts for Genesco prepared by our management were reasonably
prepared on a basis reflecting the best currently available
estimates and judgments of our management. In addition, Goldman
Sachs did not make an independent evaluation or appraisal of the
assets and liabilities (including any contingent, derivative or
off-balance-sheet assets and liabilities) of Genesco or any of
our
subsidiaries, nor was any evaluation or appraisal of the
assets or liabilities of Genesco or any of our
subsidiaries
furnished to Goldman Sachs. Goldman Sachs did not express any
opinion as to the impact of the transaction on the solvency or
viability of Genesco or Finish Line or the ability of Genesco or
Finish Line to pay its obligations when they come due. Goldman
Sachs’ opinion does not address the underlying business
decision of Genesco to engage in the transaction or the relative
merits of the transaction as compared to any alternative
business strategies that might be available to Genesco. Goldman
Sachs’ opinion is necessarily based on economic, monetary,
market and other conditions as in effect on, and the information
made available to it as of, the date of the opinion, or
June 17, 2007.
The following is a summary of the material financial analyses
delivered by Goldman Sachs to our board of directors in
connection with rendering the opinion described above. The
following summary, however, does not purport to be a complete
description of the financial analyses performed by Goldman
Sachs, nor does the order of analyses described represent
relative importance or weight given to those analyses by Goldman
Sachs. Some of the summaries of the financial analyses include
information presented in tabular format. The tables must be read
together with the full text of each summary and are alone not a
complete description of Goldman Sachs’ financial analyses.
Except as otherwise noted, the following quantitative
information, to the extent that it is based on market data, is
based on market data as it existed on or before
June 17,
2007 and is not necessarily indicative of current market
conditions.
Historical
Stock Trading Analysis
In addition, Goldman Sachs analyzed the consideration to be
received by the holders of
the Company’s common stock
pursuant to the merger agreement in relation to the market price
of our common stock on
June 15, 2007, the last trading day
prior to announcement of the transaction,
March 9, 2007,
the last trading day prior to market speculation that Genesco
may be acquired by Foot Locker following a
March 8, 2007
Foot Locker conference call during which management of Foot
Locker discussed a desire to grow through acquisitions; and the
three-month and one-year average closing market prices of our
common stock as of
March 9, 2007 as well as the 52-week
high and low closing prices of our common stock as of
March 9, 2007. For purposes of its analysis, Goldman Sachs
referred to the closing price per share of our common stock of
$36.66 on
March 9, 2007 as the
“undisturbed
price.”
This analysis indicated that the price per share to be paid to
our common shareholders pursuant to the merger agreement
represented:
|
|
|
| |
•
|
a premium of 9.9% based on the close of business market price of
$49.60 per share on June 15, 2007;
|
| |
| |
•
|
a premium of 48.7% based on the undisturbed close of business
market price of $36.66 per share on March 9, 2007;
|
| |
| |
•
|
a premium of 37.7% based on the three month average market price
as of March 9, 2007 of $39.59 per share;
|
| |
| |
•
|
a premium of 50.0% based on the one year average market price
per share as of March 9, 2007 of $36.33 per share;
|
29
|
|
|
| |
•
|
a premium of 24.7% based on the latest 52-week high market price
as of March 9, 2007 of $43.72 per share; and
|
| |
| |
•
|
a premium of 113.7% based on the latest 52-week low market price
as of March 9, 2007 of $25.50 per share.
|
Selected
Companies Analysis
Goldman Sachs reviewed and compared certain financial
information for Genesco to corresponding financial information,
ratios and public market multiples for the following publicly
traded corporations in the footwear and teen retailing
industries:
| |
|
|
|
Footwear Retailers
|
|
Teen Retailers
|
|
|
|
• Brown Shoe
Company, Inc.
|
|
• Abercrombie
& Fitch Co.
|
|
• DSW
Inc.
|
|
• Aéropostale,
Inc.
|
|
• The Finish
Line, Inc.
|
|
• American
Eagle Outfitters, Inc.
|
|
• Foot
Locker, Inc.
|
|
• The
Buckle, Inc.
|
|
• Payless
Shoesource, Inc.
|
|
• Hot Topic,
Inc.
|
|
• Shoe
Carnival, Inc.
|
|
• Pacific
Sunwear of California, Inc.
|
|
|
|
• Tween
Brands, Inc.
|
|
|
|
• Urban
Outfitters, Inc.
|
|
|
|
• The Wet
Seal, Inc.
|
Based on information it obtained from publicly available filings
and median estimates provided by Institutional Brokerage
Estimate System (a data service that compiles estimates issued
by securities analysts, referred to as IBES) for Genesco and
each of the Footwear Retailers and Teen Retailers listed above,
Goldman Sachs calculated and compared:
|
|
|
| |
•
|
the ratio of enterprise value (calculated as equity value plus
net debt) to last twelve months (LTM) earnings before interest,
taxes, depreciation and amortization (EBITDA) as of
June 15, 2007 and, in the case of Genesco, based upon the
average closing price per share of Genesco common stock for the
three month period ended March 9, 2007; and
|
| |
| |
•
|
the ratio of price per share to IBES median estimated fiscal
year end earnings per share, or one-year forward P/E multiple,
as of June 15, 2007 and, in the case of Genesco, based upon
the average closing price per share of Genesco common stock for
the three month period ended March 9, 2007.
|
30
The multiples were calculated based on market prices without
application of any transaction premium. The following table
presents the results of this analysis:
| |
|
|
|
|
|
|
|
|
|
|
|
Enterprise
|
|
|
|
|
|
|
|
Value/LTM EBITDA
|
|
|
1 yr. Forward P/E
|
|
|
|
|
Footwear Retailers
|
|
|
|
|
|
|
|
|
|
Brown Shoe Company, Inc.
|
|
|
8.0
|
x
|
|
|
16.3
|
x
|
|
DSW Inc.
|
|
|
10.6
|
x
|
|
|
21.2
|
x
|
|
The Finish Line, Inc.
|
|
|
5.6
|
x
|
|
|
25.0
|
x
|
|
Foot Locker, Inc.
|
|
|
6.0
|
x
|
|
|
17.4
|
x
|
|
Payless Shoesource, Inc. (1)
|
|
|
8.1
|
x
|
|
|
19.8
|
x
|
|
Shoe Carnival, Inc.
|
|
|
8.1
|
x
|
|
|
15.3
|
x
|
|
Teen Retailers
|
|
|
|
|
|
|
|
|
|
Abercrombie & Fitch
Co.
|
|
|
8.3
|
x
|
|
|
14.9
|
x
|
|
Aéropostale, Inc.
|
|
|
10.1
|
x
|
|
|
18.1
|
x
|
|
American Eagle Outfitters,
Inc.
|
|
|
7.5
|
x
|
|
|
13.3
|
x
|
|
The Buckle, Inc.
|
|
|
11.5
|
x
|
|
|
19.0
|
x
|
|
Hot Topic, Inc.
|
|
|
7.3
|
x
|
|
|
26.7
|
x
|
|
Pacific Sunwear of California,
Inc.
|
|
|
13.9
|
x
|
|
|
23.7
|
x
|
|
Tween Brands, Inc.
|
|
|
9.4
|
x
|
|
|
18.9
|
x
|
|
Urban Outfitters, Inc.
|
|
|
NM
|
|
|
|
27.6
|
x
|
|
The Wet Seal, Inc.
|
|
|
NM
|
|
|
|
14.5
|
x
|
|
Footwear Retailer
Median
|
|
|
8.0
|
x
|
|
|
18.6
|
x
|
|
Teen Retailer Median
|
|
|
9.4
|
x
|
|
|
18.9
|
x
|
|
|
|
|
7.1
|
x
|
|
|
14.5
|
x
|
|
Genesco (based on $54.50 per
share)
|
|
|
9.7
|
x
|
|
|
20.0
|
x
|
|
|
|
|
(1) |
|
Payless is not pro forma for its pending acquisition of The
Stride Rite Corporation. |
Present
Value of Future Stock Price Analysis
Goldman Sachs performed an illustrative analysis of the present
value of the future share price of Genesco, which is designed to
provide an indication of the present value of a theoretical
future value of a company’s equity as a function of the
company’s estimated future earnings and its assumed price
to future earnings per share multiple. For this analysis,
Goldman Sachs used the financial projections for Genesco
prepared by Genesco’s management. See
“The
Merger — Projected Financial Information”
beginning on page 35. Goldman Sachs first calculated
implied per share values for Genesco common stock for the fiscal
years
2008-2012 by
applying price to forward earnings per share multiples ranging
from 13.0x to 16.0x (based on Genesco’s historical price to
future earnings per share multiples) to estimates prepared by
Genesco management of fiscal years
2008-2012
earnings per share. Goldman Sachs then calculated present values
of the implied per share future equity values for Genesco common
stock in 2008 to 2012 discounted to
June 17, 2007, using a
discount rate of 14.0%, reflecting Genesco’s theoretical
cost of equity capital. The determination of cost of equity
capital took into account overall market and industry conditions
and company specific factors. Applying multiples of 13.0x, 14.5x
and 16.0x to estimated earnings per share for each year in this
period, this analysis resulted in a range of implied present
value of $35.77 to $52.85 per share of Genesco common stock.
Discounted
Cash Flow Analysis
Goldman Sachs performed an illustrative discounted cash flow
analysis to determine a range of implied present value per share
of Genesco common stock. All cash flows were discounted to
February 4, 2007, and
31
terminal values were based upon EBITDA multiples of estimated
fiscal year 2012 EBITDA. Goldman Sachs used discount rates
ranging from 9.0% to 12.0%, reflecting estimates of the weighted
average cost of capital of Genesco, financial forecasts for
Genesco prepared by its management and terminal EBITDA multiples
ranging from 6.0x to 7.5x based on historical EBITDA multiples
for Genesco. The determination of weighted average cost of
capital took into account overall market and industry conditions
and company specific factors. This analysis resulted in a range
of implied present value of $45.43 to $62.75 per share of
Genesco common stock.
Using the same set of projections, Goldman Sachs also performed
a sensitivity analysis to analyze the effect of increases or
decreases in annual sales growth and EBITDA margin from 2007 to
2012. The analysis utilized (i) a range of EBITDA margin in
2012 of 11.5% to 13.5%, (ii) a range of compounded annual
sales growth rates of 9.6% to 13.6% for fiscal years 2007 to
2012 and (iii) a terminal EBITDA multiple of 6.75x and
discount rate of 10.0%. The compounded annual sales growth rates
of 9.6% to 13.6% for fiscal years 2007 to 2012 represent a range
of −2.0% to 2.0% change in the annual sales growth
assumption of the financial projections provided by the
management of Genesco. The range of fiscal 2012 EBITDA margin of
11.5% to 13.5% represented a range of −1.0% to 1.0% change
in the fiscal 2012 EBITDA margin estimates provided by the
management of Genesco. This resulted in a range of implied
present value of $45.93 to $64.75 per share of Genesco common
stock.
Selected
Transactions Analysis
Goldman Sachs reviewed publicly available information for the
following announced merger or acquisition transactions in the
U.S. involving companies in the retail and footwear
industries. While none of the companies participating in the
selected transactions are directly comparable to Genesco, the
companies participating in the selected transactions are
companies with operations that, for the purposes of analysis,
may be considered similar to certain operations of Genesco.
Goldman Sachs calculated and compared the enterprise values as a
multiple of the target company’s publicly reported latest
twelve months EBITDA prior to announcement of the applicable
transaction. For purposes of this analysis, the enterprise value
was calculated by adding the announced transaction price for the
equity of the target company to the book value of the target
company’s net debt based on public information available
prior to the announcement of the applicable transaction. The
following tables set forth the transactions reviewed (listed by
acquirer/target and month and year announced) and the enterprise
value multiple of LTM EBITDA for each and the results of the
analysis.
| |
|
|
|
|
|
|
|
Enterprise Value
|
|
|
|
|
Multiple of
|
|
|
|
|
LTM EBITDA
|
|
|
|
|
• Payless
ShoeSource, Inc./The Stride Rite Corporation (May 2007)
|
|
|
10.9
|
x
|
|
• PPR
S.A./Puma AG (April 2007)
|
|
|
12.1
|
x
|
|
• Apollo
Management, L.P./Claire’s Stores, Inc. (March 2007)
|
|
|
9.4
|
x
|
|
• Berkshire
Hathaway Inc./Russell Corporation (April 2006)
|
|
|
7.2
|
x
|
|
• Leonard
Green & Partners, L.P./The Sports Authority, Inc.
(January 2006)
|
|
|
7.5
|
x
|
|
• Bain
Capital Partners, LLC/Burlington Coat Factory Warehouse
Corporation (January 2006)
|
|
|
6.7
|
x
|
|
• Apax
Partners/Tommy Hilfiger Corporation (December 2005)
|
|
|
7.1
|
x
|
|
• Prentice
Capital Management, LP, GMM Capital LLC/Goody’s Family
Clothing, Inc. (October 2005)
|
|
|
9.8
|
x
|
|
• The Stride
Rite Corporation/Saucony, Inc. (June 2005)
|
|
|
8.1
|
x
|
|
• adidas-Salomon
AG/Reebok International Ltd. (August 2005)
|
|
|
11.0
|
x
|
|
• TPG
Advisers III, Inc., TPG Advisers IV, Inc., Warburg
Pincus & Co., Warburg Pincus LLC, Warburg Pincus
Partners LLC/The Neiman Marcus Group, Inc. (May 2005)
|
|
|
10.3
|
x
|
|
• Carter’s
Inc./OshKosh B’Gosh, Inc. (May 2005)
|
|
|
9.4
|
x
|
32
| |
|
|
|
|
|
|
|
Enterprise Value
|
|
|
|
|
Multiple of
|
|
|
|
|
LTM EBITDA
|
|
|
|
|
• Federated
Department Stores, Inc./The May Department Stores Company
(February 2005)
|
|
|
8.6
|
x
|
|
• Jones
Apparel Group, Inc./Barney’s New York, Inc. (November 2004)
|
|
|
7.7
|
x
|
|
• Sun
Capital Partners, Inc., Cerberus Capital Management, L.P.,
Lubert-Adler/Klaff and Partners, L.P./Target Corporation,
Mervyn’s (July 2004)
|
|
|
5.8
|
x
|
|
• Jones
Apparel Group, Inc./Maxwell Shoe Company Inc. (June 2004)
|
|
|
8.1
|
x
|
|
• The May
Department Stores Company/Marshall Field’s (June 2004)
|
|
|
13.5
|
x
|
|
• VF
Corporation/Vans, Inc. (April 2004)
|
|
|
15.2
|
x
|
|
• Genesco/Hat
World Corporation (February 2004)
|
|
|
7.4
|
x
|
|
• Nike,
Inc./Converse Inc. (September 2003)
|
|
|
9.5
|
x
|
|
• VF
Corporation/Nautica Enterprises, Inc. (July 2003)
|
|
|
6.3
|
x
|
Enterprise
Value Multiple of LTM EBITDA
| |
|
|
|
|
|
High
|
|
|
15.2
|
x
|
|
Mean
|
|
|
9.0
|
x
|
|
Median
|
|
|
8.3
|
x
|
|
Low
|
|
|
5.8
|
x
|
Goldman Sachs noted that the $54.50 per share of our common
stock to be paid in the merger implies a 9.7x multiple of
Genesco’s LTM EBITDA.
Recapitalization
Analysis
Goldman Sachs analyzed certain illustrative recapitalization
transactions involving Genesco and the theoretical value that
our shareholders could receive in such transactions. In the
first illustrative transaction, Genesco used $200 million
of new debt financings to repurchase common stock on
February 3, 2007 and used cash generated by Genesco to
repurchase common stock on an ongoing basis in excess of a
minimum cash balance established by management of Genesco of
approximately $30 million per year based on management
projections. The theoretical post-repurchase trading value of
our shares was based upon estimated price to earnings ratios of
13.0x to 16.0x (based on Genesco’s historical price to
future earnings per share multiples) and projections for Genesco
provided by our management after giving effect to the use of
excess cash and the additional leverage. Goldman Sachs then
calculated the implied per share future equity values for our
common stock from fiscal 2008 to fiscal 2012, and then
discounted those values to
June 17, 2007 using a discount
rate of 14%. This analysis resulted in a range of implied
present value of $36.93 to $55.90 per share of our common stock.
In the second illustrative recapitalization, the analysis
assumed that Genesco used $400 million of new debt
financings to repurchase common stock on
February 3, 2007
and used cash generated by Genesco to repurchase common stock on
an ongoing basis in excess of a minimum cash balance established
by management of Genesco of approximately $30 million per year
based on management projections. The theoretical post-repurchase
trading value of our shares was based upon estimated price to
earnings ratios of 13.0x to 16.0x (based on Genesco’s
historical price to future earnings per share multiples) and
projections for Genesco provided by our management after giving
effect to the use of excess cash and the additional leverage.
Goldman Sachs then calculated the implied per share future
equity values for our common stock from fiscal 2008 to fiscal
2012, and then discounted those values to
June 17, 2007
using a discount rate of 14%. This analysis resulted in a range
of implied present value of $37.12 to $59.68 per share of our
common stock.
In the third illustrative recapitalization, the analysis assumed
that Genesco used the after-tax proceeds of a sale of the
business and assets of our Johnston & Murphy operating
division (the “Johnston & Murphy
33
Group”) and $150 million in new debt financings to
repurchase common stock on
February 3, 2007 and used cash
generated by Genesco to repurchase common stock on an ongoing
basis in excess of a minimum cash balance established by
management of Genesco of approximately $30 million per year
based on management projections. The theoretical post-repurchase
trading value of our shares was based upon estimated price to
earnings ratios of 13.0x to 16.0x (based on Genesco’s
historical price to future earnings per share multiples) and
projections for Genesco provided by our management after giving
effect to the sale of Johnston & Murphy Group, use of
excess cash and the additional leverage. Goldman Sachs then
calculated the implied per share future equity values for our
common stock from fiscal 2008 to fiscal 2012, and then
discounted those values to
June 17, 2007 using a discount
rate of 14%. This analysis resulted in a range of implied
present value of $36.65 to $56.49 per share of our common stock.
In the fourth illustrative recapitalization, the analysis
assumed that Genesco used the after-tax proceeds of a sale of
Johnston & Murphy Group and $350 million in new
debt financings to repurchase common stock on
February 3,
2007 and used cash generated by Genesco to repurchase common
stock on an ongoing basis in excess of a minimum cash balance
established by management of Genesco of approximately $30
million per year based on management projections. The
theoretical post-repurchase trading value of our shares was
based upon estimated price to earnings ratios of 13.0x to 16.0x
(based on Genesco’s historical price to future earnings per
share multiples) and projections for Genesco provided by our
management after giving effect to the sale of
Johnston & Murphy Group, use of excess cash and the
additional leverage. Goldman Sachs then calculated the implied
per share future equity values for our common stock from fiscal
2008 to fiscal 2012, and then discounted those values to
June 17, 2007 using a discount rate of 14%. This analysis
resulted in a range of implied present value of $36.91 to $60.97
per share of our common stock.
Leveraged
Buyout Analysis
Goldman Sachs performed an illustrative analysis of the range of
the price per share of our common stock that an acquirer would
theoretically pay if Genesco were acquired in a leveraged buyout
transaction that closed as of
February 4, 2007 and resold
by such acquirer in 2012 at an EBITDA multiple of 6.75x.
Assuming, among other things, (i) a sponsor targeted equity
return of 20.0%, (ii) a range of EBITDA margin in 2012 of
11.5% to 13.5%, and (iii) a range of compounded annual
sales growth rates of 9.6% to 13.6% for fiscal years 2007 to
2012, the analysis resulted in a range of implied values of
$42.52 to $54.98 per share of our common stock.
The preparation of a fairness opinion is a complex process and
is not necessarily susceptible to partial analysis or summary
description. Selecting portions of the analyses or of the
summary set forth above, without considering the analyses as a
whole, could create an incomplete view of the processes
underlying Goldman Sachs’ opinion. In arriving at its
fairness determination, Goldman Sachs considered the results of
all the analyses and did not attribute any particular weight to
any factor or analysis considered by it. Rather, Goldman Sachs
made its determination as to fairness on the basis of its
experience and professional judgment after considering the
results of all the analyses. No company or transaction used in
the above analyses as a comparison is directly comparable to
Genesco, its various businesses or the merger.
Goldman Sachs prepared these analyses for purposes of Goldman
Sachs providing its opinion to the board of directors as to the
fairness from a financial point of view of the $54.50 per share
in cash to be received by the holders of the outstanding shares
of Genesco common stock pursuant to the merger agreement. These
analyses do not purport to be appraisals nor do they necessarily
reflect the prices at which businesses or securities actually
may be sold. Analyses based upon forecasts of future results are
not necessarily indicative of actual future results, which may
be significantly more or less favorable than suggested by these
analyses. Because these analyses are inherently subject to
uncertainty, being based upon numerous factors or events beyond
the control of the parties or their respective advisors, none of
Genesco, Goldman Sachs or any other person assumes
responsibility if future results are materially different from
those forecast.
As described above, Goldman Sachs’ opinion to our board of
directors was one of many factors taken into consideration by
our board in making its determination to approve the merger
agreement. The foregoing summary does not purport to be a
complete description of the analyses performed by Goldman Sachs
in
34
connection with the opinion and is qualified in its entirety by
reference to the written opinion of Goldman Sachs attached as
Annex C.
The merger consideration was determined through
arms’-length negotiations between Genesco and Finish Line
and was approved by our board of directors. Goldman Sachs
provided advice to Genesco during these negotiations. Goldman
Sachs did not, however, recommend any specific amount of
consideration to Genesco or our board of directors or that any
specific amount of consideration constituted the only
appropriate consideration for the merger.
Goldman Sachs and its affiliates, as part of their investment
banking business, are continually engaged in performing
financial analyses with respect to businesses and their
securities in connection with mergers and acquisitions,
negotiated underwritings, competitive biddings, secondary
distributions of listed and unlisted securities, private
placements and other transactions as well as for estate,
corporate and other purposes. Goldman Sachs has acted as
financial advisor to Genesco in connection with, and has
participated in certain of the negotiations leading to, the
merger. Except in connection with this transaction, Goldman
Sachs has not provided any material investment banking services
to Genesco or Finish Line for which it has received fees in the
past three years. Goldman Sachs may provide investment banking
services to Genesco and Finish Line in the future. In connection
with any such investment banking services Goldman Sachs may
receive compensation.
Goldman Sachs is a full service securities firm engaged, either
directly or through its affiliates, in securities trading,
investment management, financial planning and benefits
counseling, risk management, hedging, financing and brokerage
activities for both companies and individuals. In the ordinary
course of these activities, Goldman Sachs and its affiliates may
provide such services to Genesco, Finish Line and their
respective affiliates, may actively trade the debt and equity
securities (or related derivative securities) of Genesco, Finish
Line and their respective affiliates for their own account and
for the accounts of their customers and may at any time hold
long and short positions of such securities.
Genesco selected Goldman Sachs as its financial advisor because
it is an internationally recognized investment banking firm that
has substantial experience in transactions similar to the
merger. Pursuant to a letter agreement, dated
April 20,
2007, Genesco engaged Goldman Sachs to act as its financial
advisor to assist our Board of Directors in their analysis and
consideration of our strategic alternatives, including the
alternative represented by the proposal made by Foot Locker and
a possible merger or sale of all or a portion of Genesco.
Pursuant to the terms of this letter agreement, Goldman Sachs is
entitled to receive a transaction fee of 1.2% of the aggregate
consideration payable in the merger, or approximately
$18.5 million, minus an initial fee of $250,000 that became
payable upon execution of the engagement letter, with one fourth
of the transaction fee payable upon execution of the merger
agreement and the remainder of the transaction fee payable upon
completion of the merger. Genesco has also agreed to reimburse
Goldman Sachs for its reasonable expenses, including
attorneys’ fees and disbursements, and to indemnify Goldman
Sachs against various liabilities, including certain liabilities
under the federal securities laws.
Projected
Financial Information
Genesco’s senior management does not as a matter of course
make public projections as to future performance or earnings
beyond the current fiscal year and is especially wary of making
projections for extended earnings periods due to the
unpredictability of the underlying assumptions and estimates.
However, senior management did provide financial forecasts to
potential acquirers in connection with their consideration of a
possible transaction with Genesco. These projections were also
provided to our board of directors and to Goldman Sachs, our
financial advisor. We have included a subset of these
projections in this proxy statement to give our shareholders
access to certain nonpublic information deemed material by our
board of directors for purposes of considering and evaluating
the merger. The inclusion of these projections should not be
regarded as an indication that management, our board of
directors, Goldman Sachs, Finish Line or any other recipient of
this information considered, or now considers, these projections
to be a reliable prediction of future results, and they should
not be relied on as such. In addition, as we have only included
a subset of the projections in
35
this proxy statement, you are cautioned not to rely on this
information as complete in making a decision whether to vote in
favor of the merger agreement.
Genesco believes the assumptions Genesco’s management used
as a basis for the projections were reasonable at the time the
projections were prepared, given the information Genesco’s
management had at the time. However, the projections do not take
into account any circumstances or events occurring after the
date they were prepared and you should not assume that the
projections will continue to be accurate or reflective of
Genesco’s management’s view at the time you consider
whether to vote for the merger agreement. Genesco advised the
recipients of the projections that its internal financial
forecasts, upon which the projections were based, are subjective
in many respects and thus susceptible to various
interpretations. The projections reflect numerous estimates and
assumptions with respect to industry performance, general
business, economic, regulatory, market and financial conditions
and other matters, including assumed effective interest rates
and effective tax rates consistent with Genesco’s
historical levels, all of which are difficult to predict and
many of which are beyond Genesco’s control. The projections
are also subject to significant uncertainties in connection with
changes to Genesco’s business and its financial condition
and results of operation, including the factors described under
“Special Note Regarding Forward-Looking Statements”
beginning on page 11. In addition, the projections reflect
projected information regarding Genesco as a stand-alone
company, without regard to the Finish Line and do not take into
account any of the transactions contemplated by the merger
agreement, including the merger and related financing, which may
cause actual results to materially differ as well. As a result,
there can be no assurance that the projected results will be
realized or that actual results will not be significantly higher
or lower than those contained in the projections; it is expected
that there will be differences between actual and projected
results. Since the projections cover multiple years, such
information by its nature becomes less reliable with each
successive year.
The financial projections were prepared for internal use and for
our board of directors, to assist potential acquirers of Genesco
with their due diligence investigations of Genesco and for use
by Goldman Sachs in its financial analysis and not with a view
toward public disclosure or toward complying with United States
generally accepted accounting principles, the published
guidelines of the SEC regarding projections or the guidelines
established by the American Institute of Certified Public
Accountants for preparation and presentation of prospective
financial information. Genesco’s independent registered
public accounting firm has not examined or compiled any of the
financial projections, expressed any conclusion or provided any
form of assurance with respect to the financial projections and,
accordingly, assumes no responsibility for them.
Additionally, since the date of the projections described below,
Genesco has made publicly available its actual results of
operations for the quarter ended
May 5, 2007 (the
“Form 10-Q”).
You should review the
Form 10-Q,
which is incorporated into this proxy statement by this
reference, to obtain this information. Readers of this proxy
statement are cautioned not to place undue reliance on the
specific portions of the financial projections set forth below.
No one has made or makes any representation to any person
regarding the validity, reasonableness, accuracy or completeness
of the information included in these projections or the ultimate
performance of Genesco compared to such information.
For the foregoing reasons, as well as the bases and assumptions
on which the financial projections were compiled, the inclusion
of specific portions of the financial projections in this proxy
statement should not be regarded as an indication that such
projections will be an accurate prediction of future events, and
they should not be relied on as such. Except as required by
applicable securities laws, Genesco does not intend to update,
or otherwise revise the financial projections or the specific
portions presented to reflect circumstances existing after the
date when made or to reflect the occurrence of future events,
even in the event that any or all of the assumptions are shown
to be in error.
Initial Projections. In order to facilitate
the board of directors’ review of the Foot Locker proposal
at its meeting on
April 20, 2007, senior management
presented a five-year financial forecast to
the Company’s
board of directors at that meeting (the
“Initial
Projections”). The Initial Projections were based on the
latest operating results available to management. Management
advised the board of directors that the Initial Projections were
preliminary and that management was still in the process of
updating the five-year forecasts. Management also furnished the
Initial Projections to Goldman Sachs and these projections were
used by
36
Goldman Sachs in preparing certain preliminary financial
analyses discussed with our board of directors at its meeting on
April 20, 2007. However, Goldman Sachs did not rely upon
the Initial Projections in preparing its analyses in connection
with rendering its opinion with respect to the fairness, from a
financial point of view, of the consideration to be received by
holders of Genesco common stock in the merger. See
“The
Merger — Background of the Merger” beginning on
page 18. A summary of the Initial Projections is set forth
below:
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Initial Projections
|
|
|
|
|
2008E
|
|
|
2009E
|
|
|
2010E
|
|
|
2011E
|
|
|
2012E
|
|
|
|
|
(Dollars in millions)
|
|
|
|
|
Net Stores
|
|
|
2,239
|
|
|
|
2,471
|
|
|
|
2,730
|
|
|
|
2,989
|
|
|
|
3,249
|
|
|
Sales
|
|
$
|
1,605
|
|
|
$
|
1,818
|
|
|
$
|
2,053
|
|
|
$
|
2,299
|
|
|
$
|
2,565
|
|
|
EBIT (per plan)(1)
|
|
$
|
131
|
|
|
$
|
157
|
|
|
$
|
185
|
|
|
$
|
213
|
|
|
$
|
243
|
|
|
EBIT (adjusted)(2)
|
|
$
|
133
|
|
|
$
|
159
|
|
|
$
|
187
|
|
|
$
|
216
|
|
|
$
|
245
|
|
|
EPS(3)
|
|
$
|
2.81
|
|
|
$
|
3.41
|
|
|
$
|
4.09
|
|
|
$
|
4.86
|
|
|
$
|
5.65
|
|
|
|
|
|
(1) |
|
Prepared by management for its financial forecast update
presented at April 20, 2007 meeting of board of directors. |
| |
|
(2) |
|
The EBIT forecast per plan was adjusted to exclude certain fixed
asset store impairment charges. |
|
|
|
|
(3) |
|
Assumes repurchases of common stock at the beginning of the
fourth quarter each year (for fiscal years 2009E to 2012E) on an
ongoing basis with projected excess cash. |
Updated Projections. Following the
April 20, 2007 meeting of our board of directors, senior
management continued to refine its financial forecasts based on
the latest operating results and plans available to management.
A summary of the updated projections resulting from this
process, which we refer to as the
“Updated
Projections” is set forth below. The Updated Projections
were provided to Finish Line. The Updated Projections were also
provided to Goldman Sachs for use in preparing certain financial
analyses discussed with our board of directors at its meeting on
May 29, 2007 and in its presentation to the board of
directors on
June 17, 2007. The primary differences between
the Initial Projections and the Updated Projections relate to
the fact that actual results for the first fiscal quarter of
2007 were lower than management’s earlier expectations and
the Company’s plan to close or convert up to 57
underperforming stores, primarily in the Underground Station
Group, which plan had not been finalized at the time of the
April 20 meeting of our board of directors. See
“The
Merger — Background of the Merger” beginning on
page 18.
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Updated Projections
|
|
|
|
|
2008E
|
|
|
2009E
|
|
|
2010E
|
|
|
2011E
|
|
|
2012E
|
|
|
|
|
(Dollars in millions)
|
|
|
|
|
Net Stores
|
|
|
2,215
|
|
|
|
2,416
|
|
|
|
2,675
|
|
|
|
2,937
|
|
|
|
3,197
|
|
|
Sales
|
|
$
|
1,587
|
|
|
$
|
1,786
|
|
|
$
|
2,018
|
|
|
$
|
2,267
|
|
|
$
|
2,529
|
|
|
EBIT (adjusted)(1)
|
|
$
|
130
|
|
|
$
|
159
|
|
|
$
|
187
|
|
|
$
|
215
|
|
|
$
|
243
|
|
|
EPS(2)
|
|
$
|
2.75
|
|
|
$
|
3.42
|
|
|
$
|
4.07
|
|
|
$
|
4.89
|
|
|
$
|
5.58
|
|
|
|
|
|
(1) |
|
EBIT was adjusted to exclude certain fixed asset store
impairment charges and all other projected store closing charges
(primarily lease termination costs), including impairments
relating to stores included in the Company’s plan to close
or convert up to 57 underperforming stores, primarily in the
Underground Station Group. Management did not present unadjusted
revised EBIT forecasts at the June 17 meeting of our board of
directors. |
|
|
|
|
(2) |
|
Calculated after giving effect to adjustments to EBIT described
in footnote (1) above for fiscal years 2008E and 2009E. Assumes
repurchases of common stock at the beginning of the fourth
quarter each year (for fiscal years 2009E to 2012E) on an
ongoing basis with projected excess cash. |
For purposes of rendering its opinion with respect to the
fairness, from a financial point of view, of the consideration
to be received by holders of Genesco common stock in the merger,
Goldman Sachs assumed that the projections prepared by
management were reasonably prepared on a basis reflecting the
best currently available estimates and judgments of Genesco
management. Goldman Sachs did not assist management in the
37
development of any financial projections. In addition, Goldman
Sachs did not make an independent evaluation or appraisal of the
assets and liabilities (including any contingent, derivative or
off-balance-sheet assets and liabilities) of Genesco or any of
its
subsidiaries, and, Goldman Sachs was not furnished with any
evaluation or appraisal of the assets or liabilities of Genesco
or any of its
subsidiaries. See
“The Merger —
Opinion of Goldman, Sachs & Co.” beginning on
page 28.
Common
Stock, Options and Restricted Stock Consideration
At the effective time of the merger, Merger Sub will be merged
with and into Genesco. In connection with the merger:
|
|
|
| |
•
|
each share of Genesco common stock issued and outstanding
immediately prior to the effective time of the merger (other
than shares held in our treasury or owned by Finish Line or
Merger Sub) will automatically be cancelled and converted into
the right to receive $54.50 in cash, without interest;
|
| |
| |
•
|
all unvested stock options will vest and all unexercised options
will be cancelled and converted into the right to receive a cash
payment equal to the number of outstanding options multiplied by
the amount by which $54.50 exceeds the option exercise
price; and
|
| |
| |
•
|
restrictions applicable to all shares of restricted stock will
lapse and those shares will be cancelled and converted into the
right to receive a cash payment equal to the number of
outstanding restricted shares multiplied by $54.50.
|
Preferred
Stock
The holders of our preferred stock outstanding upon the
completion of the merger will not be entitled to any
consideration upon the completion of the merger pursuant to the
merger agreement. Each share of Genesco preferred stock
issued and outstanding, and not otherwise properly converted to
common stock, if applicable, immediately before the merger will
remain outstanding following the merger. Finish Line has
informed us that it intends to redeem all outstanding shares of
redeemable preferred stock following the completion of the
merger in accordance with our charter, and that they also intend
to redeem the outstanding Employees’ Preferred subject to
the requisite approval and filing of the proposed charter
amendment (Proposal No. 2). Set forth below for your
convenience is a brief discussion of the options available to
holders of each class and series of preferred stock in respect
of the potential merger. We are not making a recommendation as
to whether you should convert your preferred stock, if
applicable. You should consult your financial and tax advisors
regarding your decision whether to convert your shares of
preferred stock in advance of the merger.
Subordinated Serial Preferred Stock, Series 1 (the
“$2.30 Series 1”). The outstanding
shares of $2.30 Series 1 are both convertible into Genesco
common stock by the holder and redeemable by Genesco. Finish
Line has informed Genesco that it intends to cause the surviving
corporation to call the $2.30 Series 1 shares for
redemption following the completion of the merger. Holders who
do not convert before the redemption date will receive the
redemption consideration of $40.00, plus any accrued and unpaid
dividends as of such date. If holders exercise their right to
convert into Genesco common stock prior to the closing of the
merger, each share of $2.30 Series 1 will convert into
5/6ths of a
share of Genesco common stock (which effectively means
approximately $45.42 per share assuming a conversion based on
the price per share to be paid to holders of Genesco common
stock in the merger). Upon conversion, fractional shares of
common stock will be cashed out based upon the closing price of
Genesco common stock on the NYSE on the conversion date and this
may affect the total consideration received as a result of the
conversion and merger. If holders exercise their right to
convert into merger consideration following the closing of the
merger but before the second business day preceding the
redemption date, each share of $2.30 Series 1 will convert
into approximately $45.42 in cash.
Subordinated Serial Preferred Stock, Series 3
(the “$4.75 Series 3”). The
outstanding shares of $4.75 Series 3 are both convertible
into Genesco common stock by the holder and redeemable by
Genesco. Finish Line has informed Genesco that it intends to
cause the surviving corporation to call the $4.75
Series 3 shares
38
for redemption following the completion of the merger. If
holders do not convert before the redemption date, they will
receive the redemption consideration of $100.00, plus any
accrued and unpaid dividends as of such date. If holders
exercise their right to convert into Genesco common stock prior
to the closing of the merger, each share of $4.75 Series 3
will convert into 2.10526 shares of Genesco common stock
(which effectively means approximately $114.74 per share
assuming a conversion based on the price per share to be paid to
holders of Genesco common stock in the merger). Upon conversion,
fractional shares of common stock will be cashed out based upon
the closing price of Genesco common stock on the NYSE on the
conversion date and this may affect the total consideration
received as a result of the conversion and the merger. If
holders exercise their right to convert into merger
consideration following the closing of the merger but before the
second business day preceding the redemption date, each share of
$4.75 Series 3 will convert into approximately $114.74 in
cash.
Subordinated Serial Preferred Stock, Series 4 (the
“$4.75 Series 4”). The outstanding
shares of $4.75 Series 4 are both convertible into Genesco
common stock by the holder and redeemable by Genesco. Finish
Line has informed Genesco that it intends to cause the surviving
corporation to call the $4.75 Series 4 shares for
redemption following the completion of the merger. If holders do
not convert before the redemption date, they will receive the
redemption consideration of $100.00, plus any accrued and unpaid
dividends as of such date. If holders exercise their right to
convert into Genesco common stock prior to the closing of the
merger, each share of $4.75 Series 4 will convert into
1.5151 shares of Genesco common stock (which effectively
means approximately $82.57 per share assuming a conversion based
on the price per share to be paid to holders of Genesco common
stock in the merger). Upon conversion, fractional shares of
common stock will be cashed out based upon the closing price of
Genesco common stock on the NYSE on the conversion date and this
may affect the total consideration received as a result of the
conversion and the merger. If holders exercise their right to
convert into merger consideration following the closing of the
merger but before the second business day preceding the
redemption date, each share of $4.75 Series 4 will convert
into approximately $82.57 in cash.
Subordinated Cumulative Preferred Stock (the “$1.50
Subordinated Cumulative Preferred
Stock”). The outstanding shares of $1.50
Subordinated Cumulative Preferred Stock are redeemable by
Genesco but are not convertible into common stock by the holder.
Finish Line has informed Genesco that it intends to cause the
surviving corporation to call the $1.50 Subordinated Cumulative
Preferred Stock shares for redemption following the completion
of the merger, such redemption to be effective on the next
quarterly dividend payment date following the merger in
accordance with Genesco’s charter. On the redemption date
holders will receive $30.00 per share of $1.50 Subordinated
Cumulative Preferred Stock redeemed, plus any accrued and unpaid
dividends as of such date.
Employees’ Subordinated Convertible Preferred
Stock. The outstanding shares of Employees’
Preferred are not currently redeemable but are convertible (if
fully paid) into either Genesco common stock or $1.50
Subordinated Cumulative Preferred Stock by the holder. If
holders exercise their right to convert into Genesco common
stock prior to the closing of the merger, each share of
Employees’ Preferred will convert into one share of Genesco
common stock (which effectively means $54.50 per share assuming
a conversion based on the price per share to be paid to holders
of Genesco common stock in the merger). If holders exercise
their right to convert into merger consideration following the
closing of the merger but before the redemption date, each share
of Employees’ Preferred will convert into $54.50 in cash.
Genesco’s board of directors has also agreed, pursuant to
the merger agreement, to recommend to our shareholders the
approval of the proposed charter amendment (Proposal No. 2)
to allow for the redemption by Genesco of the Employees’
Preferred after the completion of the merger at the price to be
paid per share of Genesco common stock in connection with the
merger, or $54.50 per share, without interest and net of any
unpaid amounts on such shares. Finish Line has informed Genesco
that it intends cause the surviving corporation to call the
Employees’ Preferred shares for redemption following the
completion of the merger if the charter amendment is adopted and
approved by the requisite votes at the special meeting.
The approval of Genesco’s shareholders of the charter
amendment is not a condition to the closing of the merger for
any party.
39
Delisting
and Deregistration of Genesco Capital Stock
If the merger is completed, Genesco common stock (including the
associated preferred share purchase rights) and the Genesco
Subordinated Serial Preferred Stock, Series 1 will be
delisted from the NYSE and CHX and deregistered under the
Exchange Act, as applicable. Genesco will no longer file
periodic reports with the SEC on account of these classes and
series. Genesco anticipates that it will be required to continue
to file periodic reports with the SEC on account of the
Employees’ Preferred unless the charter amendment is
approved and adopted and the Employees’ Preferred is
redeemed or until the number of holders of the Employees’
Preferred otherwise drops below 300.
Regulatory
Approvals
Under the HSR Act and the rules promulgated thereunder by the
FTC, the merger cannot be completed until Genesco and Finish
Line each file a notification and report form under the HSR Act
and the applicable waiting period has expired or been
terminated. Genesco and Finish Line each filed notification and
report forms under the HSR Act with the FTC and the Antitrust
Division of the DOJ on
July 17, 2007. If Genesco and Finish
Line do not receive a request for additional information, the
waiting period will expire at 11:59 p.m. on
August 16,
2007, if not terminated earlier. At any time before or after
completion of the merger, notwithstanding any termination of the
waiting period under the HSR Act, the Antitrust Division or the
FTC could take action under the antitrust laws as it deems
necessary or desirable in the public interest, including seeking
to enjoin the completion of the merger or seeking divestiture of
substantial assets of Genesco or Finish Line. At any time before
or after the completion of the merger, and notwithstanding any
termination of the waiting period under the HSR Act, any state
could take action under the antitrust laws as it deems necessary
or desirable in the public interest. Such action could include
seeking to enjoin the completion of the merger or seeking
divestiture of substantial assets of Genesco or Finish Line.
Private parties may also seek to take legal action under the
antitrust laws under certain circumstances.
While there can be no assurance that the merger will not be
challenged by a governmental authority or private party on
antitrust grounds, Genesco believes that the merger can be
effected in compliance with federal, state and foreign antitrust
laws. The term “antitrust laws” means the Sherman Act,
as amended, the Clayton Act, as amended, the HSR Act, the
Federal Trade Commission Act, as amended, and all other Federal,
state and foreign statutes, rules, regulations, orders, decrees,
administrative and judicial doctrines, and other laws that are
designed or intended to prohibit, restrict or regulate actions
having the purpose or effect of monopolization or restraint of
trade.
Financing
of the Merger
In connection with the merger, Finish Line will obtain the
financing necessary to cause the merger consideration to be paid
out to Genesco’s shareholders, to make any redemption
payments made to holders of issued and outstanding preferred
stock of Genesco following the merger, to refinance certain
existing indebtedness of Genesco, and to pay customary fees and
expenses in connection with the proposed merger, the financing
arrangements and the related transactions. Funding of the debt
financing is subject to the satisfaction of the conditions set
forth in the commitment letter pursuant to which the financing
will be provided. Finish Line has agreed to use its reasonable
best efforts to arrange the debt financing on the terms and
conditions set forth in the debt commitment letter. The
following arrangements are in place to provide, subject to the
satisfaction of the conditions provided in the commitment
letter, the necessary financing for the merger and related
transactions, including the payment of related transaction
costs, charges, fees and expenses:
|
|
|
| |
•
|
new senior secured credit facilities in the aggregate amount of
$1.14 billion, consisting of a $690.0 million senior
secured term loan and a $450.0 million senior secured
revolving credit facility. No more than $250.0 million of
the revolving credit facility may be drawn at the closing;
|
| |
| |
•
|
$700.0 million aggregate principal amount of debt securities or,
in lieu thereof, a senior unsecured bridge loan facility in the
amount of $700.0 million; and
|
| |
| |
•
|
cash and cash equivalents of approximately $11.0 million
held by Finish Line and its subsidiaries at closing.
|
40
Debt
Financing
Debt
Commitment Letter
Finish Line has received a fully executed debt commitment letter
(the
“commitment letter”) dated as of
June 17,
2007, from UBS Loan Finance LLC (
“UBS”) and UBS
Securities LLC (
“UBSS”). Finish Line has advised
Genesco that it currently estimates that it will obtain the
financing necessary to consummate the merger pursuant to the
terms of the commitment letter during the third week of October
2007, but the expected financing timeline could vary. Pursuant
to the commitment letter, subject to the conditions set forth
therein:
|
|
|
| |
•
|
UBS has committed to provide to Finish Line up to
$1.14 billion of senior secured credit facilities, for the
purpose of financing the merger, repaying certain existing
indebtedness of Finish Line, Genesco and their subsidiaries,
paying fees and expenses incurred in connection with the merger
and providing ongoing working capital requirements of Finish
Line and its subsidiaries (including Genesco following the
merger).
|
| |
| |
•
|
Finish Line is expected to issue and sell up to $700.0 million
in aggregate principal amount of debt securities. If the
offering of debt securities by Finish Line is not completed
substantially concurrently with the merger, UBS has committed to
provide to Finish Line up to $700.0 million of a senior
unsecured bridge facility, for the purpose of financing the
merger, repaying or refinancing certain existing indebtedness of
Finish Line, Genesco and their subsidiaries, paying fees and
expenses incurred in connection with the merger and providing
ongoing working capital and for other general corporate purposes
of Finish Line and its subsidiaries.
|
The debt commitments expire on
December 31, 2007. The
documentation governing the senior secured credit facilities and
the bridge loan facility has not been finalized and,
accordingly, the actual terms of such facilities may differ from
those described in this proxy statement.
Pursuant to the merger agreement, Finish Line is obligated to
use its reasonable best efforts to obtain the debt financing set
forth in the debt commitment letter at or prior to the closing
of the merger. In the event that any portion of the debt
financing becomes unavailable on the terms contemplated in the
commitment letter, Finish Line must use its reasonable best
efforts to arrange alternative financing from alternative
sources on terms not materially less favorable to Finish Line in
the aggregate (as determined in the good faith reasonable
judgment of Finish Line).
Conditions
Precedent to the Debt Commitments
The availability of the senior secured credit facilities and the
bridge loan facility is subject to, among other things, there
not having occurred since
June 17, 2007 any change or
condition that would constitute a company material adverse
effect (as defined in the merger agreement), the accuracy in all
material respects at the closing date of specified
representations of Genesco in the merger agreement, completion
of the merger in accordance with the merger agreement in form
and substance satisfactory to UBS and the negotiation, and
execution and delivery of definitive documentation.
Senior
Secured Credit Facilities
General
The borrower under the senior secured credit facilities will be
Finish Line and will be guaranteed by each existing and future
direct or indirect domestic subsidiary of Finish Line, including
the surviving corporation. The senior secured credit facilities
will consist of a $690.0 million senior secured term loan
facility with a term of seven years and a $450.0 million
senior secured revolving credit facility with a term of five
years. The revolving credit facility will include provisions for
the issuance of letters of credit and swingline loans.
UBSS will act as the sole advisor, arranger and book running
manager for the senior secured credit facilities. UBS AG,
Stamford Branch (“UBS AG”) will be the sole
administrative agent for the senior credit facilities, UBS AG
will be the sole collateral agent for the senior secured term
loan facility and UBS AG and a financial institution to be
designated by UBSS will be the co-collateral agents for the
senior secured revolving credit facility.
41
The senior secured revolving credit facility will be an
asset-based credit facility with extensions of credit thereunder
to be subject to limitations based upon specified percentages of
eligible receivables and eligible inventory of Finish Line.
Interest
Rate and Fees
Loans under the senior secured credit facilities are expected to
bear interest, at Finish Line’s option, at (1) a rate
equal to the London Interbank Offered Rate (“LIBOR”),
plus an applicable margin or (2) a rate equal to the higher
of (a) the prime rate of UBS and (b) the federal funds
effective rate plus 0.50%, plus an applicable margin. After the
delivery by Finish Line to the administrative agent of financial
statements for the fiscal quarter ending at least six months
following the closing date, the applicable margins for
borrowings under the revolving credit facility may be increased
or decreased subject to a pricing grid based on excess
availability under the senior secured revolving credit facility.
To the extent the corporate credit is rated less than B2 (with a
stable outlook) by Moody’s or less than B (with a stable
outlook) by S&P as of the closing date, the interest
margins for borrowings under the term loan facility will be
increased by 25 bps.
In addition, Finish Line will pay commitment fees to the lenders
under the revolving credit facility in respect of the unutilized
commitments thereunder. The commitment fee rate is 0.25% per
annum. Finish Line must also pay customary letter of credit
commissions and fees under the revolving credit facility.
Prepayments
and Amortization
Finish Line will be permitted to make voluntary prepayments upon
prior notice, without premium or penalty (other than LIBOR
breakage costs, if applicable). Finish Line will be required to
make mandatory prepayments of term loans consisting of
(1) net cash proceeds of Finish Line and its
subsidiaries
received in respect of non-ordinary course asset sales (subject
to reinvestment rights and other exceptions), (2) net cash
proceeds of Finish Line and its
subsidiaries received in respect
of issuances of debt or preferred stock (other than permitted
debt or preferred stock), (3) net cash proceeds of Finish
Line and its
subsidiaries received in respect of casualty and
condemnation events (subject to reinvestment rights) and
(4) a percentage of the excess cash flow (to be defined in
a manner to be agreed) of Finish Line and its
subsidiaries.
Finish Line will also be required to make mandatory prepayments
of the revolving loans based on levels of excess availability
under the senior secured revolving credit facility. The term
loan will amortize in equal quarterly installments in aggregate
annual amounts equal to 1% of the original principal amount of
the term loan, with the balance payable at the final maturity
date.
Guarantors
All obligations under the senior secured credit facilities will
be unconditionally guaranteed by each existing and future direct
or indirect domestic subsidiary of Finish Line, including
Genesco and its
subsidiaries.
Security
The obligations of Finish Line and the guarantors under the
senior secured credit facilities will be secured, subject to
permitted liens and other
agreed-upon
exceptions, and subject to intercreditor arrangements between
the revolving credit facility lenders and the term loan facility
lenders, by security interests in and liens on (1) all
accounts receivable, inventory and deposit accounts of Finish
Line and each guarantor and all proceeds thereof, (2) all
the capital stock of the surviving corporation and of each of
the directly and indirectly owned
subsidiaries of Finish Line
and each guarantor of such facilities (limited, in the case of
foreign
subsidiaries, to 65% of the capital stock of first-tier
foreign
subsidiaries) and (3) substantially all other
tangible and intangible assets of Finish Line, Genesco and each
other guarantor.
Other
Terms
The senior secured credit facilities will contain customary
representations and warranties and customary affirmative and
negative covenants (applicable to Finish Line and its
subsidiaries), including, among other things, restrictions on
indebtedness, liens, fundamental changes, investments and
acquisitions, sales of assets,
42
sale leasebacks, mergers and consolidations, dividends and other
distributions, redemptions, prepayments of certain subordinated
indebtedness, an excess availability requirement and a minimum
fixed charge coverage ratio. The senior secured credit
facilities will also include customary events of default,
including a change of control to be defined.
Debt
Securities
Finish Line is expected to issue and sell up to
$700.0 million in aggregate principal amount of debt
securities. The debt securities will not be registered under the
Securities Act and may not be offered in the United States
absent registration or an applicable exemption from registration
requirements. Finish Line is expected to offer the debt
securities to “qualified institutional buyers,” as
defined in Rule 144A under the Securities Act of 1933, as
amended (the “Securities Act”), and to
non-U.S. persons
outside the United States in compliance with Regulation S
under the Securities Act. The commitment letter, which is
described above under “Financing of the Merger —
Debt Financing” provides for a new $700.0 million
senior bridge facility that will be available in the event that
the contemplated offering of debt securities does not take place
at the time the merger is completed.
Bridge
Loan Facility
UBS has committed to provide up to $700.0 million in loans
to Finish Line under a senior bridge loan facility. The bridge
loan facility will be guaranteed by each guarantor of the senior
secured credit facilities on a senior unsecured basis.
If the bridge loan is not paid in full on or before the first
anniversary of the closing date, the bridge loan will
automatically convert into a senior term loan maturing on the
eighth anniversary of the closing date. Holders of such term
loan may choose to exchange such loan for senior exchange notes
maturing on the eighth anniversary of the closing date with an
equal principal amount and may fix the interest rate on any such
exchange notes. Holders of such term loans may also fix the
interest rate. Finish Line would be required to register any
exchange notes for public sale under a registration statement in
compliance with applicable securities laws.
The bridge loan facility will bear interest at a floating rate
equal to LIBOR plus an initial margin depending on the rating of
the bridge loan facility and the lease-adjusted leverage ratio.
The margin will increase over time in three-month intervals
following an initial six-month period, and will be subject to an
annual yield cap.
The bridge loan facility will contain covenants that are
expected to be generally similar to the covenants in the senior
secured facility, with adjustments as may be agreed between
Finish Line and the bridge facility lenders.
With respect to the term loans and exchange notes (other than
fixed rate term loans and exchange notes), Finish Line will be
permitted to make voluntary prepayments upon prior notice, at
par plus accrued and unpaid interest and other than LIBOR
breakage costs, if applicable. With respect to the term loans
and exchange notes bearing interest at fixed rates, limited
redemption options are available prior to the third anniversary
of the closing date. Thereafter, such fixed rate exchange notes
and term loans shall be redeemable at Finish Line’s option
at a premium coupon based on the date of redemption.
Finish Line will be required to prepay the bridge loan facility
and to redeem or offer to purchase the exchange notes under
certain circumstances, including upon certain incurrence of debt
and non-ordinary course asset sales, issuance of debt or equity
or with net proceeds from casualty or condemnation events.
UBSS will act as sole lead arranger and sole book running
manager for the bridge loan facility and UBS AG will act as the
sole administrative agent for the bridge loan facility.
Interests
of Genesco’s Directors and Executive Officers in the
Merger
In considering the recommendations of the board of directors,
Genesco’s shareholders should be aware that certain of
Genesco’s directors and executive officers have interests
in the transaction that may be different
43
from, and/or
in addition to, the interests of Genesco’s shareholders
generally. Our board of directors was aware of these potential
conflicts of interest in reaching its decision to approve the
merger agreement and to recommend that our shareholders vote in
favor of approving the merger agreement. Except as set forth
below, our directors and officers have, to our knowledge, no
material interest that differs from your interests generally.
Treatment
of Equity Awards
Upon the completion of the merger, all of our equity
compensation awards (including awards held by directors and
executive officers) will be subject to the treatment described
under “The Merger Agreement — Treatment of
Options and Other Awards” beginning on page 53. All of
the related cash payments will be subject to applicable
withholding taxes.
The table below sets forth, as of
June 30, 2007 for each of
our directors and executive officers (before any deduction for
applicable withholding taxes): the aggregate number of stock
options held by each director and executive officer, including
those that will vest upon the completion of the merger; the cash
payment that will be made in respect of the foregoing stock
options upon the completion of the merger (based on the exercise
price of the options); the aggregate number of restricted shares
held by each director and executive officer that have
restrictions that will lapse upon completion of the merger; and
the aggregate cash payment that will be made in respect of the
foregoing restricted shares upon the completion of the merger.
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock Options
|
|
|
Restricted Shares
|
|
|
|
|
|
|
|
Cash
|
|
|
|
|
|
Cash
|
|
|
Name
|
|
Number
|
|
|
Payment
|
|
|
Number
|
|
|
Payment
|
|
|
|
|
Directors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
James S. Beard
|
|
|
—
|
|
|
|
—
|
|
|
|
3,334
|
|
|
$
|
181,703
|
|
|
Leonard L. Berry
|
|
|
16,000
|
|
|
$
|
528,520
|
|
|
|
4,663
|
|
|
$
|
254,134
|
|
|
William F. Blaufuss, Jr.
|
|
|
—
|
|
|
|
—
|
|
|
|
5,262
|
|
|
$
|
286,779
|
|
|
James S. Bradford
|
|
|
—
|
|
|
|
—
|
|
|
|
3,334
|
|
|
$
|
181,703
|
|
|
Robert V. Dale
|
|
|
12,000
|
|
|
$
|
365,280
|
|
|
|
4,663
|
|
|
$
|
254,134
|
|
|
Matthew C. Diamond
|
|
|
—
|
|
|
|
—
|
|
|
|
5,235
|
|
|
$
|
285,308
|
|
|
Marty G. Dickens
|
|
|
—
|
|
|
|
—
|
|
|
|
6,406
|
|
|
$
|
349,127
|
|
|
Ben T. Harris
|
|
|
—
|
|
|
|
—
|
|
|
|
2,649
|
|
|
$
|
144,371
|
|
|
Kathleen Mason
|
|
|
16,000
|
|
|
$
|
528,520
|
|
|
|
5,672
|
|
|
$
|
309,124
|
|
|
William A. Williamson
|
|
|
16,000
|
|
|
$
|
528,520
|
|
|
|
6,477
|
|
|
$
|
352,997
|
|
|
Hal N. Pennington(1)
|
|
|
308,653
|
|
|
$
|
10,236,154
|
|
|
|
74,675
|
|
|
$
|
4,069,788
|
|
|
Robert J. Dennis(2)
|
|
|
98,036
|
|
|
$
|
2,731,827
|
|
|
|
44,447
|
|
|
$
|
2,422,362
|
|
|
Executive Officers
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
James S. Gulmi
|
|
|
118,084
|
|
|
$
|
4,150,305
|
|
|
|
22,955
|
|
|
$
|
1,251,048
|
|
|
Jonathan D. Caplan
|
|
|
83,320
|
|
|
$
|
2,751,321
|
|
|
|
18,967
|
|
|
$
|
1,033,702
|
|
|
James C. Estepa
|
|
|
46,743
|
|
|
$
|
1,298,958
|
|
|
|
39,155
|
|
|
$
|
2,133,948
|
|
|
Kenneth J. Kocher
|
|
|
25,287
|
|
|
$
|
664,774
|
|
|
|
10,494
|
|
|
$
|
571,923
|
|
|
John W. Clinard
|
|
|
39,034
|
|
|
$
|
1,196,888
|
|
|
|
13,455
|
|
|
$
|
733,298
|
|
|
Roger G. Sisson
|
|
|
78,301
|
|
|
$
|
2,642,752
|
|
|
|
15,290
|
|
|
$
|
833,305
|
|
|
Mimi Eckel Vaughn
|
|
|
50,183
|
|
|
$
|
1,605,735
|
|
|
|
13,070
|
|
|
$
|
712,315
|
|
|
Matthew N. Johnson
|
|
|
5,610
|
|
|
$
|
171,388
|
|
|
|
1,503
|
|
|
$
|
81,914
|
|
|
Paul D. Williams
|
|
|
7,925
|
|
|
$
|
248,762
|
|
|
|
1,582
|
|
|
$
|
86,219
|
|
|
|
|
|
(1) |
|
Mr. Pennington also serves as the chief executive officer
of Genesco. |
| |
|
(2) |
|
Mr. Dennis also serves as the president and chief operating
officer of Genesco. |
Change
in Control Severance and Retention Arrangements
Each of the executive officers has an employment protection
agreement that will become effective upon shareholder approval
of the merger agreement (the “effective time of the
employment protection agreement”)
44
and has a term ending on the third anniversary of the effective
time of the employment protection agreement unless the executive
is earlier terminated in accordance with the agreement or
retires. These agreements have the following provisions, which
may or will be triggered following the completion of the merger,
as applicable:
|
|
|
| |
•
|
During the term of the employment protection agreement:
|
|
|
|
| |
•
|
The executive shall have the position, authority and
responsibilities commensurate with the highest held, exercised
and assigned during the
90-day
period prior to the effective time of the employment protection
agreement.
|
|
|
|
| |
•
|
The executive shall receive compensation in an amount not less
than that which the executive was receiving immediately prior to
the effective time of the employment protection agreement.
|
|
|
|
| |
•
|
The executive shall be eligible to participate during each
fiscal year in a bonus or incentive compensation plan with terms
at least as favorable as the plan in effect immediately prior to
the effective time of the employment protection agreement and
with a target and maximum award potential at least equal to such
plan.
|
|
|
|
| |
•
|
The executive is also entitled to participate in incentive and
savings plans, retirement programs, and benefit plans, to
receive reimbursement of expenses, vacation, and fringe
benefits, office support and staff, all generally at least equal
to the most favorable provided in the
90-day
period immediately preceding the effective time of the
employment protection agreement.
|
|
|
|
| |
•
|
If the executive’s employment is terminated by death or
disability during the term of the agreement, the executive is
entitled to receive all accrued obligations of Genesco to such
executive, including such executive’s salary, any deferred
compensation, all amounts owing to the executive under any
applicable employee benefit plan, and a bonus equal to the
average of the two most recent annual bonuses received by the
executive, prorated for the number of days in the current fiscal
year that the executive was employed.
|
|
|
|
| |
•
|
If the executive is terminated for cause or voluntarily
terminates his employment during the term of the agreement, he
is entitled to receive the same compensation payable in case of
termination by death or disability, except that the prorated
bonus would not be payable.
|
| |
| |
•
|
If the executive’s employment is actually or constructively
terminated by Genesco without cause during the term of the
agreement, the executive will be entitled to receive:
|
|
|
|
| |
•
|
his base salary through the termination date and any other
accrued obligations;
|
| |
| |
•
|
a lump-sum severance allowance (the “Severance
Payment”) equal to the multiple specified below times
(i) the executive’s annual base salary, plus
(ii) the average of the executive’s two most recent
annual bonuses, plus (iii) the present value of the annual
cost to Genesco of obtaining coverage equivalent to the coverage
provided by Genesco prior to the merger under any welfare
benefit plans (including medical, dental, disability, group life
and accidental death insurance), subject to a right to elect
continuation of certain welfare benefits instead, plus
(iv) the annualized value of certain fringe benefits
provided to the executive prior to the merger; and
|
| |
|
|
|
|
|
Executive Officer
|
|
Multiple
|
|
|
|
|
Hal N. Pennington
|
|
|
3
|
|
|
Robert J. Dennis
|
|
|
2
|
|
|
James S. Gulmi
|
|
|
2
|
|
|
James C. Estepa
|
|
|
2
|
|
|
Jonathan D. Caplan
|
|
|
2
|
|
|
Kenneth J. Kocher
|
|
|
2
|
|
|
John W. Clinard
|
|
|
2
|
|
|
Roger G. Sisson
|
|
|
2
|
|
|
Mimi Eckel Vaughn
|
|
|
2
|
|
|
Matthew N. Johnson
|
|
|
1
|
|
|
Paul D. Williams
|
|
|
1
|
|
45
|
|
|
| |
•
|
reimbursement for any excise tax owed thereon and for taxes
payable by reason of the reimbursement.
|
The executive officers are also entitled to certain payments
under the general severance plan, however, amounts payable under
the employment protection agreements are to be reduced by any
amount received under the general severance plan.
The following table shows the amount of the Severance Payment
payable to each of the executive officers, based on compensation
and benefit levels in effect on
June 30, 2007 and assuming
the merger is completed on
December 31, 2007, and the
executive’s employment terminates effective
December 31, 2007 under circumstances that entitle him to
the maximum potential Severance Payment immediately thereafter.
The table also shows the estimated value of tax reimbursement
expected to be due under Section 4999 of the Internal
Revenue Code and the employment protection agreement in respect
of these severance payments together with the other payments
indicated above, including those with respect to the accelerated
outstanding equity awards upon the completion of the merger.
| |
|
|
|
|
|
|
|
|
|
Executive Officer
|
|
Severance Payment
|
|
|
Tax Reimbursement
|
|
|
|
|
Hal N. Pennington
|
|
$
|
5,578,694
|
|
|
$
|
1,980,133
|
|
|
Robert J. Dennis
|
|
$
|
2,377,440
|
|
|
|
—
|
|
|
James S. Gulmi
|
|
$
|
1,363,239
|
|
|
|
—
|
|
|
James C. Estepa
|
|
$
|
2,544,713
|
|
|
|
—
|
|
|
Jonathan D. Caplan
|
|
$
|
1,732,662
|
|
|
$
|
478,865
|
|
|
Kenneth J. Kocher
|
|
$
|
804,446
|
|
|
|
—
|
|
|
John W. Clinard
|
|
$
|
849,537
|
|
|
|
—
|
|
|
Roger G. Sisson
|
|
$
|
893,175
|
|
|
|
—
|
|
|
Mimi Eckel Vaughn
|
|
$
|
859,409
|
|
|
$
|
310,693
|
|
|
Matthew N. Johnson
|
|
$
|
240,132
|
|
|
|
—
|
|
|
Paul D. Williams
|
|
$
|
260,554
|
|
|
|
—
|
|
It is currently anticipated that Mr. Pennington will not be
retained to continue his role as chairman and chief executive
officer of the surviving corporation following the merger or
otherwise in a formal capacity. The Severance Payments will be
made at the closing of the merger for Mr. Pennington and
any other executive who is not retained by Finish Line following
the completion of the merger.
New
Management Arrangements
As of the date of this proxy statement, no member of our senior
management has entered into any amendments or modifications to
existing employment agreements or arrangements with us in
connection with the merger. Finish Line has informed us that it
currently intends to retain certain members of our existing
senior management team with the surviving corporation after the
merger is completed. Certain members of senior management are
currently engaged in discussions with representatives of Finish
Line regarding revised terms of employment that would become
effective at or after the closing of the merger. As of the date
of this proxy statement, except with respect to Mr. Dennis,
whose anticipated terms of employment by Finish Line are
summarized below, no member of our senior management has entered
into any agreement, arrangement or understanding with Finish
Line, Merger Sub or their affiliates regarding employment with
the surviving corporation. Although we believe certain other
members of our management team are likely to enter into new
arrangements with Finish Line, Merger Sub or their affiliates
regarding employment with the surviving corporation, these
matters are subject to further negotiations and discussion and
no terms or conditions have been finalized. The new arrangements
are currently expected to be entered into at or prior to the
completion of the merger. In addition, it is possible that one
or more of our executive officers could be invited to join the
board of directors of the surviving corporation
and/or
Finish Line following the merger.
Robert J. Dennis, our current president and chief operating
officer, is currently expected to serve as the new president of
Finish Line following the consummation of the merger. On
July 23, 2007, subsequent to the
46
execution of the merger agreement, Mr. Dennis and Finish
Line entered into a letter agreement pursuant to which the
parties confirmed that if the merger closes Mr. Dennis will
enter into a mutually satisfactory definitive employment
agreement with Finish Line at the closing of the merger that
will replace and supersede his current employment protection
agreement with Genesco and will contain certain terms and
conditions, as described briefly below.
The initial term of Mr. Dennis’s employment will be
three years, subject to certain automatic extension periods.
Mr. Dennis will have a base salary of $600,000 and will
also be eligible to earn incentive bonuses pursuant to Finish
Line’s bonus program. Mr. Dennis’s employment
agreement will contain a perpetual confidentiality covenant as
well as non-competition and non-solicitation covenants triggered
by termination under certain circumstances.
If Mr. Dennis’s employment terminates due to death or
disability, he will be entitled to receive (i) any base
salary earned through the date of termination, (ii) any
earned but unpaid portion of his bonus for the fiscal year
preceding the year of termination, (iii) reimbursement of
any unreimbursed business expenses properly incurred by
Mr. Dennis, and (iv) such employee benefits, if any,
as to which Mr. Dennis may be entitled under the Finish
Line’s employee benefit plans (the payments and benefits
described in (i) through (iv) being his “accrued
rights”). If Mr. Dennis’s employment is
terminated by Finish Line without “cause” or by
Mr. Dennis for “good reason” (as such terms are
defined in the letter agreement) during the initial three-year
term of employment, Mr. Dennis will be entitled to
(i) his accrued rights and (ii) subject to the
execution of a general release of claims in favor of Finish Line
and its affiliates, an amount equal to two times (x) his
annual base salary, (y) the average of his two most recent
annual bonuses paid (omitting from the average any year for
which no bonus is paid) and (z) the present value of the
annual cost to the Finish Line of obtaining insurance coverage
equivalent to the coverage provided by the Finish Line for
Mr. Dennis under any welfare benefit plans plus the
annualized value of fringe benefits provided to him (plus any
tax reimbursement payments associated therewith). If
Mr. Dennis’s employment is terminated by the Finish
Line without “cause” or by Mr. Dennis for
“good reason” at any time following the initial
three-year term of employment, Mr. Dennis will be entitled
to (i) his accrued rights, and (ii) subject to the
execution of a general release of claims in favor of Finish Line
and its affiliates, continued medical benefits for one year
following termination and an amount equal to the sum of
(x) his annual base salary and (y) a pro-rata portion
of any annual bonus he would have received for the year of
termination based upon the Finish Line’s actual results for
the year of termination (with such proration based on the number
of days during the year of termination that he was employed by
the Finish Line), payable to Mr. Dennis when the annual
bonus would have been otherwise payable. Notwithstanding the
above, in the event Mr. Dennis’s employment is
terminated by the Finish Line without “cause” or by
Mr. Dennis for “good reason” (in each case within
90 days prior to or 2 years following a subsequent
“change in control” of Finish Line (to be defined in
the employment agreement)) Mr. Dennis would be entitled to
the following instead of what is described above: (i) his
accrued rights, (ii) subject to the execution of a general
release of claims on behalf of Finish Line and its affiliates,
an amount equal to the sum of (x) 2.5 times the sum of
(a) his annual base salary, (b) his target annual
bonus for the year of termination, and (c) the value of any
other bonus he could have earned during the year of termination
pursuant to the Finish Line’s then existing bonus programs,
and (y) continued provision of group health benefits for
two years. Additionally, Mr. Dennis will be entitled to
accelerated vesting of all unvested equity awards immediately
upon the occurrence of a change in control, whether or not a
termination of employment occurs. In the event Mr. Dennis
terminates his employment without “good reason” within
the 30-day
period that begins on the first anniversary of a change in
control, Mr. Dennis will be entitled to (i) his
accrued rights and (ii) subject to the execution of a
general release of claims on behalf of Finish Line and its
affiliates, a lump sum severance payment equal to one times his
existing base salary. In the event of the termination of
Mr. Dennis’s employment by Finish Line for cause or by
Mr. Dennis without good reason, he will only be entitled to
his accrued rights (as defined above). Additionally, the Finish
Line will provide Mr. Dennis with full golden parachute
excise tax
gross-up,
but only if the benefits to be paid to Mr. Dennis exceed
110% of the Section 280G safe harbor limit.
Mr. Dennis will receive a stock option award for
175,000 shares of Finish Line’s common stock with an
exercise price equal to the fair market value of Finish
Line’s common stock on the grant date (expected to be
47
the date Mr. Dennis commences employment with
the Company
upon the consummation of the merger), vesting in equal annual
installments over three years from the grant date. Additionally,
on such date Mr. Dennis will also receive a restricted
stock award for 75,000 shares of Finish Line’s common
stock, which shares will cliff vest three years from the grant
date.
Benefit
Arrangements with Surviving Corporation
The commitments by Finish Line with respect to benefit
arrangements are described below under “The Merger
Agreement — Employee Benefits” beginning on page
65.
Indemnification
and Insurance
See “The Merger Agreement — Indemnification and
Insurance” beginning on page 66.
Material
U.S. Federal Income Tax Consequences of the Merger to Our
Shareholders
The following is a summary of certain material U.S. federal
income tax consequences of the merger to holders of Genesco
common stock whose shares of Genesco common stock are converted
into the right to receive cash pursuant to the merger. This
summary does not purport to consider all aspects of
U.S. federal income taxation that might be relevant to our
shareholders. For purposes of this discussion, we use the term
“U.S. holder” to mean a beneficial owner of
shares of Genesco common stock that is, for U.S. federal
income tax purposes:
|
|
|
| |
•
|
a citizen or resident of the United States;
|
| |
| |
•
|
a corporation created or organized under the laws of the United
States or any of its political subdivisions;
|
| |
| |
•
|
a trust that (i) is subject to the supervision of a court
within the United States and the control of one or more
U.S. persons or (ii) has a valid election in effect
under applicable U.S. Treasury regulations to be treated as
a U.S. person; or
|
| |
| |
•
|
an estate that is subject to U.S. federal income tax on its
income regardless of its source.
|
A
“non-U.S. holder”
is a person (other than a partnership) that is not a
U.S. holder.
If a partnership holds Genesco common stock, the tax treatment
of a partner will generally depend on the status of the partner
and the activities of the partnership. A partner of a
partnership holding Genesco common stock should consult its tax
advisor.
This discussion is based on current law, which is subject to
change, possibly with retroactive effect. It applies only to
holders that are beneficial owners who hold shares of Genesco
common stock as capital assets, and may not apply to shares of
Genesco common stock received in connection with the exercise of
employee stock options or otherwise as compensation, holders who
hold an equity interest, directly or indirectly, in Finish Line
or the surviving corporation after the merger, or to certain
types of beneficial owners who may be subject to special rules
(such as insurance companies, banks, tax-exempt organizations,
financial institutions, broker-dealers, partnerships,
S corporations or other pass-through entities, mutual
funds, traders in securities who elect the mark-to-market method
of accounting, holders subject to the alternative minimum tax,
shareholders that have a functional currency other than the
U.S. dollar, or holders who hold Genesco common stock as
part of a hedge, straddle or a constructive sale or conversion
transaction). This discussion does not address the receipt of
cash in connection with the cancellation of shares of restricted
stock or options to purchase shares of Genesco common stock, or
any other matters relating to equity compensation or benefit
plans. This discussion also does not address any aspect of
state, local or foreign tax laws.
U.S.
Holders
The exchange of shares of Genesco common stock for cash pursuant
to the merger will be a taxable transaction to U.S. holders
for U.S. federal income tax purposes. In general, a
U.S. holder whose shares of Genesco common stock are
converted into the right to receive cash pursuant to the merger
will recognize
48
capital gain or loss for U.S. federal income tax purposes
equal to the difference, if any, between the amount of cash
received in exchange for the shares (determined before the
deduction of any applicable withholding taxes) and the
U.S. holder’s adjusted tax basis in the shares. Gain
or loss will be determined separately for each block of shares
(i.e., shares acquired at the same cost in a single
transaction). The gain or loss generally will be long-term
capital gain or loss provided that a U.S. holder’s
holding period for the shares is more than 12 months at the
time of the completion of the merger. Long-term capital gains of
individuals are eligible for reduced rates of taxation. There
are limitations on the deductibility of capital losses.
U.S. holders who claim a loss that exceeds certain
thresholds may be required to file a disclosure statement with
the Internal Revenue Service.
Backup withholding of tax (currently at a rate of 28%) may apply
to cash payments to which a non-corporate U.S. holder is
entitled under the merger agreement, unless the holder or other
payee (i) is an entity that is exempt from backup
withholding (generally including corporations, tax-exempt
organizations and certain qualified nominees) and, when
required, provides appropriate documentation to that effect,
(ii) provides a taxpayer identification number (social
security number, in the case of individuals, or employer
identification number, in the case of other shareholders),
certifies that the number is correct and that the holder has not
been notified by the Internal Revenue Service that it is subject
to backup withholding due to underreporting of interest or
dividends, and otherwise complies with applicable requirements
of the backup withholding rules. Each U.S. holder should
complete and sign the Substitute
Form W-9
included as part of the letter of transmittal and return it to
the paying agent in order to provide the information and
certification necessary to avoid backup withholding, unless an
exemption applies and is established in a manner satisfactory to
the paying agent.
Backup withholding is not an additional tax. Any amounts
withheld under the backup withholding rules will be allowable as
a refund or a credit against a U.S. holder’s
U.S. federal income tax liability provided the required
information is timely furnished to the Internal Revenue Service.
Cash received pursuant to the merger will also be subject to
information reporting under certain circumstances unless an
exemption applies.
Special
Considerations of Holders of Preferred Stock
As discussed above in “The Merger — Preferred
Stock” beginning on page 38, holders of preferred
stock are not directly affected by the merger. Any holder of
preferred stock who converts a share of preferred stock into
Genesco common stock pursuant to the terms of the preferred
stock prior to the merger should generally be treated as any
other holder of Genesco common stock with respect to the
converted shares, and the material U.S. federal income tax
consequences to the exchange of the common stock for the right
to receive cash in the merger generally should be as set forth
above. Holders of preferred stock who exercise their right to
convert their preferred stock into the merger consideration
following the closing of the merger should generally recognize
gain or loss for U.S. federal income tax purposes in a
similar manner as if they had converted their preferred stock
into common stock and exchanged their common stock for the right
to receive cash in the merger.
Holders of preferred stock whose preferred stock is redeemed by
Finish Line following the merger (as described above in
“the Merger — Preferred Stock”), should
generally recognize gain or loss for U.S. federal income
tax purposes in an amount equal to the difference, if any,
between the amount of cash received (including amounts otherwise
paid on behalf of the holder) in exchange for the shares
(determined before the deduction of any applicable withholding
taxes) and the holder’s adjusted tax basis in the shares.
In the event that the charter amendment is not approved and
adopted, and a holder of Employees’ Preferred converts a
portion but not all of the shares of the Employees’
Preferred owned by such holder into merger consideration after
the consummation of the merger, the tax consequences to the
holder may be different than those described above. Holders
of all outstanding classes and series of preferred stock should
consult their own tax advisors.
49
Non-U.S.
Holders
Any gain realized on the receipt of cash pursuant to the merger
by a
non-U.S. holder
generally will not be subject to U.S. federal income tax
unless:
|
|
|
| |
•
|
the gain is effectively connected with a trade or business of
the
non-U.S. holder
in the United States (and, if required by an applicable income
tax treaty, is attributable to a U.S. permanent
establishment of the
non-U.S. holder);
|
| |
| |
•
|
the
non-U.S. holder
is an individual who is present in the United States for
183 days or more in the taxable year of that disposition,
and certain other conditions are met; or
|
| |
| |
•
|
Genesco is or has been a “United States real property
holding corporation” for U.S. federal income tax
purposes and the
non-U.S. holder
owned more than 5% of Genesco’s common stock at any time
during the five years preceding the merger.
|
An individual
non-U.S. holder
described in the first bullet point immediately above will be
subject to tax on the net gain derived from the merger under
regular graduated U.S. federal income tax rates. An
individual
non-U.S. holder
described in the second bullet point immediately above will be
subject to a flat 30% tax on the gain derived from the merger,
which may be offset by U.S. source capital losses, even
though the individual is not considered a resident of the United
States. If a
non-U.S. holder
that is a foreign corporation falls under the first bullet point
immediately above, it will be subject to tax on its net gain in
the same manner as if it were a U.S. person as defined
under the Code and, in addition, may be subject to the branch
profits tax equal to 30% of its effectively connected earnings
and profits or at such lower rate as may be specified by an
applicable income tax treaty.
A
non-U.S. holder
will be subject to substantial limitations on its ability to
claim a loss as a result of the merger.
Non-U.S. holders
who claim a loss that exceeds certain thresholds may be required
to file a disclosure statement with the Internal Revenue
Service.
Non-U.S. holders
should consult their own tax advisors regarding the tax
consequences of the merger.
Genesco believes that it is not and has not been a “United
States real property holding corporation” for
U.S. federal income tax purposes.
Backup withholding (currently at a rate of 28%) may apply to the
cash received by a non-corporate shareholder pursuant to the
merger, unless the shareholder or other payee certifies under
penalty of perjury that it is a
non-U.S. holder
in the manner described in the letter of transmittal (and the
payor does not have actual knowledge or reason to know that the
beneficial owner is a U.S. person as defined under the
Code) or otherwise establishes an exemption in a manner
satisfactory to the paying agent. Backup withholding is not an
additional tax and any amounts withheld under the backup
withholding rules may be refunded or credited against a
non-U.S. holder’s
U.S. federal income tax liability, if any, provided that
such
non-U.S. holder
furnishes the required information to the Internal Revenue
Service in a timely manner. Cash received in the merger will
also be subject to information reporting, unless an exemption
applies.
The U.S. federal income tax consequences set forth above
are not intended to constitute a complete description of all tax
consequences relating to the merger. Because individual
circumstances may differ, each holder should consult the
holder’s tax advisor regarding the applicability of the
rules discussed above to the holder and the particular tax
effects to the shareholder of the merger in light of the
holder’s particular circumstances, including the
application of state, local and foreign tax laws, and, if
applicable, the tax consequences of the receipt of cash in
connection with the cancellation of restricted shares or options
to purchase shares of Genesco common stock, including the
transactions described in this proxy statement relating to our
other equity compensation and benefit plans.
Certain
Relationships Between Finish Line and Genesco
There are no material relationships between Finish Line and
Merger Sub or any of their respective affiliates, on the one
hand, and Genesco or any of our affiliates, on the other hand,
other than in respect of the merger agreement.
50
Litigation
Related to the Merger
We are aware of one asserted class action lawsuit related to the
proposed merger filed against us. On
April 24, 2007, a
purported class action lawsuit styled
Maxine Phillips, on
Behalf of Herself and All Others Similarly Situated v.
Genesco, Inc., Hal N. Pennington, James S. Beard, Leonard L.
Berry, William F. Blaufuss, Jr., James W. Bradford, Robert
V. Dale, Matthew C. Diamond, Marty G. Dickens, Ben T. Harris,
Kathleen Mason, William A Williamson, Jr., and Robert J.
Dennis, was filed in the Chancery Court for the State of
Tennessee, Twentieth Judicial District of Nashville (Case
No. 07-905-III).
The complaint alleges, among other things, that the individual
defendants (officers and directors of Genesco) refused to
properly consider an initial offer made by Foot Locker to
purchase Genesco. Plaintiff asserts that, instead of attempting
to negotiate with Foot Locker to obtain the highest price
reasonably available for Genesco and its shareholders, the
individual defendants initially refused to respond to the offer,
and subsequently rejected the offer without allowing for the
possibility of further negotiations or solicitation of a higher
purchase price from Foot Locker or other potential buyers. The
complaint seeks an order certifying a class, a declaration that
the defendants have breached their fiduciary and other duties,
and an order requiring the defendants to implement a procedure
or process to obtain the highest possible price for shareholders
including, but not limited to, reasonable negotiations with Foot
Locker. Plaintiff also seeks her costs and attorneys’ fees.
The individual defendants and Genesco have not yet filed an
answer to the complaint. Following the execution of the merger
agreement with Finish Line, plaintiff’s counsel indicated,
and continues to indicate, that plaintiff intends to file an
amended complaint alleging breach of fiduciary duties by the
individual defendants in connection with the board of
director’s approval of the merger agreement and the
disclosures made in this proxy statement and seeking injunctive
relief.
Amendment
to Rights Agreement
Immediately prior to the execution of the merger agreement, the
Amended and Restated
Rights Agreement, dated
August 28,
2000, between Genesco and Computershare Trust Company,
N.A., as successor to First Chicago Trust Company of New
York (the
“Rights Agreement”), was amended to render
the shareholder rights inapplicable to both the merger agreement
and the completion of transactions contemplated under the merger
agreement.
Fees and
Expenses of the Merger
We estimate that we will incur, and will be responsible for
paying, transaction-related fees and expenses, consisting
primarily of financial, legal, accounting and tax advisory fees,
SEC filing fees and other related charges, totaling
approximately $22.3 million. This amount includes the
following estimated fees and expenses:
| |
|
|
|
|
|
|
|
Amount to
|
|
|
Description
|
|
be Paid
|
|
|
|
|
SEC filing fee
|
|
$
|
39,219
|
|
|
Printing, proxy solicitation and
mailing expenses
|
|
|
110,000
|
|
|
Financial, legal, accounting and
tax advisory fees and expenses
|
|
|
22,000,000
|
|
|
Miscellaneous expenses
|
|
|
125,000
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
22,274,219
|
|
|
|
|
|
|
|
51
THE
MERGER AGREEMENT
(PROPOSAL NO. 1)
This section of the proxy statement describes the material
provisions of the merger agreement but does not purport to
describe all of the terms of the merger agreement. The following
summary is qualified in its entirety by reference to the
complete text of the merger agreement, which is attached as
Annex A to this proxy statement and incorporated into this
proxy statement by reference. We urge you to read the full text
of the merger agreement because it is the legal document that
governs the merger. It is not intended to provide you with any
other factual information about us. Such information can be
found elsewhere in this proxy statement and in the public
filings we make with the SEC, as described in the section
entitled “Where You Can Find More Information”
below.
The
Merger
The merger agreement provides for the merger of Merger Sub with
and into Genesco upon the terms, and subject to the conditions,
of the merger agreement. The merger will be effective at the
time the articles of merger are filed with the Secretary of
State of the State of Tennessee (or at a later time, if agreed
upon by the parties and specified in the articles of merger). We
expect to complete the merger as promptly as practicable after
meeting the conditions precedent to the merger, including but
not limited to that our shareholders approve the merger
agreement.
As the surviving corporation, Genesco will continue to exist
following the merger. Upon completion of the merger, the
directors of Merger Sub will be the initial directors of the
surviving corporation and the officers of Genesco will be the
initial officers of the surviving corporation. All officers of
the surviving corporation will hold their positions until their
successors are duly elected and qualified or until the earlier
of their resignation or removal.
Genesco or Finish Line may terminate the merger agreement prior
to the completion of the merger in some circumstances, whether
before or after the approval of the merger agreement by
shareholders. Additional details on termination of the merger
agreement are described in “— Termination of the
Merger Agreement.”
Common
Stock Merger Consideration
Each share of Genesco common stock issued and outstanding
immediately before the merger will automatically be cancelled
and will cease to exist and will be converted into the right to
receive $54.50 in cash, without interest and less any applicable
withholding taxes, other than:
|
|
|
| |
•
|
shares held in treasury or owned by Finish Line or Merger Sub
immediately prior to the merger that will be cancelled; and
|
| |
| |
•
|
shares held by subsidiaries of Finish Line (other than Merger
Sub) or Genesco, which will remain outstanding after completion
of the merger.
|
After the merger is effective, each holder of a certificate
representing shares of Genesco common stock will no longer have
any rights with respect to such shares, except for the right to
receive the merger consideration.
Preferred
Stock Treatment
The holders of our preferred stock outstanding upon the
completion of the merger will not be entitled to any
consideration upon the completion of the merger pursuant to the
merger agreement. Each share of Genesco preferred stock issued
and outstanding, and not otherwise properly converted to common
stock if applicable, immediately before the merger will remain
outstanding following the merger. Finish Line has informed us
that it intends to redeem all outstanding shares of redeemable
preferred stock following the completion of the merger in
accordance with our charter, and that it also intends to redeem
the outstanding Employees’ Preferred subject to the
requisite approval and filing of the proposed charter amendment
52
(Proposal No. 2). See “The Merger —
Preferred Stock” beginning on page 38, for further
discussion of the treatment and rights of Genesco preferred
stock in connection with the merger.
Treatment
of Options and Other Awards
Upon the completion of the merger, all outstanding options to
acquire Genesco common stock under our equity incentive plans
will become fully vested and immediately exercisable, and each
option not exercised prior to the merger will be cancelled and
converted into the right to receive a cash payment equal to the
number of shares of Genesco common stock underlying the option
multiplied by the amount by which $54.50 exceeds the exercise
price for each share of Genesco common stock underlying the
option, without interest and less any applicable withholding
taxes. Additionally, restrictions applicable to all shares of
restricted stock will, in connection with the merger, lapse and
those shares will be cancelled and converted into the right to
receive a cash payment equal to the number of outstanding
restricted shares, multiplied by $54.50, without interest and
less any applicable withholding taxes.
The effect of the merger upon our employee stock purchase plan
and certain other employee benefit plans is described below
under “— Employee Benefits” beginning on
page 65.
Treatment
of Convertible Debentures
The 4.125% Convertible Subordinated Debentures due 2023
(the
“Convertible Debentures”) issued by us and under
that certain
indenture dated as of
June 24, 2003, between
us and The Bank of New York (the
“Indenture”), and
outstanding immediately prior to the effective time of the
merger, by virtue of the merger and the terms of the
Indenture
and a supplemental
indenture required to be entered into upon
the merger under the terms of the
Indenture (the
“Supplemental Indenture”), will not be convertible at
or after the effective time of the merger into shares of our
common stock, and following the effective time of the merger,
the Convertible Debentures will be convertible, pursuant to the
terms of the
Indenture and the Supplemental
Indenture, into cash
in an amount equal to the product of (i) $54.50 (the per
share price to be paid for Genesco’s common stock in the
merger) and (ii) the number of shares of our common stock
into which the Convertible Debentures could have been converted
as of the effective time of the merger, including fractional
shares. Finish Line has agreed pursuant to the merger agreement
that it shall, and shall cause the surviving corporation to, at
all times from and after the effective time of the merger
maintain sufficient funds to satisfy its obligations to holders
of Convertible Debentures upon the conversion thereof as
described above.
Payment
for the Shares
Before the merger, Finish Line will designate a paying agent
reasonably acceptable to us to make payment of the merger
consideration as described above. At or prior to the effective
time of the merger, Finish Line will deposit, or cause to be
deposited, in trust with the paying agent the funds necessary to
pay the merger consideration to the applicable shareholders.
Upon the completion of the merger and the settlement of any
transfers that occurred prior to the effective time, we will
close our common stock ledger. After that time, there will be no
further transfer of shares of Genesco common stock.
As soon as reasonably practicable after the completion of the
merger, the surviving corporation will send, or cause the paying
agent to send, to all common stock holders a form of letter of
transmittal and instructions advising how to surrender their
common stock certificates in exchange for the merger
consideration. The paying agent will pay common stock holders
their merger consideration after they have (1) surrendered
their common stock certificates to the paying agent and
(2) provided to the paying agent their signed letter of
transmittal and any other items specified by the letter of
transmittal. Interest will not be paid or accrue in respect of
the merger consideration. The surviving corporation will reduce
the amount of any merger consideration paid to common stock
holders by any applicable withholding taxes. YOU SHOULD NOT
FORWARD YOUR STOCK CERTIFICATES TO THE PAYING AGENT WITHOUT A
LETTER OF TRANSMITTAL, AND YOU SHOULD NOT RETURN YOUR STOCK
CERTIFICATES WITH THE ENCLOSED PROXY.
53
If any cash deposited with the paying agent is not claimed
within one year following the effective time of the merger, the
cash will be returned to the surviving corporation upon demand
subject to any applicable unclaimed property laws. Any unclaimed
amounts remaining immediately prior to when the amounts would
escheat to or become property of any governmental authority will
be returned to the surviving corporation free and clear of any
prior claims or interest thereto.
If the paying agent is to pay some or all of your merger
consideration to a person other than you, as the registered
owner of a common stock certificate, you must have your
certificates properly endorsed or otherwise in proper form for
transfer, and you must pay any transfer or other taxes payable
by reason of the transfer or establish to Finish Line’s
satisfaction that the taxes have been paid or are not required
to be paid.
The transmittal instructions will tell you what to do if you
have lost your certificate, or if it has been stolen or
destroyed. You will have to provide an affidavit to that fact
and, if required by the surviving corporation, post a bond in an
amount that the surviving corporation reasonably directs as
indemnity against any claim that may be made against it in
respect of the certificate.
Representations
and Warranties
The merger agreement contains representations and warranties
made by us to Finish Line and Merger Sub and representations and
warranties made by Finish Line and Merger Sub to us. The
assertions embodied in those representations and warranties were
made solely for purposes of the merger agreement and may be
subject to important qualifications and limitations agreed by
the parties in connection with negotiating its terms (including
exceptions described in the confidential disclosure schedules to
the merger agreement). Moreover, some of those representations
and warranties may not be accurate or complete as of any
particular date because they are subject to a contractual
standard of materiality or material adverse effect different
from that generally applicable to public disclosures to
shareholders or used for the purpose of allocating risk between
the parties to the merger agreement rather than establishing
matters of fact. For the foregoing reasons, you should not rely
on the representations and warranties contained in the merger
agreement as statements of factual information.
In the merger agreement, Genesco, Finish Line and Merger Sub
each made representations and warranties relating to, among
other things:
|
|
|
| |
•
|
corporate organization and existence;
|
| |
| |
•
|
corporate power and authority to enter into and perform its
obligations under, and enforceability of, the merger agreement;
|
| |
| |
•
|
required regulatory filings and consents and approvals of
governmental entities;
|
| |
| |
•
|
the absence of conflicts with or defaults under organizational
documents, other contracts and applicable laws and judgments;
|
| |
| |
•
|
litigation;
|
| |
| |
•
|
broker’s fees; and
|
| |
| |
•
|
information supplied for inclusion in this proxy statement.
|
In the merger agreement, Finish Line and Merger Sub also each
made representations and warranties relating to solvency, the
availability of the funds necessary to perform its obligations
under the merger agreement, and the operations of Finish Line
and Merger Sub.
Genesco also made representations and warranties relating to,
among other things:
|
|
|
| |
•
|
capital structure;
|
| |
| |
•
|
subsidiaries;
|
| |
| |
•
|
documents filed with the SEC;
|
54
|
|
|
| |
•
|
undisclosed liabilities;
|
| |
| |
•
|
absence of certain changes or events since February 3, 2007;
|
| |
| |
•
|
compliance with applicable laws;
|
| |
| |
•
|
contracts and other agreements;
|
| |
| |
•
|
intellectual property matters;
|
| |
| |
•
|
real and leased property matters;
|
| |
| |
•
|
insurance matters;
|
| |
| |
•
|
tax matters;
|
| |
| |
•
|
compliance with the Employee Retirement Income Security Act of
1974, as amended, and other employee benefit matters;
|
| |
| |
•
|
labor matters;
|
| |
| |
•
|
environmental matters;
|
| |
| |
•
|
the absence of any breach of organizational documents, material
contracts and applicable laws as a result of the execution,
delivery and performance of the merger agreement;
|
| |
| |
•
|
board of directors approval of the merger agreement and the
transactions contemplated thereby, including the merger, and
board of directors recommendation to our shareholders to approve
the merger agreement and the transactions contemplated thereby,
including the merger;
|
| |
| |
•
|
state takeover statutes and our rights plan;
|
| |
| |
•
|
the required votes of our shareholders in connection with the
merger agreement;
|
| |
| |
•
|
our suppliers and vendors;
|
| |
| |
•
|
our inventory;
|
| |
| |
•
|
the receipt of a fairness opinion from our financial
advisor; and
|
| |
| |
•
|
affiliate transactions.
|
Many of Genesco’s representations and warranties are
qualified by a material adverse effect standard. For purposes of
the merger agreement, “material adverse effect” on
Genesco (a “Company Material Adverse Effect”), is
defined to mean:
|
|
|
| |
•
|
any event, circumstance, change or effect that, individually or
in the aggregate, is materially adverse to the business,
condition (financial or otherwise), assets, liabilities or
results of operations of Genesco and Genesco’s
subsidiaries, taken as a whole; provided, however, that none of
the following shall constitute, or shall be considered in
determining whether there has occurred, and no event,
circumstance, change or effect resulting from or arising out of
any of the following shall constitute, a “material adverse
effect” on Genesco:
|
|
|
|
| |
•
|
the announcement of the execution of the merger agreement or the
pendency of completion of the merger (including the threatened
or actual impact on relationships of Genesco and Genesco’s
subsidiaries with customers, vendors, suppliers, distributors,
landlords or employees (including the threatened or actual
termination, suspension, modification or reduction of such
relationships));
|
| |
| |
•
|
changes in the national or world economy or financial markets as
a whole or changes in general economic conditions that affect
the industries in which Genesco and Genesco’s subsidiaries
conduct their business, so long as such changes or conditions do
not adversely affect Genesco and Genesco’s subsidiaries,
taken as a whole, in a materially disproportionate manner
relative to other similarly situated participants in the
industries or markets in which they operate;
|
55
|
|
|
| |
•
|
any change in applicable law, rule or regulation or generally
accepted accounting principles or interpretation thereof after
the date of the merger agreement, so long as the changes do not
adversely affect Genesco and Genesco’s subsidiaries, taken
as a whole, in a materially disproportionate manner relative to
other similarly situated participants in the industries or
markets in which they operate;
|
| |
| |
•
|
the failure, in and of itself, of Genesco to meet any published
or internally prepared estimates of revenues, earnings or other
financial projections, performance measures or operating
statistics; provided, however, that the facts and circumstances
underlying any such failure may, except as provided in any of
the other provisions of this definition of material adverse
effect, be considered in determining whether a material adverse
effect has occurred);
|
| |
| |
•
|
a decline in the price, or a change in the trading volume, of
Genesco common stock on the NYSE or the CHX;
|
| |
| |
•
|
compliance with the terms of, and taking any action required by,
the merger agreement, or taking or not taking any actions at the
request of, or with the consent of, Finish Line; and
|
| |
| |
•
|
acts or omissions of Finish Line or Merger Sub after the date of
the merger agreement (other than acts or omissions specifically
contemplated by the merger agreement).
|
Conduct
of Business Pending the Merger
We have agreed in the merger agreement that, until the
completion of the merger (or the termination of the merger
agreement), except as expressly contemplated by the merger
agreement or consented to in writing by Finish Line (which
consent shall not be unreasonably withheld, conditioned or
delayed) or required by applicable law, we and each of our
subsidiaries will:
|
|
|
| |
•
|
conduct our businesses in the ordinary course on a basis
consistent with past practice;
|
| |
| |
•
|
use reasonable best efforts, on a basis consistent with past
practices, to:
|
|
|
|
| |
•
|
preserve intact our business organizations, keeping available
the services of our current officers, employees and consultants,
and preserve our relationships with customers, suppliers, and
others having significant business relations with us;
|
| |
| |
•
|
advertise, promote, and market Genesco’s products;
|
| |
| |
•
|
keep our material properties substantially intact, preserve our
goodwill and business, and maintain all physical properties in
good repair and condition;
|
| |
| |
•
|
perform and comply in all material respects with the terms of
our material contracts; and
|
| |
| |
•
|
maintain, and comply in all material respects with, all
governmental approvals or requirements necessary for the
operation of Genesco’s business or the holding of any
interest in any of Genesco’s properties;
|
|
|
|
| |
•
|
use reasonable best efforts to keep in effect material insurance
policies in coverage amounts substantially similar to those in
effect as of the date of the merger agreement; and
|
| |
| |
•
|
deliver or cause of be timely delivered to (1) the holders
of the Company’s 4.125% Convertible Subordinated
Debentures due 2023, issued by the Company and under that
certain indenture dated as of June 24, 2003, between the
Company and The Bank of New York and (2) holders of the
Company’s preferred stock, all notices required pursuant to
the terms of the indenture and the Company’s charter and
bylaws in connection with the merger.
|
We have also agreed that, until the completion of the merger,
except as expressly contemplated or permitted by the merger
agreement or consented to in writing by Finish Line (which
consent shall not be unreasonably withheld, conditioned or
delayed), we will not, and will not permit any of our
subsidiaries to:
|
|
|
| |
•
|
change the compensation payable to any officer, employee, agent
or consultant or enter into or amend any employment, change in
control, bonus, severance, termination, retention or other
agreement or
|
56
|
|
|
| |
|
arrangement with any officer, employee, agent or consultant of
Genesco or Genesco’s subsidiaries, or adopt or increase the
benefits (including fringe benefits), severance or termination
pay under, any employee benefit plan or agreement or otherwise,
except as required by law or in accordance with existing
agreements or employee benefit plans and in the case of
compensation for officers (other than executive officers),
employees, agents or consultants, in the ordinary course of
business consistent with past practice, and other than any
separation, retention or incentive agreement entered into after
the date of the merger agreement with any non-executive officer
of Genesco or any of Genesco’s subsidiaries pursuant to
which the aggregate benefits (to the extent additional to
existing benefits of a similar nature) do not exceed $250,000 in
the aggregate or $25,000 for any person individually, provided
Genesco provides Finish Line at least two (2) business days
prior written notice;
|
|
|
|
| |
•
|
make any prohibited loans or advances to any of its officers,
employees, agents or consultants, or make any material change in
our existing borrowing or lending arrangements for or on behalf
of any persons pursuant to a plan or otherwise; subject to
certain exceptions for newly hired employees and for employees
in the context of promotions based on job performance or
workplace requirements;
|
| |
| |
•
|
subject to certain specified exceptions, split, combine or
reclassify any of our capital stock or make any change in the
number of shares of our capital stock authorized, issued or
outstanding or grant, sell or otherwise issue or authorize the
issuance of any share of capital stock, any other voting
security or any security convertible into, or any option,
warrant or other right to purchase (including any equity-based
award), or convert any obligation into, shares of our capital
stock or any other voting security, declare, set aside, make or
pay any dividend or other distribution with respect to any
shares of our capital stock, sell or transfer any shares of our
capital stock, or acquire, redeem or otherwise repurchase any
shares of our capital stock or any rights, warrants or options
to purchase any of our capital stock, or any securities
convertible into or exchangeable for any such shares;
|
| |
| |
•
|
amend, or otherwise alter or modify in any respect, the charter
or bylaws of Genesco or any Genesco subsidiary;
|
| |
| |
•
|
except as provided in Genesco’s financial budget and plans
previously made available to Finish Line, sell or transfer or
mortgage, pledge, lease, license, terminate any lease or
license, or otherwise dispose of or encumber any tangible or
intangible asset or related assets with a value in excess of
$3,000,000, other than sales and non-exclusive licenses of
products and services of Genesco and Genesco’s subsidiaries
in the ordinary course of business consistent with past practice;
|
| |
| |
•
|
except as provided in Genesco’s financial budget and plans
previously made available to Finish Line, authorize any single
capital expenditure or a series of related expenditures in
excess of $3,000,000;
|
| |
| |
•
|
except as may be required as a result of a change in law or
generally accepted accounting principles (“GAAP”) (or
any interpretation thereof), change any of the accounting
practices or principles used by Genesco or any of Genesco’s
subsidiaries;
|
| |
| |
•
|
except as provided in Genesco’s financial budget and plans
previously made available to Finish Line, write up, write down
or write off the book value of any material assets of Genesco
and material Genesco subsidiaries, other than in the ordinary
course of business and consistent with past practice or as may
be required by GAAP or the Financial Accounting Standards Board;
|
| |
| |
•
|
settle or compromise any pending or threatened suit, action or
claim which:
|
|
|
|
| |
•
|
is material to Genesco and Genesco’s subsidiaries taken as
a whole;
|
| |
| |
•
|
requires payment to or by Genesco or any of Genesco’s
subsidiaries (exclusive of attorneys’ fees, including
success fees) in excess of $3,000,000;
|
| |
| |
•
|
involves restrictions on the business activities of Genesco that
would be material to Genesco and Genesco’s subsidiaries
taken as a whole; or
|
| |
| |
•
|
would involve the issuance of Genesco securities;
|
57
|
|
|
| |
•
|
adopt a plan of complete or partial liquidation, dissolution,
merger, consolidation, or recapitalization of Genesco or any of
Genesco’s subsidiaries (other than the merger agreement and
the merger);
|
| |
| |
•
|
except as required by law or contracts in existence on the date
of the merger agreement (subject to certain specified
exceptions), establish, adopt, enter into or amend any
collective bargaining, bonus, profit sharing, thrift, restricted
stock, pension, retirement, deferred compensation, employment,
termination, severance or other plan, agreement, trust, fund,
policy or arrangement for the benefit of any current or former
directors, officers or employees of Genesco or any of
Genesco’s subsidiaries, pay any discretionary bonuses to
any director, officer employee of Genesco or any of
Genesco’s subsidiaries, except for the exercise of
discretionary elements under compensation, employment or other
benefit plans or arrangements existing as of the date of the
merger agreement, or change in any material respect the manner
in which contributions to any plan or arrangement are made or
the basis on which contributions are determined;
|
| |
| |
•
|
except in each case as required by applicable law or treasury
regulation, make, revoke or change any material tax election,
file any amended tax return with respect to any material tax,
settle or compromise any material federal, state, local or
foreign tax liability, surrender any right to claim a material
tax refund, waive any statute of limitations in respect of a
material amount of taxes, agree to an extension of time with
respect to an assessment or deficiency for a material amount of
taxes or change any annual tax accounting period;
|
| |
| |
•
|
purposefully and knowingly take any action that would result in
any representation or warranty of Genesco becoming untrue in any
material respect at the closing of the transactions contemplated
by the merger agreement, to the extent such breach would
reasonably be expected to cause any closing condition not to be
satisfied;
|
| |
| |
•
|
enter into any new line of business other than the development
and testing of concepts reasonably related to the current
businesses of Genesco and Genesco’s subsidiaries, or
discontinue any significant and material line of business;
|
| |
| |
•
|
acquire (by merger, consolidation, acquisition of stock or
assets, joint venture or otherwise or through a direct or
indirect ownership interest or investment) any person or
division thereof, except that Genesco can engage in such
acquisition having a transaction price less than $3,000,000
without obtaining Finish Line’s prior consent;
|
| |
| |
•
|
incur, assume or prepay any indebtedness for borrowed money for
any indebtedness in an aggregate amount in excess of $3,000,000,
except to refund or refinance commercial paper or in the
ordinary course of business (including for purposes of funding
working capital in the ordinary course of business) consistent
with past practice;
|
| |
| |
•
|
incur, assume, guarantee, endorse or otherwise become liable or
responsible (whether directly, contingently or otherwise) for
any indebtedness for borrowed money of any other person in an
aggregate amount in excess of $3,000,000, except the incurrence
of, guarantee with respect to or provision of credit support
for, indebtedness of Genesco or any of Genesco’s
subsidiaries for borrowed money under Genesco’s or
Genesco’s subsidiaries’ existing credit facilities in
the ordinary course of business;
|
| |
| |
•
|
make any loans, advances or capital contributions to, or
investments in, any other person, except in the ordinary course
of business consistent with past practice;
|
| |
| |
•
|
pledge or otherwise encumber shares of capital stock or other
voting securities of any of Genesco’s subsidiaries, other
than permitted liens (as defined in the merger agreement);
|
| |
| |
•
|
mortgage or pledge any of its material assets, tangible or
intangible, or create any lien thereupon (other than permitted
liens or liens arising under and created by contracts without
any breach thereof or under the merger agreement or default
thereunder or under the merger agreement);
|
58
|
|
|
| |
•
|
enter into any material contract other than in the ordinary
course of business consistent with past practice to the extent
such contract would be material to Genesco and Genesco’s
subsidiaries, taken as a whole;
|
| |
| |
•
|
voluntarily terminate or modify in any material adverse respect
any material contract;
|
| |
| |
•
|
enter into material supply agreements with suppliers, except in
the ordinary course of business consistent with past practice;
|
| |
| |
•
|
enter into any foreign exchange contract or other hedging
contract except in the ordinary course of business consistent
with past practice; or
|
| |
| |
•
|
obligate itself to do any of the above actions.
|
Notwithstanding the foregoing, nothing contained in the merger
agreement shall give Finish Line, directly or indirectly, the
right to control or direct Genesco’s or Genesco’s
subsidiaries’ operations prior to the effective time of the
merger; prior to the effective time of the merger, each of
Genesco and Finish Line shall exercise, consistent with the
terms and conditions of the merger agreement, complete control
and supervision over its and its
subsidiaries’ respective
operations; and no consent of Finish Line shall be required with
respect to any matter set forth above or elsewhere in the merger
agreement to the extent the requirement of such consent would be
inconsistent with applicable law.
Efforts
to Complete the Merger
Upon the terms and subject to the conditions set forth in the
merger agreement, each of the parties to the merger agreement
has agreed to use its reasonable efforts to take, or cause to be
taken, all actions, to file, or cause to be filed, all
documents, and to do, or cause to be done, and to assist and
cooperate with the other parties in doing, all things necessary,
proper or advisable to consummate and make effective the merger,
including: (1) the taking of all acts necessary to satisfy
the conditions necessary for the completion of the merger;
(2) the obtaining of all necessary actions or non-actions,
expirations of all necessary waiting periods, waivers, consents,
clearances, approvals, orders and authorizations from
governmental entities and any other third parties; (3) the
defending of any suits, claims, actions, investigations or
proceedings, whether judicial or administrative, challenging the
merger agreement or the completion of the merger; and
(4) the execution or delivery of any additional instruments
necessary to consummate the merger.
Finish Line has agreed to use its reasonable best efforts to
arrange the debt financing to fund the proposed merger and
related transactions contempla